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ABSTRACT 
Computational and Theoretical Analysis of Influenza Virus Evolution and Immune 
System Dynamics 
by 
Keyao Pan 
Influenza causes annual global epidemics and severe morbidity and mortality. The 
influenza virus evolves to escape from immune system antibodies that bind to it. The 
immune system produces influenza virus specific antibodies by VDJ recombination 
and somatic hypermutation. In this dissertation, we analyze the mechanism of in-
fluenza virus evolution and immune system dynamics using theoretical modeling and 
computational simulation. 
The first half of this thesis discusses influenza virus evolution. The epidemiological 
data inspires a novel sequence-based antigenic distance measure for subtypes HlNl 
and H3N2 virus, which are superior to the conventional measure using hemagglutina-
tion inhibition assay. Historical influenza sequences show that the selective pressure 
increases charge in immunodominant epitopes of the H3 hemagglutinin influenza pro-
tein. Statistical mechanics and high-performance computing technology predict fixa-
tion tendencies of the H3N2 influenza virus by free energy calculation. We introduce 
the notion of entropy from physics and informatics to identify the epitope regions of 
HI-subtype influenza A with application to vaccine efficacy. We also use entropy to 
quantify selection and diversity in viruses with application to the hemagglutinin of 
H3N2 influenza. Using the bacterial E. coli as a model, we show the evidence for 
recombination contributing to the evolution of extended spectrum ,8-lactamases (ES-
BLs) in clinical isolates. A guinea pig experiment supports the discussion on influenza 
virus evolution. 
The second half of the thesis discusses immune system dynamics. We design a 
two-scale model to describe correlation in B cell VDJ usage of zebrafish. We also 
introduce a dynamical system to model original antigenic sin in influenza. 
This dissertation aims to help researchers understand the interaction between 
influenza virus and the immune system with a quantitative approach. 
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Chapter 1 
Introduction 
1.1 Influenza as a Global Health Threat 
Influenza A virus circulates in the human population every year, typically causing 3-5 
million severe illnesses and 250,00D-500,000 fatalities all over the world [14]. Hemag-
glutinin (HA) and neuraminidase (NA) are two kinds of virus surface glycoproteins 
encoded by the influenza genome. The subtype of influenza is jointly determined by 
the type of hemagglutinin ranging from Hl to H16, and that of neuraminidase rang-
ing from Nl to N9. On the surface of the virus membrane, HA exists as a cylindrical 
trimer containing three HA monomers, and each monomer comprises two domains, 
HAl and HA2. Hemagglutinin is also a key factor in virus evolution, because it is the 
major target of antibodies, and HA escape mutation changes· the antigenic character 
of the virus presented to the immune system. The H3N2 virus causes the largest 
fraction of influenza illness. 
The recent outbreak of HlNl pandemic flu has caused immediate international 
concern. From its earliest case in mid-March 2009 to mid-May 2009, SOOD-9000 
infections and 7D-80 . deaths were recorded in 4D-50 countries and regions, and as 
of mid-May 2009, over 90% of infections and deaths were in Mexico and the USA 
[15]. Historically, three subtypes of influenza A virus have been able to circulate 
in the human population. The Spanish flu pandemic in 1918-20 was HlNl, which 
circulated in the world until1957. HlNl reappeared in 1977 and persists today [16]. 
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The Asian flu pandemic in 1956-58 was H2N2, which spread widely in the human 
population during the time interval 1957-68 [17]. The Hong Kong flu pandemic in 
1968-69 was H3N2, which has circulated in the human population as the dominant 
subtype until recently [17]. Other subtypes rarely infected humans, although cases of 
H5N1 and H9N2 have been reported. 
1.2 Biology of Influenza Virus 
Influenza A is a type of RNA virus, belonging to the family Orthomyxoviridae. A 
functional Influenza A particle consists of a spherical lipid bilayer shell, with 8 distinct 
RNA strains that encode 11 kinds of proteins. Two kinds of glycoproteins, hemag-
glutinin (HA) and neuraminidase (NA), adhere to the surface of the virus particle. 
HA contributes to the binding of the virus particle to the sialic acid on the surface 
of the target upper respiratory tract epithelial cells and facilitates subsequent fusion 
and entry [18, 19, 20]. NA is the key component that facilitates virus release from 
surface membrane of infected·cells (21]. Nucleocapsid protein (NP), a nucleoprotein, 
encapsulates and transports viral RNA inside the host cell [22]. The matrix protein, 
M1, binds to the inner side of the viral lipid bilayer membrane and helps assemble 
virus particles inside host cells, and is the central component in budding of virus 
particles (21]. M2, a glycoprotein inside the lipid bilayer, serves as the ion channel 
adjusting the pH value inside the virus particle, uncoating the virus particle, and con-
tributes to efficient virion replication (23]. Additionally, there are two non-structural 
proteins, namely NS1 and nuclear export protein (NEP, formerly named NS2), as well 
as four RNA polymerases replicating the virus RNA in the nucleus of the infected 
cell, namely PA, PB1, recently discovered PB1-F2 (24], and PB2. NS1 interferes with 
the cellular antivirus system (25], and NEP exports newly synthesized viral ribonu-
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cleoprotein (RNP) complexes comprising viral RNA, NP, and PB1 from the nucleus 
[26]. 
The 2009 swine flu virus possesses H1 hemagglutinin (HA) and N1 neuraminidase 
(NA) on the surface of the virion, of which the hemagglutinin is the main target of 
host antibodies. The human immune system responds primarily to the five epitope 
regions of the hemagglutinin protein [27, 28]. Host.antibodies bind to five epitopes in 
hemagglutinin and lead to high escape evolution rates of amino acids in the epitopes. 
An early identification of H1 epitopes was carried out by antibody mapping of the 
A/PR/8/1934 (H1) hemagglutinin, with an additional study of laboratory mutations 
[3]. However, these H1 epitopes contain far fewer amino acids than do the epitopes 
in H3 determined by modern methods [28] and are incomplete. Alignment of H1 
strains in 1918-2009 indicates many mutation positions outside the originally identi-
fied epitopes. We here use sequence alignment and information entropy to complete 
the definition of H1 epitopes. 
1.3 Vaccination and Antigenic Distance Measure 
Vaccination is an effective way to reduce the influenza morbidity and mortality. The 
efficacies of influenza vaccines vary from year to year, in part due to different anti-
genic distances between the circulating influenza strains and the vaccine. Antigenic 
distance between a vaccine strain and a viral strain can be estimated by the number 
of mutations in the hemagglutinin sequence between the two strains [29, 30]. Fer-
ret animal model studies are used to further refine the notion of antigenic distance. 
These methods correlate with epidemiological studies of vaccine efficacy in humans 
with R2 = 0.59 and 0.43-0.57, respectively [2, 31]. By considering only those mu-
tations that occur in the dominant epitope, the Pepitope theory provides a prediction 
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of vaccine efficacy that correlates with epidemiological studies of vaccine efficacy in 
humans with R2 = 0.81. 
Vaccine efficacy has a linear correlation with the antigenic distance between the 
vaccine strain and the circulating virus strain [2, 31]. Since Pepitope correlates well with 
influenza vaccine efficacy in humans, it can be used to estimate antigenic distance. For 
example, when pepitope is larger than 0.19, the vaccine no longer offers protection. 
This correlation can be used to find optimal strains for vaccine design with minimal 
antigenic distance from expected circulating strains. Here we calculate the antigenic 
distance for H1 influenza A and apply the method to evaluate efficacy of a candidate 
swine flu vaccine. 
The annual trivalent vaccine for influenza contains one H3N2 strain, one H1N1 
strain, and one influenza B strain. This vaccine is currently the primary tool to pre-
vent influenza infection and to control influenza epidemics. Due to the fast evolution 
of the influenza virus, the components of the influenza vaccine are changed for many 
flu seasons. Even though the vaccine is usually redesigned to match closely the newly 
evolved influenza virus strains, there occasionally has been a suboptimal match be-
tween vaccine and virus. Partly for this reason, vaccine effectiveness has varied in 
different years. The desire to have a vaccine with high effectiveness makes the pre-
diction of the circulating influenza strain for the next influenza season a key step in 
vaccine design. A goal of the WHO is to recommend vaccine strains for the next 
flu season that will have the smallest antigenic distances to the dominant circulat-
ing strains in the next flu season, which often means using the dominant circulating 
strains in the current flu season as a reference. 
A variety of distance measures have been developed to evaluate the degree of 
match between the vaccine strain and the dominant circulating strain. The hemag-
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glutinin protein (HA) of influenza is primarily focused upon for this distance calcula-
tion since hemagglutinin is the dominant antigen for protective human antibodies and 
exhibits the highest evolutionary rate among all the influenza genes [32]. A widely 
used definition of antigenic distance is calculated from hemagglutination inhibition 
data from ferret animal model studies. To compare a pair of strains, a 2-by-2 HI titer 
matrix is built, and the antigenic distance is extracted from this matrix. This dis-
tance can be further refined by a dimensional projection technique termed antigenic 
cartography [30]. The mathematical basis of antigenic cartography is the dimen-
sion reduction of the shape space in which each point represents an influenza virus 
strain· and the distance between a pair of points represents the antigenic distance be-
tween the corresponding strains. Note that antigenic cartography does not yield the 
distance data itself, but assesses the distance between the given vaccine strain and 
dominant circulating strain by globally considering the effect of all the strains and the 
antigenic distances among them. In the original literature of antigenic cartography 
[30], hemagglutination inhibition data were the input of the antigenic cartography 
algorithm that obtains the final results of distances. Antigenic distances can also be 
defined by the amino acid sequences of the strains using computer-aided methods, 
in which the fraction of substituted amino acid in the dominant hemagglutinin epi-
tope bound by antibody is defined by Pepitope as a sequence-based antigenic distance 
measure [2, 33, 1]. The amino acid sequences are downloaded from databases and 
processed to obtain these distance measures. The Pepitope sequence-based method has 
been shown to be an effective antigenic distance measure between two strains of H3N2 
[34, 2, 33]. To be clear, antigenic distance is a quantity that should define difference 
of viral strains, as determined by the human immune system. Ferret HI data are not 
the only or even the best measure of antigenic distances. 
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The vaccine effectiveness, which varies from year to year, correlates with the 
antigenic distance between the vaccine strain and the dominant circulating strain. 
Thus the vaccine effectiveness can be predicted by calculating the antigenic distance. 
Such a priori estimation of the vaccine effectiveness guides health authorities to 
determine the appropriate strain for the vaccine component for the coming flu season. 
For H3N2 influenza, the Pepitope method offers a prediction of vaccine effectiveness 
that has a higher correlation coefficient with vaccine effectiveness in humans than do 
distances derived by other methods [2, 33). 
1.4 Prediction of Influenza Evolution 
1.4.1 Using Shannon entropy and Relative Entropy 
A common strategy by which viruses evade pressure from the immune system is to 
evolve and change their antigenic profile. Viruses with a low evolutionary rate that 
infect only humans, such as the small pox virus [35), can be effectively controlled 
by vaccinating the human population. By contrast, viruses with a high evolutionary 
rate, such as HIV, hepatitis B, and influenza A, resist being eliminated by the immune 
system by generating a plethora of mutated virus particles and causing chronic or 
repeated infection. In this study, we take subtype H3N2 influenza A virus as a 
model evolving virus. H3 hemagglutinin is under selection by the immune response 
mainly on the five epitope regions in the HAl domain [36), labeled epitopes A to 
E, as shown in Figure 5.1. The immune pressure and the escape mutation drive the 
evolution of the H3N2 virus. The underlying mutation rate of the HA gene is 1.6 x 
10-5 /amino acid position/day [37), measured using the method modified from that in 
an earlier study on the HA mutation rate [38). Note that the mutation rate does not 
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necessarily equal to the evolution rate, or the fixation rate. The mutation rate equals 
to the evolutionary rate only if the evolution is neutral. The non-neutrality of the 
HA evolution is shown in the Results section. Evolution of the hemagglutinin viral 
protein causes occasional mismatch between the virus and the vaccine and decreases 
vaccine effectiveness [2, 34]. As more amino acid substitutions are introduced into 
influenza sequences, the antigenic characteristics of influenza strains drift away [39], 
and influenza epidemic severity of subtype H1N1 [40] and subtype H3N2 [41] increases. 
The H3N2 virus has a distinguished evolutionary history, largely affected by the 
immune pressure. The H3N2 virus emerged in the human population in 1968 and has 
been circulating in the population since 1968. The phylogenetic tree of H3 hemag-
glutinin since 1968 has a linear topology in which most sequences are close to the 
single trunk of the tree, and the lengths of the branches are short [42, 30, 43]. His-
torical hemagglutinin sequences fall into a series of clusters, each of which has similar 
genetic or antigenic features and circulates for 2-8 years before being replaced by 
the next cluster [44, 30]. The evolution of different amino acid positions of hemag-
glutinin shows a remarkable heterogeneity: a subset of positions undergo frequent 
change, while some positions are conserved [4]. This heterogeneity is quantified by 
the Shannon entropy at each position of the amino acid sequence of hemagglutinin [1]. 
Shannon entropy has been used to locate protein regions with high diversity, such as 
the antigen binding sites ofT-cell receptors [45]. Shannon entropy has been used to 
identify antibody binding sites, or epitopes, which are under immune pressure and so 
are rapidly evolving [1]. The heterogeneity of amino acid substitution suggests that 
point mutations randomly occurring in distinct positions have different contributions 
to the virus fitness. 
The selection pressure on the H3N2 virus to evolve is reflected in the difference 
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Figure 1.1 : The tertiary structure of the HAl domain of H3 hemagglutinin (PDB 
code: lHGF). The surface of HAl facing outward is the exposed surface when the 
hemagglutinin trimer is formed. · The other two HAl domains (not shown) in the 
HA trimer are located at the back of the structure displayed here. The solid balls 
represent five epitopes. Color code: blue is epitope A, red is epitope B, cyan is epitope 
C, yellow is epitope D, and green is epitope E. 
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between the H3 hemagglutinin sequences in two consecutive seasons. We consider 
Northern hemisphere strains. When the epidemic initiates in a new season, we assume 
that each position of an HA sequence inherits the amino acid from a sequence of the 
previous season or has a different amino acid due to random mutation and selection. 
This assumption comes from the fact that the H3N2 virus circulating in each influenza 
season migrates from a certain geographic region in which the virus is preserved 
between two influenza seasons [43, 32]. In the absence of selection, the histogram of 
the 20 amino acid usage in one position in the current season is similar to that in 
the same position in the previous season except for changes due to the small random 
mutation rate. The difference between the two histograms beyond that expected due 
to mutation quantifies selection. 
Synthesizing these factors, we introduce an entropy method to describe the evolu-
tion of influenza. The entropy method extracts an evolutionary pattern from aligned 
sequences. Shannon entropy quantifies the amount of sequence information in each 
position of aligned sequences [46, 47]. The sequence information reflects the varia-
tion, which is equivalently diversity, in each position, and so Shannon entropy has 
been used to measure the diversity in each position [48, 49, 50]. Shannon entropy 
has also been used to measure the structural conservation in the protein folding dy-
namics [51, 52]. See [53] for a detailed review of the applications of Shannon entropy. 
On the other hand,. relative entropy measures gain of sequence information at each 
position and requires a background amino acid frequency distribution [54]. Relative 
entropy was also used as a sequence conservation measure to detect functional pro-
tein sites [55, 56]. Further, a dimension reduction technique using relative entropy 
has identified sectors in proteins [57, 56]. As an extension of these previous works, 
we apply Shannon entropy and relative entropy to jointly measure two quantities in 
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each position: sequence information in one season and gain of sequence information 
from one season to the next season. Simultaneous analysis of Shannon entropy and 
relative entropy sheds. light on the evolutionary pattern of the H3N2 virus evolution 
when data from multiple seasons are available. In the HAl domain, positions in the 
epitope regions have increased Shannon entropy, and this feature was applied to lo-
cate the epitopes of Hl hemagglutinin [1]. We here use Shannon entropy to quantify 
the virus diversity in each amino acid position in each season. The entropy relative 
to the previous season [58] is also used to analyze the evolution of the HAl domain 
in one single season and to quantify the selection pressure on the virus in each amino 
acid position in each season. The selection and the virus diversity are two significant 
state variables determining the dynamics of evolution. 
1.4.2 Using the Number of Charged Amino Acids 
Influenza A virus causes annual global epidemics resulting in severe morbidity and 
mortality. The dominant circulating virus today is the H3N2 virus, which emerged 
in 1968 and is defined by two kinds of surface glycoproteins: H3 hemagglutinin and 
N2 neuraminidase. It is currently believed that hemagglutinin is relevant to virus 
attachment and entry into the cell, while neuraminidase facilitates virus release [20]. 
Hemagglutinin also plays a central role in the process of immuno escape, in which 
the antibodies mainly attack five epitopes, denoted as epitopes A-E, on the surface 
of the hemagglutinin protein [59, 28]. Because of antigenic changes through time, 
influenza vaccines are redesigned each year to provide improved protection against 
evolved circulating strains. The efficacy of the annual vaccine is variable due to the 
escape mutation of the influenza virus [29], especially mutation at the five epitopes 
on the hemagglutinin [2]. 
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By analyzing the results of over 50 epidemiological studies of H3N2 influenza dur-
ing the period 1968-2004, [2, 60, 31, 33] showed that the escape mutation of influenza 
A virus can be measured by Pepitope, the proportion of mutated amino acids in the 
dominant epitope of hemagglutinin, where the dominant epitope is defined as the 
epitope with the largest such proportion among the five epitopes. Compared with 
Psequence' the proportion of mutated amino acids in the whole sequence of hemagglu-
tinin, and the ferret antisera assays, Pepitope between vaccine strains and dominant 
circulating strains in the same flu season correlated better with the vaccine effica-
cies in the northern hemisphere [2]. Therefore Pepitope is an appropriate measurement 
for the antigenic distances between vaccine strains and dominant circulating strains. 
With the definition of the dominant epitope, the escape mutation at the dominant 
epitope induces the largest antigenic distance between vaccine strains and dominant 
strains, and endows the dominant epitope with the immunodominance. 
In Gupta et al.'s model [2], which correlates well with vaccine efficacy in humans, 
every mutated amino acid is assigned the same weight. However, free energy calcu-
lations suggest that different amino acid substitutions have different contributions to 
the escape from the immune pressure. In general, the calculated differences in bind-
ing free energy b.b.G = b.Gmutated - b.Gwildtype are different for different mutations, 
where b.Gmutated and b.Gwndtype denote binding free energy between two proteins one 
of which has and does not have a point mutation, respectively. For the experimentally 
measured difference in binding free energy b.b.G between human growth hormone 
(hGH) and its first bound receptor (hGHbp ), individual alanine substitutions of hy-
drophobic amino acids on the epitope of hGHbp induced the largest increase in b.b.G, 
followed by charged amino acids [8]. Nevertheless, we show that charged amino acids 
correlate more strongly with viral evolution. Nakajima [9] found that the majority 
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of escape mutations of H3 hemagglutinin of the strain A/Kamata/14/91 were the 
mutations that introduce charged amino acids, and that the frequency of selected 
mutations to charged residues was significantly higher than that expected by random 
chance. A related study by Smith et al. [30] found a similar over-representation of 
mutations to charged amino acids in the evolution of influenza. 
We here consider the effect of different physical properties on the escape from 
immune pressure. We focus on the charged amino acids in the epitopes. These amino 
acids are strongly hydrophilic, and they reduce the tendency of antibodies to bind to 
hemagglutinin. Charged amino acids play a critical role in protein-protein interaction 
by creating salt bridges and salt bridge networks. Charged amino acids introduce 
specificity in binding [10]. Amino acid substitutions involving charged residues in the 
vicinity of receptor-binding region of HA affect the binding affinity between HA and 
its receptor [11]. The evolution of charged amino acids, therefore, may provide useful 
information on viral escape from antibody pressure. A discussion of charge evolution 
in proteins has been given by Leunissen [12], who observed a large variance in the 
evolutionary trends among different protein families. Here we use stochastic methods 
to model the evolution of charged amino acids on the epitopes of H3 hemagglutinin 
strains collected from humans since 1968. 
The metaanalysis of 50 epidemiological human vaccine efficacy studies shows that 
the single dominant epitope is the critical region that determines the epidemiological 
vaccine efficacy [2]. There are five non-overlapping epitopes on the surface of H3 
HA molecule, namely epitope A-E, to which different sets of antibodies bind. In 
each epitope, the p value is defined as the fraction of mutated amino acids [2]. The 
dominant epitope is defined as the epitope with the greatest p value. The greatest 
p value is Pepitope· Epidemiological data on the vaccine efficacies in 18 previous flu 
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seasons when H3N2 subtype was dominant were collected from approximately 50 
studies [2]. The identities of the vaccine strains and dominant circulating strains 
were also obtained to calculate Pepitope· H3N2 vaccine efficacy correlates with Pepitope 
with R2 = 0.81. This strong correlation shows that Pepitope defined by the single 
dominant epitope is a quantitative definition of antigenic distance. Importantly, the 
Pepitope calculated from the dominant epitope correlated better with vaccine efficacy 
than did antigenic distance including all HA amino acids [2]. 
The results of [61] show that subdominant epitopes are not the critical regions 
_for vaccine efficacy. In an effort to improve the definition of antigenic distance, four 
modifications of the definition of antigenic distance were tested for their ability to 
improve the correlation with vaccine efficacy: 1) incorporating p values from sub-
dominant epitopes, 2) distinguishing conservative and non-conservative amino acids 
mutations, 3) mutations in amino acids adjacent to the epitopes, and 4) the calcula-
tion of mutations in neuraminidase [61]. These four modifications of the definition of 
antigenic distance, including use of subdominant epitope p values, all failed to sub-
stantially improve the correlation with vaccine efficacy data in the years 1971-2004. 
These results motivate our focus on the dominant epitiope in the present analysis. 
The reduced alphabet Markov model (RAMM) described in this thesis is an amino 
acid substitution model. It is built from the H3 hemagglutinin strains circulating in 
1972-1987 when epitope B was the dominant epitope. This time span is shortly after 
the emergence of H3N2 virus in 1968, and this newly emerged virus subtype needed 
some time to adapt to host immune system, because emergence of new subtypes 
such as H2N2 in 1957 and H3N2 in 1968 went with Asian flu and Hong Kong flu 
outbreaks, indicating that subtypes like H3N2 were more virulent in the beginning 
and less adaptive to human. Further, the phylogenetic tree of H3N2 also shows 
14 
that H3N2 evolved faster at the very beginning than in the later stage [30]. So the 
pattern of evolution illustrates the escape mutation of the virus before substantial 
adaptation to host immune system was developed. Because the sequence database 
has been derived from patient samples and categorized by antigenic strain and date 
of collection, the human data do not necessarily reflect fixed variants, but, rather, 
snapshots along an evolutionary continuum. 
Mutations of amino acids in different positions in the epitope are viewed as inde-
pendent and identical Markov chains, whose parameters are the transition matrix P 
or the instantaneous rate matrix Q. Markov models of protein evolution include the 
point accepted mutation (PAM) model [62] and the block substitution matrix (BLO-
SUM) model [63]. These models are derived by counting mutations in aligned amino 
acid sequences, and this approach provides the transition matrices P ( t) of a Markov 
chain in a period of evolutionary timet. Adachi and Hasegawa [64] introduced the 
maximum likelihood method to estimate the elements of the transition matrix, and 
maximum likelihood was also employed to estimate the evolutionary time t when fix-
ing the transition matrix P (t) [65]. The instantaneous rate matrix Q was calculated 
from the Laplace transform of P (t) [65, 66]. For a review of applications to 2000, see 
[67]. Some recent studies estimated the effect of possible multiple mutations at the 
same position within evolutionary timet [68, 69]. The instantaneous rate matrix has 
been estimated from observed frequencies of 20 amino acids [70]. 
The transition matrices P and the instantaneous rate matrices Q of most previous 
models are 20 x 20 matrices trained by analyzing databases with numerous alleles 
in many taxa. In the present case, the training data are limited, which can cause 
overfitting and introduce large errors to the fit model. One way to circumvent this 
difficulty is to decrease the number of parameters: 20 amino acids may be classified 
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into several groups with similar biophysical properties. Here we grouped 20 amino 
acids as 5 charged amino acids and 15 uncharged amino acids. 
To test whether the mathematical models can be applied to data outside of the 
existing human data, we investigated their relevance to animal models of influenza 
infection. Guinea pigs have been shown to be infected with unadapted H3N2 strains. 
In most cases, the infection is limited to the upper respiratory tract, causes little 
apparent morbidity, and can be spread to cage mates via aerosol [71]. As part of our 
analysis of the Pepitope calculations, we developed additional evolutionary data derived 
through analysis of progeny viruses in animal model systems. Interestingly, the pat-
tern of variations in the Guinea pig infection correlated well with the predictions of 
the model and with the human evolutionary data. 
1.4.3 Using Free Energy Calculation 
Influenza A virus causes annual global epidemics resulting in 5-15% of the population 
being infected, 3:-5 million severe cases, and 250,000-500,000 fatalities [14]. The 
subtype of influenza A is determined by two surface glycoproteins-hemagglutinin (H) 
and neuraminidase (N). The H3N2 virus has been one of the dominant circulating 
subtypes since its emergence in 1968. The antibodies lgG and IgA are the major 
components of the immune system that control influenza infection, binding to the 
influenza hemagglutinin [72]. There are five epitopes at the antibody binding sites 
on the top of H3 hemagglutinin, namely epitopes A-E. The epitope bound most 
prolifically by antibody is defined as the dominant epitope, and it is central to the 
process of virus neutralization by antibody and virus escape substitution [2]. The 
cellular immune system, on the other hand, plays a relatively less recognized role 
in handling the invasive influenza virus [72]. The cellular system along with the 
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innate immune system exerts a somewhat more homogeneous immune reaction against 
genetically distinct influenza strains [73, 72]. 
Vaccination is currently the primary method to prevent and control an influenza 
epidemic in the human population (14]. Influenza vaccination raises the level of 
antibody specific for hemagglutinin and significantly enhances the binding affinity 
between antibody and hemagglutinin. Vaccine effectiveness depends on the antigenic 
distance between the hemagglutinin of the administered vaccine strain and that of 
the dominant circulating strain in the same season [2, 74]. Memory immune response 
from virus in previous seasons as well as vaccination in the current and previous 
seasons impose selective pressure on the current circulating virus to force it to evolve 
away from the virus strains recognized by memory antibodies that selectively bind to 
hemagglutinin. 
As a result of the immune pressure and the escape evolution of the influenza virus, 
which is largely substitution in the dominant epitope of hemagglutinin, the influenza 
vaccine must be redesigned and administered each year, and the vaccine effectiveness 
has been suboptimal in some flu seasons [2, 33]. The escape evolution in the dominant 
epitope is at a higher rate than that in the amino acid sites outside the dominant 
epitope [42]. Sites in the dominant epitope also show higher Shannon entropy of the 
20 amino acids than do those outside the dominant epitope [1]. High substitution 
rate and Shannon entropy in the dominant epitope of hemagglutinin suggest that 
the dominant epitope is under the strongest positive selection by human antibodies. 
The immune pressure against each genotype of the dominant epitope can be at least 
partially quantified by the binding constant between antibody and hemagglutinin. 
The H3N2 virus and human immune system in this work are simplified to be a 
system consisting of the H3 hemagglutinin and the corresponding human antibody. 
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State 1: Separated State 2: Separated 
antibody and AGt• State 1a AGtb State1b A~tb State 2b l!.G, State 2a l!.G,. antibody and wildtype evolved 
hemagglutinin hemagglutinin 
A Gat l!.G.., 
State 3: Complex State 4: Complex 
of antibody and l!.G, State 3a l!.G., State 3b l!.G.,. State 4b t.G ... State 4a t.G .. of antibody and 
wildtype evolved 
hemagglutinin hemagglutinin 
Figure 1.2 : The scheme of the free energy calculation. The free energy difference of 
one substitution is calculated by !:l.!:l.G = !:l.G43 - !:l.G21 . Staten, n = 1-4, is the real 
system. State na has the same configuration of atoms as state n except that all the 
hydrogen atoms have mass 16.000 amu. Compared to state na, state nb contains one 
additional Einstein crystal of product atoms (n = 1, 3) or reactant atoms (n = 2, 4). 
The mass of hydrogen atoms in state nb is also 16.000 amu. Free energy !:l.G21b and 
!:l.G43b are obtained by thermodynamic integration. 
Exposure by infection or vaccination produces an affinity-matured antibody with the 
binding constant to the corresponding hemagglutinin equal to 106-107 M-1 , while 
the binding constant of an antibody uncorrelated to the hemagglutinin is below 102 
M-1 [72]. Escape substitutions may decrease the binding constant by changing the 
antibody binding free energy !:l.G. Some substitutions decrease the antibody binding 
constant more than others and have higher probabilities to be fixed, because decrease 
in the antibody binding constant is favorable to the virus. Here we define the differ-
ence of antibody binding free energy as !:l.!:l.G = !:l.G42 - !:l.G31 in which !:l.G31 and 
!:l.G42 are antibody-wildtype hemagglutinin binding free energy and antibody-evolved 
hemagglutinin binding free energy, respectively, as shown in 7 .1. The fixation ten-
dency of each substitution is a function of the difference of the antibody binding free 
energy [75] of the escape substitution. 
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Epitope A orB of the H3N2 virus was dominant in most influenza seasons [2]. 
Epitope B of the H3N2 virus was the dominant epitope presenting more substitutions 
than any other epitope in the recent years. Epitope B was also dominant in 1968 
when H3N2 virus emerged. Thus during these periods of time, the substitutions in 
epitope B directly affect the antibody binding constant and reflect the direction of 
the virus escape substitution. To attain a global view of the effects of substitutions in 
epitope B, it is necessary to compute a matrix containing the differences of antibody 
binding free energy caused by each possible single substitution in epitope B. There 
are 21 amino acid sites in epitope B, and each residue in the wild type strain may 
substitute to any of the 19 different types to amino acid residues, hence we need 
to calculate a 19 x 21 matrix with 399 elements. Such a matrix is a free energy 
landscape quantifying the immune selection over each evolved influenza strain. In 
this free energy landscape, the virus tends to evolve to a position with low binding 
affinity of antibody to evade antibodies and reduce the immune pressure. Calculation 
of this landscape will enable us to study the mechanism of immune escape from a 
quantitative viewpoint, providing a criterion to describe and foresee the evolution of 
influenza virus. 
1.5 Modeling of Zebrafish Immune System 
B cell-mediated adaptive immunity exists in jawed animals [76}. B cells protect hosts 
by secreting antibodies that recognize and neutralize pathogens and foreign sub-
stances. Immunity generated by B cells is hence indispensable to the hosts' survival. 
The primary immune response occurs when a novel type of antigen is detected by 
the immune system. The antigen is processed and presented to nai've B cells, which 
mature in the germinal center. In the maturation process, the B cells acquire the ca-
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pability to recognize and neutralize a specific antigen. First, a naYve B cell recombines 
one V gene segment, one D gene segment, and one J gene segment in the genome 
to create the nucleotide sequence encoding the antibody. Second, this nucleotide se-
quence undergoes multiple rounds of somatic hypermutation, and B cells with high 
affinity to the antigen are selected. The selected mature B cells differentiate into the 
antibody-secreting plasma cells or long-lived memory B cells that effectively activate 
the secondary immune response against the same antigen in the future. Janeway 
et al. provide a more detailed review of the B cell-mediated immune reaction [72]. 
Understanding the dynamics of and relationship between VDJ recombination and 
somatic hypermutation informs one about the centrru mechanism of B cell immunity. 
Recent experimental studies provide information on the B cell maturation process 
in zebrafish. Zebrafish (Danio rerio) have been increasingly used as a model animal 
to study the immune system because experiments on zebrafish are easy to perform, 
zebrafish reproduce quickly, and zebrafish possess one of the most primitive adaptive 
immune systems, which is a model for the adaptive immune systems in humans and 
mice [77, 78, 79]. The genome of zebrafish contains 39 V gene segments, five D 
gene segments, and five J gene segments, which together encode the V region of 
immunoglobulin IgM heavy chain in zebrafish [80, 81]. High-throughput sequencing 
of the complete IgM repertoires in 14 six-month-old zebrafish revealed that one fish 
carries up to 5000-6000 distinct nucleotide sequence of IgM with 39 x 5 x 5 = 975 VDJ 
recombinations [7]. VDJ usage, the probabilities that each of the 975 possible VDJ 
recombinations is used in the IgM repertoire, has a correlation coefficient between 
individual zebrafish up to r = 0. 75 [7]. 
In the present study, we developed a two-scale model to illustrate that B cell mat-
uration processes in distinct individuals, even though random, may converge to the 
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same VDJ recombination in the same environment of antigens. We use delay ordinary 
differential equations (ODEs) to simulate the immune response against multiple anti-
gens circulating in the environment. We use the generalized N K model to describe B 
cell maturation processes against one antigen. The original N K model builds a ran-
dom rugged energy landscape on which peptides evolve [82, 83]. The parameters of 
the N K model for short peptides have been fit to the observed data. Mora et al. fit a 
random energy model, similar to the N K model, with a large number, approximately 
103 , of parameters to experimentally measured probabilities of D gene segment usage 
in zebrafish [84]. As an extension of the original N K model, the generalized N K 
model takes into account the interaction between distinct subdomains of a protein 
and protein-protein interaction [85]. The generalized N K model can describe mat-
uration of the whole V region of antibodies [34] and evolution of proteins in general 
[86]. In this study, we use the generalized N K model to analyze the convergence in 
the VDJ usage of immune response of two fish exposed to the same set of antigens. 
We extracted results of the generalized N K model to assign VDJ recombination to 
each type of mature B cells, the dynamics of which are solved by the ODE model. 
Correlation coefficients between the VDJ usage calculated from theory agree with 
experiment, in which most pairs of zebrafish had a weak correlation with r::; 0.2 and 
a small fraction of pairs had r > 0.5 [7]. 
The two-scale model is motivated by the nature of immune response. The adap-
tive immune system receives different antigens at various time points .. An antigen 
can initiate a primary or secondary immune response, depending on whether the in-
fected individual has seen the antigen before. During the immune response B cells 
undergo rounds of somatic hypermutation and selection. The ODE system models at 
a mean field level the dynamics of B cell repertoires [87, 88]. The generalized N K 
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model computes the repertoire of B cells that respond and evolve in response to the 
. antigen. The generalized N K model explicitly simulates the somatic hypermutation 
and selection of the B cell repertoire reacting to a specific type of antigen in one 
individual [85, 34]. We c~mbined the ODE model and the generalized N K model to 
build the present two-scale model, a model that can zoom out to yield a global view 
of the dynamics of B cell repertoires and zoom in to focus on the somatic evolution 
of the B cells reacting to one type of antigen. 
1.6 Original Antigenic Sin 
Immune memory is mounted from previous infection or vaccination, stores the infor-
mation for recognizing the corresponding antigen, and is activated during the future 
infection of the same type of pathogen. Long-term immune memory has been ob-
served for various pathogens including smallpox [89], malaria [90], hepatitis B [91], 
dengue [92], and Influenza A [93]. This long-lasting effect prevents the reinfection 
by pathogens such as smallpox via recognizing and rapidly eliminating those rein-
fected pathogen particles. Smallpox virus, also called variola virus, propagates only 
in humans and has a relatively low mutation rate [35]. In contrast, Influenza A virus 
propagates in human, pigs, and aquatic birds, with a higher mutation rate that is ap-
proximately 2.0 x 10-6 /nucleotide/infectious cycle [37], or 1.6 x 10-5 /amino acid/day. 
Calculation of the binding free energy between human antibodies and circulating In-
fluenza A strains shows that the virus mutates away from the genotypes that code for 
hemagglutinin proteins that are well recognized by the human immune system [94]. 
Thus for Influenza A, there is a significant antigenic distance between the circulating 
strain in a given year and the immune memory from previous years. 
Original antigenic sin is the phenomenon in which prior exposure to an antigen 
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leads to a subsequent suboptimal immune response to a related antigen. In some 
years, when the antigenic distance between the vaccine strain and the circulating 
strains fell into a certain range, the existence of original antigenic sin frustrated the 
effort to decrease Influenza A infection rate by vaccination. Historical data of the In-
fluenza A vaccine indicates that vaccine efficacy does not monotonically decrease with 
the distance between the vaccine strains and the circulating strains, but rather has 
a minimum at an intermediate level of antigenic distance [2]. Interestingly, since the 
efficacy of the vaccine with this intermediate antigenic distance from the circulating 
strains is lower than the case with larger distance, which is equivalent to unvaccinated 
people, original antigenic sin could make vaccinated people more susceptible to the 
virus than those who are unvaccinated. 
One of the earliest works discussing the mechanism of original antigenic sin at the 
antibody level includes [34], which attributed original antigenic sin to the localization 
of subsequent immune response in the amino acid sequence space around the primary 
one. The affinity between an antibody and an antigen is given by the generalized 
NK model (GNK model) derived from the NK model originally introduced to model 
a rugged fitness landscape [82, 95] and evolution processes [96, 97, 98], to model the 
three-dimensional structure of protein molecules rather than peptides. The sequences 
of a group of antibodies for Influenza A are allowed to mutate freely and independently 
in the affinity landscape to maximize the individual affinities to the virus. B cells 
that make antibodies with highest affinities are expanded and propagated to the next 
round of the simulation. The mutation of the virus is captured by changing the fitness 
landscape. The final average affinity correlates well with the observed data in history 
[2]. 
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1.7 Summary of Results 
The remaining part of this thesis is organized as follows: Chapter 2 uses the Pepitope 
theory to predict vaccine effectiveness. Chapter 3 provides further evidence that the 
Pepitope theory is more accurate than the conventional ferret animal model. Chapter 
4 identifies the epitope regions of H1 hemagglutinin using Shannon entropy. Chap-
ter 5 estimates future H3N2 evolution and migration using currently available H3 
hemagglutinin sequences. Chapter 6 shows that the number of charged amino acids 
increased in the dominant epitope B of the H3N2 virus since introduction in humans 
in 1968. Chapter 7 used free energy calculations with Einstein crystals as reference 
states to calculate the difference of antibody binding free energy (AAG) induced by 
amino acid substitution at each position in epitope B of the H3N2 influenza hemag-
glutinin. Chapter 8 shows evidence for recombination contributing to the evolution in 
clinical conditions. Chapter 9 builds a two-scale model in zebrafish and to explain the 
reported correlation between VDJ usage of B cell repertoires in individual zebrafish. 
Chapter 10 explains the mechanism of original antigenic sin with a dynamical system. 
Finally, chapter 11 summarizes this thesis. 
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Chapter 2 
A Novel Sequence-Based Antigenic Distance 
Measure for HlNl, with Application to Vaccine 
Effectiveness and the Selection of Vaccine Strains 
HlNl influenza causes substantial seasonal illness and was the subtype of the 2009 
influenza pandemic. Precise measures of antigenic distance between the vaccine and 
circulating virus strains help researchers design influenza vaccines with high vaccine 
effectiveness. We here introduce a sequence-based method to predict vaccine effec-
tiveness in humans. Historical epidemiological data show that this sequence-based 
method is as predictive of vaccine effectiveness as hemagglutination inhibition (HI) 
assay data from ferret animal model studies. Interestingly, the expected vaccine effec-
tiveness is greater against HlNl than H3N2, suggesting a stronger immune response 
against HlNl than H3N2. The evolution rate of hemagglutinin in HlNl is also shown 
to be greater than that in H3N2, presumably due to greater immune selection pres-
sure. 
2.1 Introduction 
The annual trivalent vaccine for influenza contains one H3N2 strain, one HlNl strain, 
and one influenza B strain. This vaccine is currently the primary tool to prevent 
influenza infection and to control influenza epidemics. Due to the fast evolution of 
the influenza virus, the components of the influenza vaccine are changed for many 
flu seasons. Even though the vaccine is usually redesigned to match closely the 
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newly evolved influenza virus strains, there occasionally has been a suboptimal match 
between vaccine and virus. Partly for this reason, vaccine effectiveness has varied 
in different years. The desire to have a vaccine with high effectiveness makes the 
prediction of the circulating influenza strain for the next influenza season a key step 
in vaccine design. A goal of the WHO is to recommend vaccine strains for the next 
flu season that will have the smallest antigenic distances to the dominant circulating 
strains in the next flu season, which often means using the dominant circulating 
strains in the current flu season as a reference. 
A variety of distance measures have been developed to evaluate the degree of 
match between the vaccine strain and the dominant circulating strain. The hemag-
glutinin protein (HA) of influenza is primarily focused upon for this distance calcula-
tion since hemagglutinin is the dominant antigen for protective human antibodies and 
exhibits the highest evolutionary rate among all the influenza genes [32]. A widely 
used definition of antigenic distance is calculated from hemagglutination inhibition 
data from ferret animal model studies. To compare a pair of strains, a 2-by-2 HI titer 
matrix is built, and the antigenic distance is extracted from this matrix. This dis-
tance can be further refined by a dimensional projection technique termed antigenic 
cartography [30]. The mathematical basis of antigenic cartography is the dimen-
sion reduction of the shape space in which each point represents an influenza virus 
strain and the distance between a pair of points represents the antigenic distance be-
tween the corresponding strains. Note that antigenic cartography does not yield the 
distance data itself, but assesses the distance between the given vaccine strain and 
dominant circulating strain by globally considering the effect of all the strains and the 
antigenic distances among them. In the original literature of antigenic cartography 
[30], hemagglutination inhibition data were the input of the antigenic cartography 
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algorithm that obtains the final results of distances. Antigenic distances can also be 
defined by the amino acid sequences of the strains using computer-aided methods, 
in which the fraction of substituted amino acid in the dominant hemagglutinin epi-
tope bound by antibody is defined by Pepitope as a sequence-based antigenic distance 
measure [2, 33, 1]. The amino acid sequences are downloaded from databases and 
processed to obtain these distance measures. The Pepitope sequence-based method has 
been shown to be an effective antigenic distance measure between two strains of H3N2 
[34, 2, 33]. To be clear, antigenic distance is a quantity that should define difference 
of viral strains, as determined by the human immune system. Ferret HI data are not 
the only or even the best measure of antigenic distances. 
The vaccine effectiveness, which varies from year to year, correlates with the anti-
genic distance between the vaccine strain and the dominant circulating strain. Thus 
the vaccine effectiveness can be predicted by calculating the antigenic distance. Such 
a priori estimation of the vaccine effectiveness guides health authorities to determine 
the appropriate strain for the vaccine component for the coming flu season. For H3N2 
influenza, the Pepitope method offers a prediction of vaccine effectiveness that has a 
higher correlation coefficient with vaccine effectiveness in humans than do distances 
derived by other methods [2, 33]. In this chapter, we develop the Pepitope method 
for HlNl influenza. In Materials and Methods we describe the epidemiological data 
used to calculate vaccine effectiveness and the animal mod~l or sequence data used to 
calculate antigenic distance. In Results we show the correlation of antigenic distance 
with vaccine effectiveness. We discuss the results in the Discussion. 
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2.2 Materials and Methods 
2.2.1 Identities of Vaccine Strains and Dominant Circulating Strains 
The vaccine strain selection by WHO in each year follows a standard procedure. The 
vaccine strains are reviewed every year and are usually changed every two to three 
years. We used the HlNl vaccine strains and HlNl dominant circulating strains in 
the epidemiological literature that provided vaccine effectiveness data used in this 
study. 
2.2.2 Estimation of Vaccine Effectiveness 
The HlNl vaccine effectiveness is gathered from epidemiological literature regarding 
the influenza-like illness rate of unvaccinated (u) and vaccinated people (v). Vaccine 
effectiveness can be described by the following definition: 
. a . u-v · 
vaccme euectlveness = --. 
u 
(2.1) 
To calculate vaccine effectiveness and its standard error, we let Nu and Nv denote 
the number of subjects in the unvaccinated and vaccinated group, nu and nv denote 
the number of illness in the unvaccinated and vaccinated group, respectively. The 
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values and the standard errors of u, v, and vaccine effectiveness are 
u = nu/Nv. (2.2) 
v = nv/Nv (2.3) 
VE u-v nv.Nv -nvNv. (2.4) = --= 
u nv.Nv 
Uv. = w. (2.5) u 
Uv = w (2.6) v 
UVE = (;;) (~r + (:ur = (~) 2 u; + (:2r u~. (2.7) 
If the vaccine effectiveness is averaged from N studies, u~E = c~::::i u~Ei) I N 2 where 
uVEi is the standard error of the i-th study. 
Compared to H3N2, subtype H1N1 viruses were dominant in fewer years. Based 
on the proportions of samples of H3N2, H1N1, and influenza B collected in each year 
during 1977-2009, widespread H1N1 circulation was observed in approximately 10 
seasons. Epidemiological studies on vaccine effectiveness were absent for some years 
when H1N1 circulated. Additionally, we used the criteria listed below to filter all 
available literature. 
To ensure that the vaccine effectiveness we collected from the literature is for 
H1N1, the seasons and the geographic regions of the epidemiological studies in the 
literature were compared with the influenza activity information in WHO Weekly 
Epidemiological Records to confirm that those regions were dominated by H1N1 in 
those seasons. Subjects were restricted to 18-64 year old healthy adult humans to 
avoid effects of an underdeveloped immune system in children or of immunosenescence 
in senior people. If more than one measure of vaccine effectiveness was collected for 
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the same season, they were averaged to minimize the statistical noise. 
In order to minimize the effect on vaccine effectiveness from co-circulating sub-
types such as H3N2, only the epidemiological data collected in the regions and in 
the flu seasons in which the HlNl subtype was dominant were applied to calculate 
the vaccine effectiveness in this study. The seasons in which the HlNl subtype was 
dominant were reported by the literature on HlNl vaccine effectiveness. The studies 
cited in Table 8.2 for the calculation of vaccine effectiveness gave the subtype of the 
predominant epidemic virus as well as of the virus sampled from the subjects with 
influenza-like illness (ILl). In addition, the dominance of HlNl subtype is also avail-
able in the CDC Morbidity and Mortality Weekly Reports and the WHO Weekly 
Epidemiological Record. For the data in Table 8.2, the dominance of HlNl subtype 
was shown in these references. 
The vaccine effectiveness collected from various flu seasons and regions were mea-
sured with standard errors. Biases in the vaccine effectiveness are due to the complex-
ity of the vaccine effectiveness measurement, including the character of the human 
population studied, such as age, immune history, and health condition; the influence 
of co-circulating H3N2 influenza strains; the character of the vaccine distributed, such 
as live attenuated virus vaccine, inactivated split-virus vaccine produced by virion dis-
assembly, or subunit vaccine only containing hemagglutinin and neuraminidase; the 
method of epidemiological measurement of influenza infection, such as virus detec-
tion, confirmed symptomatic influenza, or influenza-like illness (ILl); the design of 
the experiment, such as natural infection or experimental challenge study; and the 
progression of the epidemic in the population under study. These biases are thus 
inevitable with current technology. Here, we applied the following methods to min-
imize biases in the vaccine effectiveness data. Subjects in the studies were confined 
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to 18-64 years old healthy adult humans to preclude the interference of the feeble 
immune system in children or in senior people, because variation in the capability 
of the immune system is a determinant of the vaccine effectiveness given the same 
pair of vaccine strain and dominant circulating strain. Only epidemiological studies 
in the season and the region in which HlNl subtype was dominant were used to ob-
tain the vaccine effectiveness data. The vaccine involved in the referred studies is an 
inactivated vaccine. Other types such as cold-adapted nasal spray vaccine were ex-
cluded. The epidemiological measurement of infection in all the referred studies used 
ILl as the criterion. Not all studies designed the experiment as a challenge study. 
We assume that the epidemic propagates in the population in a similar way in each 
season. These criteria are used to filter the available references and to obtain vaccine 
effectiveness data with minimum bias. The standard errors of the data are presented 
here. These criteria reduced the number of practical references for each season. Our 
metaanalysis considered 50 peer-reviewed papers, all we could find in the literature. 
We list the ones that satisfy our selection criteria for each of the years, typically 1-3 
per year. 
2.2.3 Antigenic Distance Measured By Sequence Data 
Figure 2.1 shows the HAl domain with five epitopes of the Hl subtype hemagglutinin. 
As the improvement of a previous definition of Hl epitopes [3], these five Hl epitopes 
are recognized by host antibodies and are identified by mapping the well-defined 
epitopes in H3 hemagglutinin [36, 28] to Hl hemagglutinin and using sequence entropy 
to find additional sites under selection [1]. 
The antigenic distance between the vaccine strain and the dominant circulating 
strain is the input for the vaccine effectiveness prediction. The fraction of mutated 
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amino acids in the epitope region of HA, or the p-value, is an antigenic distance 
measure to quantify the similarity between two strains [2]. One p-value is calculated 
for each Hl epitope 
al _ number of mutations in the epitope 
p-v ue- number of amino acids in the epitope (2.8) 
The Pepitope is defined as the maximum of five p-values for the five epitopes, and 
the dominant epitope is defined as the corresponding epitope. This definition, i.e. 
assumption, has lead for H3N2 to vaccine effectiveness predictions that correlate with 
those observed [2]. 
Another sequence-based antigenic distance measure uses the fraction of mutated 
amino acid in all the five epitopes 
number of mutations in all the five epitopes 
Paii-epitope = number of amino acids in all the five epitopes · {2.9) 
As an alternative to Pepitope and Pall-epitope' Psequence is also used with the definition 
number of mutations in the HAl domain of hemagglutinin 
Psequence =total number of amino acids in the HAl domain of hemagglutinin 
(2.10) 
2.2.4 Antigenic Distance Measured by Hemagglutination Inhibition 
The animal model method to determine the distance between the vaccine strain and 
the dominant circulating strain employs the HI assay to give the HI table. See Table 
2.1: Here Hi;, i,j = 1, 2 are four HI titers measuring the capability of antibody j to 
inhibit hemagglutinin i. Note that in reality, health authorities including WHO and 
·CDC provide HI tables with at least eight antisera to evaluate the antigenic distance 
. between candidate vaccine strains and dominant circulating strain. These HI tables 
are mathematically equivalent to several 2 x 2 HI tables each of which defines the 
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Figure 2.1 : HAl domain of the Hl hemagglutinin in the ribbon format (PDB code: 
1RU7). Epitope A (blue), B (red), C (cyan), D (yellow), and E (red) are space filling. 
These five Hl epitopes are the analogs of the well-defined H3 epitopes [1]. 
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Table 2.1 : HI table with two strains and four HI titers. 
Ferret antisera Ferret antisera 
against Strain 1 against Strain 2 
Strain 1 Hu 
Strain 2 
antigenic distance between one pair of strains in the original HI table. For each pair 
of strains, we picked up four entries determined by the identities of these two strains 
and the two corresponding antisera from the original HI table. The 2 x 2 HI tables 
in this manuscript are used to elaborate the formulae for d1 and d2 • In this context 
Strain 1 is the vaccine strain and Strain 2 is the dominant circulating strain. Two 
distance measures have been derived from these four HI titers in the HI table [29, 99]: 
(2.11) 
(2.12) 
Note that antigenic cartography is carried out on the asymmetrical distance, d1 [30]. 
When the vaccine strain and the dominant circulating strain in one season were not 
identical, we searched the literature for the HI tables with these two strains. The d1 
and d2 values were averaged if multiple HI tables were found for one season. 
Table 2.2 : Summary of results. Nine pairs of vaccine strains and dominant circulating strains in seven flu seasons in the 
Northern hemisphere were collected from literature. The quantities nu, Nu, n,.,, Nv, Pepitope, Paii-epitope, Psequence, dt, and 
d2 are defined· in Materials and Methods. Only those seasons when HlNl virus was dominant in at least one country 
or region where vaccine effectiveness data were available were considered. Two different vaccines have occasionally been 
adopted in different geographic regions for the same season, in which case two sets of data were added in this table. An 
asterisk signifies that co-circulating H3N2 was also found in the same country or region in that season; however, the 
interference to the final result from H3N2 is expected to be small, and so the sets of data with a single asterisk were 
preserved. 
~ 
~ 
Seaoon Vaccine strain Dominant Vaccine n,. N,. nv Nv Dominant Pepitope Pall·epitope Paequence dl do 
Circulating str&int effectiveness epltope 
(%) 
1982-83 A/Brazil/11/78 A/England/333/80 37.0 ± 12.01 48 118 31 1211 A 0.083 0.0311 0.0184 01o 1.4110 
1983-84 A/Brazil/11/78 A/Victoria/7 /83 38.1 ± 10.31- 3 30 60 21 671 c 0.121 0.0497 0.0337 1.1311-13 13.6611,13 
55 298 46 aoo• 
1986-87 (a) A/Tajwan/1/86 A/Tajwan/1/86 64.8 ± 14.33•4 11 217 13 7234. 0 0 0 0 
1986-87 (b) A/Chile/1/83 A/Tajwan/1/86 18.5 ± 12.15 92 878 75 8785 B 0.318 0.0807 0.0399 412,14-18 24.4814,16-18 
1988-89 A/Tajwan/1/86 A/Taiwan/1/86 43.1 ± 10.03•5 119 1125 89 11265 0 0 0 0 
1995-96 (a) A/Thxas/36/91 A/Texaa/36/91 60.0 ± 27.86 6 12 2 106 0 0 0 0 
1995-96 (b)* A/Singapore/6/86 A/Texas/36/91 32.2 ± 5.87 99 652 57 6847 A 0.125 0.0559 0.0307 0.8614,19,20 2.4314,20 
176 652 149 6847 
2001HJ7 A/New Caledonla/20/99 A/New Caledonla/20/99 40.5 ± 2.58 1085 230729 1221 4366008 0 0 0 0 
2007-()8° A/Solomon lslands/3/2006 A/Solomon Islands/3/2006 62.8 ± 12.69 94 262 8 609 0 0 0 0 
:j:Multiple strains are circulating in each season, while each strain has a specific proportion in the virus population 
in a certain region and season. The strain with the greatest proportion is defined as the dominant circulating strain, 
which is listed in this table. The dominant circulating strains in this table were chosen based on the literature on vaccine 
effectiveness, which also gave the region where the effectiveness data were collected. 
Literature used in the metaanalysis: 1. [100]; 2. [101]; 3. [102]; 4. [103]; 5. [104]; 6. [105]; 7. [106]; 8. [107]; 9. [108]; 
10. [109]; 11. [110]; 12. [29]; 13. [111]; 14. [112]; 15. {113]; 16. [114]; 17. [115]; 18. [116]; 19. [117]; 20. (118]. 
w 
CJ1 
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2.3 Results 
We performed a metaanalysis of identities of the vaccine strains and dominant circu-
lating strains, vaccine effectiveness, and antigenic distances between vaccine strains 
and dominant circulating strains measured with the HI assay using ferret antisera. 
In one season dominated by HlNl, epidemiological statistics in a certain region re-
ported in literature was used to fix the values of nu, Nu, n,, Nv, and the mean and 
standard error of the vaccine effectiveness. HI assay data in literature are also used 
to determine antigenic distance d1 and d2 between the vaccine strain and dominant 
circulating strain. Results of the metaanalysis are listed in Table 8.2. Sequence-based 
antigenic distances Pepitope, Pall-epitope, and Psequence are calculated from the sequences 
of the vaccine strain and dominant circulating strain by equations 2.8, 2.9, and 2.10, 
respectively. Values of Pepitope, Paii-epitope 1 and Psequence in each season dominated b:f 
HlNl are also listed in Table 8.2. 
While the number of data points is limited, a linear relationship exists between 
vaccine effectiveness and Pepitope by using least squares. Similar to the case for H3N2 
influenza [2], Pepitope strongly correlates with HlNl vaccine effectiveness, with R2 = 
0.68. The fitted model predicts a vaccine effectiveness of 52.7% when Pepitope = 0, 
and vaccine effectiveness is greater than zero when Pepitope < 0.442. In Figure 2.2, 
the fitted trend line is within one standard error of all data points with Pepitope > 0, 
validating the ability of the Pepitope model to predict the vaccine effectiveness with 
only the sequences of the vaccine strain and the dominant circulating strain. 
Although statistical errors exist in the observed vaccine effectiveness, the collected 
vaccine effectiveness data reject the null hypothesis that the vaccine effectiveness is 
independent of Pepitope· The nine pairs of vaccine strains and dominant circulating 
strains in Table 8.2 have five difference antigenic distances between vaccine strain and 
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dominant circulating strain defined by Pepitope· The nine pairs of strains were thus 
categorized into group 1-5 with Pepitope equal to 0, 0.083, 0.121, 0.125, and 0.318, 
respectively, and the average vaccine effectiveness and standard error were calculated 
for each group. The vaccine effectiveness differences between these five groups were 
significant, such as group 1 and group 4 (p = 0.0079) and group 1 and group 5 
(p = 0.0054). Moreover, statistical analysis shows that the introduction of Pepitope 
is valuable in the selection process of vaccine strains. The slope of the fit line is 
significantly smaller than zero (p = 0.0027). Hence the linear model is able to predict 
the vaccine effectiveness with the knowledge of Pepitope· In other words the non-zero 
slope of vaccine effectiveness as a function of Pepitope is significant to the level of 0.27%. 
Two other sequence-based antigenic distance measures alternative to Pepitope are 
Paii-epitope and Psequence· Unlike Pepitope, which focuses upon the mutations in the an-
tibody binding regions, Paii-epitope calculates the fraction of mutated amino acids in 
all the five epitopes, and Psequence calculates the fraction of mutated amino acids in 
the whole HAl domain of hemagglutinin. The Psequence measure is also one of the 
optional distance measures for phylogenetic softwares. In Figure 2.3, the correlation 
between HlNl vaccine effectiveness and Pall-epitope has R2 = 0. 70. In Figure 2.4, the 
correlation between HlNl vaccine effectiveness and Psequence has R2 = 0.66. The pre-
dicted 54% vaccine effectiveness when Paii-epitope in Figure 2.3 and when Psequence = 0 
in Figure 2.4 are almost the same as the 53% predicted by the Pepitope method. By 
contrast Paii-epitope and Psequence for H3N2 have less impressive correlations with H3N2 
vaccine effectiveness [61, 2], and Paii-epitope and Psequence are not as effective as Pepitope 
as antigenic distance measures and vaccine effectiveness predictors for H3N2. 
The HI assay and derived distance measures d1 and d2 are still the most widely 
used measures by researchers and health authorities to identify newly collected cir-
38 
culating strains. These methods are used to recommend the vaccine strain for the 
coming flu season [119, 120, 121], to draw the antigenic map [30], and to support 
the phylogenetic data [119]. Figure 2.5 and 2.6 describe the correlation between 
vaccine effectiveness and antigenic distances d1 and d2 from the HI assay. A corre-
lation is found in both figures. In the season 1995-96 in Israel, the vaccine strain 
is A/Singapore/6/86 (H1N1) and the dominant circulating strain is A/Texas/36/91 
(H1N1), between which the averaged d1 is 0.86. Since the vaccine effectiveness is only 
32.2%, its discrepancy to the corresponding effectiveness 42.5% in the trend line is 
much larger than one standard error of vaccine effectiveness. Similarly, the same pair 
of vaccine strain and dominant circulating strain introduces a data point further from 
the trend line if d2 is used as the distance measure. We also notice that two strains 
could be antigenically identical as measured with HI assay but antigenically distinct 
as measured with Pepitope· As shown in Table 8.2, in the season 1982-1983, the H1N1 
vaccine strain A/Brazil/11/78 and dominant circulating strain A/England/333/80 
presented the antigenic distance measured with ·HI assay d1 = 0 and the sequence-
based antigenic distance measure Pepitope = 0.083. The H3N2 vaccine strain and dom-
inant circulating strain showed identical d1 and d2 values but distinct Pepitope values in 
the seasons 199~1997 and 2004-2005 [2]. Note that if Pepitope is incorporated into the 
linear models shown in Figure 2.5 and 2.6, the R2 value is increased. We fit a linear 
model vaccine effectiveness= a+f31Pepitope+f32dl +f3ad2+€ in which € is an error term. 
The fitted model is vaccine effectiveness = 0.54- 2.179pepitope + 0.068d1 + 0.003d2 with 
R2 = 0.72. 
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Figure 2.2 : Vaccine effectiveness for influenza-like illness correlates with Pepitope, R2 = 
0.68 (solid line). Data from Table 8.2. The trend line quantifies vaccine effectiveness 
as a decreasing linear function of Pepitope· Vaccine effectiveness= -1.19 Pepitope+0.53. 
Also shown is the vaccine effectiveness to H3N2 (dashed line) [2]. 
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Figure 2.3 : Vaccine effectiveness for influenza-like illness correlates with Pall-epitope 
with R2 = 0.70. Data from Table 8.2. The trend line quantifies vaccine effectiveness 
as a decreasing linear function of Pall-epitope· Vaccine effectiveness = -4.16 Pall-epitope + 
0.54. 
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Figure 2.4: Vaccine effectiveness for influenza-like illness correlates with Psequence with 
R2 = 0.66. Data from Table 8.2. The trend line quantifies vaccine effectiveness as a 
decreasing linear function of Psequence· Vaccine effectiveness = -7.37 Psequence + 0.54. 
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Figure 2.5 : The correlation with R2 = 0.53 between vaccine effectiveness for 
influenza-like illness and d1, the antigenic distance defined by HI assay using fer-
ret antisera. Data from Table 8.2. The d1 values were averaged if multiple HI assay 
experimental data were found. The trend line quantifies vaccine effectiveness as a 
decreasing linear function of d1. Vaccine effectiveness= -0.085 d1 + 0.50. 
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Figure 2.6 : The correlation with R2 = 0.46 between vaccine effectiveness for 
influenza-like illness and d2 , the antigenic distance defined by HI assay using fer-
ret antisera. Data from Table 8.2. The d2 values were averaged if multiple HI assay 
experimental data were found. The trend line quantifies vaccine effectiveness as a 
decreasing linear function of d2 • Vaccine effectiveness = -0.013 d2 + 0.51. 
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2.4 Discussion 
2.4.1 Verification of the Pepitope Model 
Originally the Pepitope model was implemented for the H3N2 virus, where Pepitope corre-
lates with H3N2 vaccine effectiveness with a significantly larger R2 than do Paii-epitope 
and Psequence [2, 61). In the case of H1N1, the advantage of Pepitope over Paii-epitope 
and Psequence is not as remarkable as for H3N2. We speculate that antibodies against 
the H3N2 virus may bind to a small fixed region on the surface of H3 hemagglutinin 
while antibodies against the H1N1 virus may have multiple binding regions available. 
In other words, we speculate that the dominant epitope in H3 hemagglutinin may 
contribute substantially to the escape of the H3N2 virus from host antibodies, while 
escape mutations may occur in the dominant epitope as well as perhaps the subdom-
inant epitopes of H1 hemagglutinin. Our speculation comes from the fact that the 
epitope region in H1Nl contains more amino acid positions than does that in H3N2 
[1). 
Two recent epidemiological studies [122, 123) present further support of the Pepitope 
model. Before the emergence of the H1N1 pandemic flu in April2009, the 2008-2009 
flu season was dominated by subtype H1N1 seasonal flu. Both the dominant circulat-
ing strain and the vaccine strain in the 2008-2009 season were A/Brisbane/57 /2007 
(H1N1) [124]. The observed vaccine effectiveness against seasonal flu was 44% (95% 
CI: 33% to 59%) [122). The Pepitope model predicts the vaccine effectiveness as 53%, 
which falls into the 95% CI of the reported vaccine effectiveness. 
After April 2009, a new peak of influenza activity emerged. The dominant cir-
culating strain in this period was the pandemic H1N1 strain A/California/7 /2009 
[125, 126]. The reported effectiveness of the 2008-2009 seasonal flu vaccine against 
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the H1N1 pandemic flu was -50% to -150% [122] and -10% (95% CI: -43% to 15%) 
[123]. The value of Pepitope between A/California/7 /2009 and A/Brisbane/57 /2007 is 
0. 77 with epitope B as the dominant epitope. The vaccine effectiveness forecast by the 
Pepitope model is -39%, which agrees with the measured vaccine effectiveness values. 
2.4.2 Comparison of H3N2 and HlNl Vaccine Effectiveness and Evolu-
tion Rates 
The Pepitope model has been previously applied to the prediction of H3N2 vaccine 
effectiveness [2]. The H3N2 vaccine effectiveness with Pepitope = 0 is 44.6%, and 
vaccine effectiveness is greater than zero for Pepitope < 0.184 [2]. Thus, H1N1 vaccines 
tend to have higher vaccine effectiveness compared to H3N2 vaccines, as shown in 
Figure 2.2. The comparison between H3N2 and H1N1 vaccine effectiveness (Figure 2.2 
versus Figure 2 of [2]) illustrates that H1N1 vaccine has higher effectiveness than the 
H3N2 vaccine as a function of Pepitope· This observation suggests that. the host immune 
system is more effective at recognizing and eliminating the H1N1 virus (Pepitope = 
0), and that humoral cross immunity is stronger for H1 hemagglutinin (Pepitope > 
0). This observation also explains why an H3N2 epidemic is usually a more severe 
health threat than an H1N1 epidemic. We propose that H1N1 has a longer history of 
circulating in the human population, so human immune system may recognize H1N1 
more effectively, and this may be the reason that under stronger immune pressure, 
the H1N1 virus may have a higher degree of adaptation to the human host. In the 
following discussion, we verify this hypothesis by two facts. First, the H1N1 virus 
has a larger antigenic diversity than does the H3N2 virus. Second, the H1N1 virus 
presents higher evolutionary rate in the per dominant season basis. 
To compare the· antigenic diversities of H1N1 and H3N2, we downloaded from the 
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NCBI database on 13 August 2009 all the amino acid sequences of H3 hemagglutinin 
collected in the 18 years with H3N2 dominant circulating strains [2] and those of H1 
hemagglutinin collected in 7 years with H1N1 dominant circulating strains (Table 8.2). 
Thus 18 subsets of H3N2 sequences and 7 subsets of H1N1 sequences were formed. 
The centers of these subsets are the corresponding vaccine strains in the same season 
of the circulating virus. The radius of each subset is obtained by the calculation of 
Pepitope· First, the strains with the top 5% Pepitope antigenic distance measure to the 
center of each subset were selected, to focus on the extent of viral evolution. Second, 
the Pepitope between these selected strains and the center were averaged in each year 
as the radius. Third, the radii were averaged over all the 18 years for H3N2 and over 
7 years for H1Nl. That is, the average radius of the top 5% was calculated in each 
year. As a result, the average H3N2 subset radius with the vaccine strains as the 
centers is 0.211. The average H1N1 radius is 0.520 with the vaccine strains as the 
centers. This difference between the H3N2 radius and the H1N1 radius is significant 
with the p-value 0.0118 using the Wilcoxon rank-sum test. Consequently, the H1N1 
virus has a larger antigenic diversity in each season compared to the H3N2 virus, as 
shown in Figure 2.7. 
We also compared the evolutionary rates of H1N1 and H3N2 because evolutionary 
rate of the virus is an index of the selection pressure of the virus. The virus under-
goes less immune pressure in a non-dominant season and high immune pressure in a 
dominant season. It has been noticed that in H1 and H3 hemagglutinin, the region 
outside epitopes presents significantly lower evolutionary rate than do the epitopes 
[1, 42]. This phenomenon indicates that without immune pressure, the spontaneous 
evolutionary rates of both H1N1 and H3N2 are low. Therefore, a higher evolution-
ary rate of one virus subtype in a dominant season comes from the higher immune 
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pressure rather than neutral evolution, and we reject the alternative scenario that the 
higher evolutionary rate causes a virus subtype to be dominant in one season. So the 
evolutionary rate per dominant season is a natural measure of the virus evolution. 
Between 1983 to 1997, H3N2 was dominant in 8 of 15 years, and between 1977 to 
2000, HlNl was dominant in 5 of 24 years [42]. Between 1980 to 2000, the HAl 
domain of H3 hemagglutinin has a higher annual evolutionary rate of 3. 7 x 10-3 nu-
cleotide substitution/site/year than does the HAl domain of Hl hemagglutinin, which 
has the annual evolutionary rate of 1.8 x 10-3 nucleotide substitution/site/year [42]. 
Measured on a per dominant season basis, however, the HAl domain of Hl hemag-
glutinin evolves faster in its dominant season with the rate of 8.6 x 10-3 nucleotide 
substitution/site/dominant season than does the H3 hemagglutinin with the rate of 
6.9 x 10-3 nucleotide substitution/site/dominant season. The difference is signifi-
cant with a p-value 0.0008. Similarly, between 2000 and 2007, the HAl domain of 
Hl hemagglutinin evolves faster in its dominant season with the rate of 10.2 x 10-3 
nucleotide substitution/site/dominant season than does the H3 hemagglutinin with 
the rate of 7.4 x 10-3 nucleotide substitution/site/dominant season. The difference is 
significant with a p-value 0.0005 [127]. Here we have divided the annual evolutionary 
rate by the proportion of dominant years for both Hl and H3 hemagglutinin. Even on 
a short time scale without fixation, Hl hemagglutinin shows a comparable or higher 
mutation rate of 9.1 x 10-6 nucleotide substitution/site/day than H3 hemagglutinin 
of 4.2 x 10-6 nucleotide substitution/site/day (p = 0.26) [37], probably caused by the 
adaptation to the higher immune pressure, at least for some strains. To make this 
last point, we have assumed that the mutation rate of the HA gene is the same as 
that of the NS gene. We assume that the same polymerase is operating on these two 
genes, and so the mutation rates are expected to be the same. The comparisons of 
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Figure 2.7: The comparison between H3N2 (triangle up) and HlNl (triangle down) 
in regard to the antigenic diversity, the evolutionary rate between 1980 and 2000 
(left), the evolutionary rate between 2000 to 2007 (right), and the mutation rate on 
a short time scale without fixation. The antigenic diversity is measured with Pepitope, 
the unit of evolutionary rate is 10-3 nucleotide substitution/site/year, and the unit 
of mutation rate is 10-6 nucleotide substitution/site/day. 
evolutionary rates and mutation rates between H3N2 and HlNl are summarized in 
Figure 2.7. 
2.4.3 The Pepitope Model as a Supplement to HI Assay 
For both HlNl (this chapter) and H3N2 [2], the HI assay correlates less well with vac-
cine effectiveness than does Pepitope. Collection of HI assay data measuring antigenic 
distance is also more time-consuming and more expensive compared to the Pepitope 
model. Many hundreds of strains are circulating and collected in an average flu sea-
son, thus an HI table with tens of thousands of entries needs to be built to assess the 
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antigenic distance between each pair of strains. With the high-throughput sequenc-
ing technology generating hemagglutinin sequence data, such antigenic distances are 
easily measured with the sequence-based antigenic distance measure Pepitope, which 
correlates to a greater degree with vaccine effectiveness than do the HI data. 
The Pepitope model is developed to provide researcher and health authorities with 
a new tool to quantify antigenic distance and design the vaccine. We do not suggest 
that Pepitope should substitute for the current HI assay, but rather suggest that Pepitope 
serves as an additional assessment when selecting vaccine strains. Using Pepitope to 
supplement to HI assay data may allow researchers and health authorities to more 
precisely quantify the antigenic distance between dominant circulating strains and 
candidate vaccine strains. The adoption of the Pepitope theory may also allow re-
searchers to minimize the cost and the number of ferret experiments and to correct 
HI assay data in some situations. 
2.5 Supplementary Materials 
2.5.1 Humoral Immune System Plays a Major Role in Immunity to In-
fluenza 
The influenza vaccine considered in this study is the trivalent inactivated vaccine 
(TIV) administered. by intramuscular injection. The effective components of TIV are 
hemagglutinin (HA) and neuraminidase (NA) that noticeably induce the humoral 
immunity but activate the cellular immunity less vigorously [128]. The other, cold-
adaptive trivalent live attenuated influenza vaccine (LAIV) is also believed to induce 
the cellular. immunity to a low level [128] .. 
The humoral immunity greatly relies on the antigenic distance between the hemag-
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glutinin of the vaccine and that of the dominant circulating strain. On the other hand, 
the cellular immune system focuses on the highly conserved internal proteins, which 
are the Matrix protein 1 (M1) and the nucleoprotein (NP) [73]. In contrast to the 
antibodies, CD8+ and CD4+ T cells show notable cross immunity to a wide variety of 
strains [73]. Like the cellular immune system, the antigen-unspecific innate immune 
system generates a homogeneous immune reaction against different influenza strains 
[72]. 
For all these reasons ferret antisera, in which antibodies are the major immune 
component, is used in the hemagglutination inhibition (HI) assay as the conventional 
way to measure the antigenic distance between the vaccine strain and the dominant 
circulating strain. Therefore, we consider the antibody rather than the cellular or 
innate immune system to be the dominant element in our quantification of antigenic 
distance between two influenza strains and the key factor for influenza vaccine effec-
tiveness. 
2.5.2 Evaluation of Vaccine Effectiveness 
By definition, vaccine efficacy is measured by controlled trials with initially susceptible 
subjects, while vaccine effectiveness is measured by epidemiological observance of 
susceptible population without giving placebo [129]. Vaccine efficacy is relatively 
more idealized than vaccine effectiveness, because vaccine effectiveness depends on 
vaccine efficacy and other environmental factors [130]. Although the terms vaccine 
efficacy and vaccine effectiveness are interchangeable to some extent [130], we use the 
term vaccine effectiveness because factors other than vaccine strain and dominant 
circulating strain are involved in the studies used in our metaanalysis. The data 
source for vaccine effectiveness calculation used ILl as the primary endpoint, and 
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studies we use contained controlled unvaccinated groups. 
The data from four studies require additional clarification. The paper by Edwards 
et al. [104] did not provide the retrospectively reported influenza-like illness data 
prior to the 1987-88 season, so we use the number of ill subjects presenting for 
throat culture to calculate the morbidity rate u and v. Note that in this study, 
subjects with influenza-like disease were required to show up for a throat culture, 
and when characterized by vaccination status the numbers of such patients is thus a 
reasonable estimation of the illness rate u and v. Moreover, in other seasons when 
both retrospective data and number of presenting ill subjects were available, the 
vaccine effectiveness calculated from retrospective data and numbers of presenting 
ill subjects are similar to each other, especially for subtype HlNl [104]. In Grotto 
et al. 's study [106] using influenza strains from Israel in the 1995-96 season, the 
numbers of sampled HlNl and H3N2 strains in Israel was 7 and 35, respectively. 
The samples were collected from six clinics in December that was in the middle of 
the influenza season. However, the number of both subjects and viruses sampled are 
limited. At the global level with more available data, it was observed that HlNl and 
H3N2 were co-circulating with comparable frequencies, and HlNl virus was found in 
North America and part of Eurasia including Israel [131]. The proportion of HlNl in 
samples during the 1995-96 season in USA ranks #5 in HlNl proportion since 1977 
[42]. In the same season, H3N2 vaccine strain and dominant circulating strain were 
a perfect match, so the decrease in the overall vaccine effectiveness is expected to be 
due to the mismatch in the HlNl component. Therefore we treat HlNl here as a 
co-circulating strain and take into account the vaccine effectiveness reported in this 
article [106]. Keitel et al. [103] reported that the dominant circulating strain in the 
1983-84 season was A/Chile/1/83 rather than A/Victoria/7/83 in this table and in 
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other cited studies. The illness rate u and v are small, and so the standard error of 
vaccine effectiveness is 64.8%, which is unacceptable. Thus the use of Keitel et al. 's 
data for 1983-84 season is not appropriate to the vaccine effectiveness assessment. 
The reference by Couch et al. [102] did not provide original data nu, Nu, nv, and Nv 
for the calculation of vaccine effectiveness. Error bars of vaccine effectiveness in these 
seasons were calculated with other data sources. 
2.5.3 Robustness of the Pepitope Model 
Influenza vaccine effectiveness may depend not only on the antigenic distance between 
the vaccine strain and the dominant circulating strain quantified by Pepitope, but also 
on the percentage of people vaccinated, the time of vaccination in the influenza sea-
son, influenza virus transmissibility and reproduction rate, and individual's immune 
history. Thus, development of the public health system and a greater fraction of the 
population being vaccinated may result in a trend of both H1N1 and H3N2 vaccine 
effectiveness. The statistics of vaccine effectiveness could be biased by these factors. 
Nevertheless, greater than 50% of the H1N1 and H3N2 vaccine effectiveness are ex-
plained by Pepitope, since R2 > 1/2. To show that the model of vaccine effectiveness 
can be well reduced to a linear form between Pepitope and vaccine effectiveness, we 
calculated the residuals of linear regression of vaccine effectiveness on Pepitope, and 
performed another linear regression of these residuals versus year. The trend line 
of the residuals has a slope of -0.0002/year and the null hypothesis that the slope 
equals zero is not rejected (p = 0.96), as shown in Figure 2.8. The residuals of H3N2 
vaccine effectiveness [2] were also correlated with the year and the slope -0.0013/year 
is not significantly different with zero (p = 0.58), as shown in Figure 2.9. Therefore 
the contribution of other simple time-dependent factors other than Pepitope to H1N1 
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Figure 2.8 : The linear regression with R2 = 0.0003 of the residuals of H1N1 vaccine 
effectiveness versus year. Data from Table 1 and Figure 2 in the main text. The slope 
of the trend line is -0.0002/year. ANOVA test: H 0 : slope = 0, F = 0.0021, and 
p = 0.96. The null hypothesis that these residuals are independent of time cannot be 
rejected. 
and H3N2 vaccine effectiveness in humans is negligible. Our analysis suggests that 
the vaccine effectiveness data in this chapter are negligibly affected by these potential 
biases. 
Despite the limited number of available data points in this study, the correlation 
line between the Pepitope and the vaccine effectiveness has statistical meaning. In 
Figure 2 in the main text, the trend line is vaccine effectiveness= -1.19 Pepitope+0.53, 
the greatest determinant of which is the data point 1986--87 (b). If this data point is 
removed, the trend line becomes vaccine effectiveness = -1.63 Pepitope + 0.54, which is 
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Figure 2.9 : The linear regression with R2 = 0.018 of the residuals of H3N2 vaccine 
effectiveness versus year. Data from [2]. The slope of the trend line is -0.0013/year. 
ANOVA test: H0 : slope= 0, F = 0.32, and p = 0.58. The null hypothesis that these 
residuals are independent of time cannot be rejected. 
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not fundamentally distinct with the original trend line. In the data point 1986-87 (b), 
the difference of the vaccine effectiveness predicted by these two models is 0.13, which 
is roughly one standard error. In reality, most Pepitope values are less than 0.1, and so 
most of the differences between these two predicted vaccine effectiveness values are 
less than 0.034, which is within the noise levels of the epidemiological measurements. 
The basis for calculating Pepitope is a set of well defined epitopes. An early defi-
nition of the five epitopes in H1 hemagglutinin [3] did not identify numerous amino 
acid positions in which mutations were frequently selected in history. These positions 
are presumably under strong antigenic pressure to be selected for escape mutation. 
The more recent definition of H1 epitopes incorporates these additional amino acid 
positions as well as amino acids from the epitopes of H3 hemagglutinin [1]. Likely 
additional experiments on the H1 epitopes will allow further refinement of the cal-
culation of Pepit()pe· Only nine epidemiological data points are available since the 
reemergence of H1N1 virus in humans in 1977. The Pepitope model parameters may 
be further improved as epidemiological data are accumulated. 
The antigenic properties are determined by a small number of amino acid sub-
stitutions, because the positions and the amino acids introduced by mutation have 
distinct effects on the change of antigenic distance between vaccine strain and domi-
nant circulating strain. For example, mutations yielding charged amino acids in the 
dominant epitope are favorable for the virus, and may be the key amino acid substi-
tution for the antigenic properties [132]. An improved sequence-based model might 
assign different amino acid substitutions with weights determined by the decrease of 
binding constant between HA and antibody using free energy calculation [94]. With 
the current knowledge, the less precise but safe Pepitope model assigns the amino acid 
substitutions in the dominant epitope with weight one, and assigns other amino acid 
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substitutions with weight zero. The Pepitope model can nevertheless correlate with 
the vaccine effectiveness better than the antisera data. That is, for both H1N1 and 
H3N2, the Pepitope method is superior to other methods in current use. 
2.5.4 Comparison of the Pepitope Model and the HI Assay for H3N2 Virus 
In some cases Pepitope model detects antigenic variants better than the HI assay. In 
the 2003-04 Northern hemisphere flu season, the majority of isolated H3N2 strains 
were similar to A/Fujian/411/2002 using HI assay [133], hence WHO recommended 
a A/Fujian/411/2002-like strain as the 2004-05 Northern hemisphere H3N2 vaccine 
component, and A/Wyoming/3/2003 was selected. Although A/Wyoming/3/2003 
is similar to A/Fujian/411/2002 circulating in 2004-05 ("antigenically equivalent" 
by HI data [134]), the vaccine effectiveness was only moderate [2]. Interestingly, 
the Pepitope between A/Fujian/411/2002 and A/Wyoming/3/2003 was also moderate 
(Pepitope = 0.095), predicting the moderate vaccine effectiveness. In fact, the Pepitope 
method can also detect antigenic variants more rapidly as they emerge [135]. 
Chapter 3 
Comment on Ndifon et al, "On the use of 
hemagglutination-inhibition for influenza 
surveillance: Surveillance data are predictive of 
influenza vaccine effectiveness" 
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. In 2006, Gupta et al. published an analysis of vaccine efficacy in humans for H3N2 
influenza A. We collected vaccine efficacy data from the epidemiological literature for 
years between 1971 and 2003. In total, 19 efficacy values were obtained. We deter-
mined correlations between vaccine efficacy and four measures of antigenic dist~nce. 
The first measure is the fraction of amino acid differences between the vaccine strain 
and the dominant circulating strain in the hemagglutinin HAl sequence, Psequence· 
The second measure is the fraction of amino acid differences between the dominant 
epitope of the vaccine and dominant circulating strain, Pepitope· The third measure is 
the logarithm base 2 of the ratio of homologous to heterologous titers, d1 [29]. The 
fourth measure is the square root of the ratio of the homologous titers to the heterol-
ogous titers, d2 [99]. The correlations of the different measures of antigenic distance 
with vaccine efficacy are shown in Table 3.1. 
In 2009, Ndifon et al. published an analysis of a subset of these data, 11 data 
points, with some modifications [136]. Four new data points were added: some early 
data from 1968 and 1969, data for 1980/1981, and recent data for 2004/2005. Data 
for 1971/1972, provided in [2], were omitted from [136]. 
There are a number of discrepancies in the data of Table 1 of Ndifon et al. [136]. In 
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1972/1973 the vaccine strain was listed as A/Hong Kong/1/68. The correct vaccine 
strain was A/Aichi/2/68 (also known as X31) [2, 137, 138]. A value of Pepitope of 
0.263 was listed in [136], rather than the correct 0.190 [2]. In 1994/1995, a dominant 
circulating strain of A/Shangdong/9 /93 was listed [136], rather than a mixture of 
strains that more closely resemble A/Johannesburg/33/94 than A/Shangdong/9/93 
[2, 139], and which we represent by the former [2]. A value of Pepitope of 0 was listed in 
[136], rather than 0.105 [2]. In 1995/1996 the vaccine efficacy was listed as 42.0% [136], 
rather than 45% [2]. In 1996, vaccine and circulating strains of A/Wuhan/359/95 
and A/Nanchang/933/95 were listed [136] instead of the correct A/Nanchang/933/95 
vaccine and A/Wuhan/359 /95 US CDC-determined circulating strain [2, 140, 141 J. In 
1997, the dominant circulating strain of A/Nanchang/933/95 was listed [136] instead 
of A/Wuhan/359 /95 [2, 141], leading to Pepitope of 0 [136] instead of 0.095 [2]. In 
1997/1998 a Pepitope value of 0.227 [136] was listed instead of the correct 0.238 [2]. 
The vaccine discrepancies in [136] stem from the incorrect assumption that the WHO 
"recommended" strain was administered, rather than the "like" vaccine strain that 
was actually manufactured and administered. Finally, in 2003/2004 efficacy data for 
individuals vaccinated within 2 weeks of illness were removed from the dataset, even 
though it is known that the immune response to influenza reaches quite high levels 
and influenza virus is suppressed within 2-3 days of exposure. A low efficacy value of 
0.8% [136] rather than 12% [2] was reported. 
Once these amendments are made, the 23 data in aggregate from [2, 136] reveal a 
correlation between vaccine efficacy and the Pepitope theory of R2 = 0.76 (see Figure 
3.1). We focus here on the difference between Pepitope and the rAHM measure of 
antigenic distance reported as correlating well with vaccine efficacy in [136]. We note 
that the definition of rAHM is identical to that of d2 • In [136], only half of the data 
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were used, those for which the vaccine and dominant circulating strain were distinct, 
a total of 11 data points. These 11 data points were used to test the Pepitope, Psequence, 
and d2 = rAHM measures of antigenic distance. With the corrections discussed 
above made, there are 14 data points fitting this criterion. If a large amount of 
vaccine efficacy data were available, removing a small subset of data would not be 
problematic. Removing 50% of the data, so that there are no data for small to 
moderate antigenic distances, lead to a number of artifacts. The first artifact is 
that the linear fit of r AHM to the 11 data points of vaccine efficacy extrapolates to 
a vaccine efficacy of 18% when the vaccine is identical to the dominant circulating 
strain, with R2 = 0.56 (see Figure 3.1, left insert). While the R2 is sizable, the 
prediction of 18% is discrepant from the average vaccine efficacy of 43% when the 
vaccine is identical to the dominant circulating strain. That rAHM does not predict 
moderate antigenic distances well is made clear when the rAHM data are fit to all 
years, with R2 = 0.54 instead of R2 = 0. 76 for the Pepitope theory. When Pepitope is 
fit to the amended 14 data points, the linear fit extrapolates to a vaccine efficacy of 
27% for an identical vaccine and dominant circulating strain (see Figure 3.1, right 
insert), with R2 = 0.27, not the nearly zero value reported in [i36]. The prediction 
of the Pepitope theory is more accurate than that of the rAHM measure on these 
out-of-sample data, although the correlation coefficient is lower. We note that 4 
out of the 6 points with Pepitope > 0.19 have a negative efficacy. This predictive 
ability is rather similar to that of the rAHM data, for which 4 out of the 5 points 
with rAHM > 5 have negative vaccine efficacy [136]. In the 2004/2005 season, both 
A/California/7 /2004 and A/Fujian/411/2002 were circulating strains, in addition 
. to a substantial amount of circulating influenza B. The antigenic distance between 
A/Wyoming/3/2003 and A/California/7 /2004 is Pepitope = 0.286, and the antigenic 
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distance between A/Wyoming/3/2003 and A/Fujian/411/2002 is Pepitope = 0.095. 
Thus, while the predicted efficacy for the former is not positive, for the latter it is 
20%. Antigenic distance for A/California/7/2004 alone cannot predict the expected 
vaccine efficacy against multiple nearly-dominant circulating strains. Indeed, the 
reported efficacy of 9.2% [136] is roughly the average of the 0% and 20% predicted 
efficacies from the Pepitope theory. When the 2004/2005 data point is eliminated, the 
Pepitope prediction extrapolates to 37% efficacy for identical vaccine and dominant 
circulating strain, with R2 = 0.46. 
In summary, the Pepitope theory is more accurate and has a larger R2 value than 
the rAHM ferret animal model data when all the human H3N2 influenza A vaccine 
efficacy data are considered. When trained on half of the data, the Pepitope theory 
more accurately predicts the out-of-sample, small and moderate antigenic distance 
efficacies than does the rAHM data. When the data point for the 2004/2005 season 
with multiple nearly-dominant circulating strains is removed, the Pepitope theory and 
rAHM data fit have similar R2 values on years for which the vaccine and dominant 
circulating strains are distinct. Both Pepitope and rAHM predict that vaccine efficacy 
decreases to zero beyond a critical antigenic distance, given by P:pitope = 0.19. We 
note that the Pepitope theory requires only sequence information, whereas rAHM is 
constructed from hemagglutinin inhibition data measured in ferrets. 
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Figure 3.1 : Vaccine efficacy versus the Pepitope or rAHM measures of antigenic dis-
tance. In inset are the data for which the vaccine and dominant circulating strain are 
distinct. 
Table 3.1 : Correlation of H3N2 Influenza A vaccine efficacy in humans with different 
measures of antigenic distance. 
Method Correlation Reference for data 
Pepitope 0.76 [2, 136] 
Psequence 0.59 [2] 
dl 0.57 [2] 
d2 0.43 [2] 
rAHM 0.54 [136] 
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Chapter 4 
The Epitope Regions of Hl-Subtype Influenza A, 
with Application to Vaccine Efficacy 
The recent emergence of H1N1 (swine flu) illustrates the ability of the influenza virus 
to create antigens new to the human immune system, even within a given hemagglu-
tinin and neuraminidase subtype. This new H1N1 strain is sufficiently distinct, for 
example, from the A/Brisbane/59/2007 (H1N1)-like virus strain of influenza in the 
2008/09 Northern hemisphere vaccine that protection is not expected to be substan-
tial. The human immune system responds primarily to the five epitope regions of the 
hemagglutinin protein. By determining the fraction of amino acids that differ between 
a vaccine strain and a viral challenge strain in the dominant epitope regions, a mea-
sure of antigenic distance that correlates with epidemiological studies of H3 influenza 
A vaccine efficacy in humans with R2 = 0.81 is derived. This measure of antigenic 
distance is called Pepitope· The relation between vaccine efficacy and Pepitope is given 
byE= 0.472.47 x Pepitope· We here identify the epitope regions of H1 hemagglutinin, 
so that vaccine efficacy may be reliably estimated for H1N1 influenza A. 
4.1 Introduction 
The recent outbreak of H1N1 (swine flu) has caused immediate international concern. 
From its earliest case in mid-March 2009 to mid-May 2009, 80009000 infections and 
7080 deaths were recorded in 4050 countries and regions, and as of mid-May, over 
90% of infections and deaths were in Mexico and the USA [14]. Historically, three 
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subtypes of influenza A virus have been able to circulate in the human population. 
The Spanish flu pandemic in I9I8-20 was HINI, which circulated in the world until 
I957. HINI reappeared in I977 and persists today [I6]. The Asian flu pandemic 
in I95658 was H2N2, which spread widely in the human population during the time 
interval I957-68 [I7]. The Hong Kong flu pandemic in I968-69 was H3N2, which 
has circulated in the human population as the dominant subtype until recently [I7]. 
Other subtypes rarely infected humans, although cases of H5NI and H9N2 have been 
reported. 
The 2009 swine flu virus possesses HI hemagglutinin {HA) and NI neuraminidase 
on the surface of the virion, of which the hemagglutinin is the main target of host 
antibodies. The human immune system responds primarily to the five epitope re-
gions of the hemagglutinin protein [27, 28]. Host antibodies bind to five epitopes in 
hemagglutinin and lead to high escape evolution rates of amino acids in the epitopes. 
An early identification of HI epitopes was carried out by antibody mapping of the 
A/PR/8/I934 {HI) hemagglutinin, with an additional study of laboratory mutations 
[3]. However, these HI epitopes contain far fewer amino acids than do the epitopes 
in H3 determined by modern methods [28] and are incomplete. Alignment of HI 
strains in I9I8-2009 indicates many mutation positions outside the originally identi-
fied epitopes. We here use sequence alignment and information entropy to complete 
the definition of HI epitopes. 
Vaccination is an effective way to reduce the influenza morbidity and mortality. 
The efficacies of influenza vaccines vary from year to year, in part due to different 
antigenic distances between the circulating influenza strains and the vaccine. Anti-
genic distance between a vaccine strain and a viral strain can be estimated by the 
number of mutations in the hemagglutinin sequence between the two strains [29, 30]. 
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Ferret animal model studies are used to further refine the notion of antigenic distance. 
These methods correlate with epidemiological studies of vaccine efficacy in humans 
with R2 = 0.59 and 0.43-0.57, respectively [2, 31]. By considering only those mu-
tations that occur in the dominant epitope, the Pepitope theory provides a prediction 
of vaccine efficacy that correlates with epidemiological studies of vaccine efficacy in 
humans with R2 = 0.81. 
Vaccine efficacy has a linear correlation with the antigenic distance between the 
vaccine strain and the circulating virus strain [2, 31]. Since Pepitope correlates well with 
influenza vaccine efficacy in humans, it can be used to estimate antigenic distance. 
For example, when Pepitope is larger than 0.19, the vaccine no longer offers protection. 
This correlation can be used to find optimal strains for vaccine design with minimal 
antigenic distance from expected circulating strains. Here we calculate the antigenic 
distance for H1 influenza A and apply the method to evaluate efficacy of a candidate 
swine flu vaccine. 
4.2 Methods 
4.2.1 Mapping the Epitope from H3 Hemagglutinin to Hl Hemagglutinin 
In this chapter, the amino acid positions ofHl (A/PR/8/1934) and H3 (A/ Aichi/2/1968) 
hemagglutinin are denoted using H1 and H3 numbering, respectively [142, 143]. Two 
hemagglutinin sequences of A/PR/8/1934 (H1) and A/ Aichi/2/1968 (H3) are· aligned 
using ClustalW. Amino acids in H1 sequence corresponding to epitope A-E in H3 are 
defined as mapped epitope A-E in Hl. Similarity between H3 epitopes and corre-
sponding mapped H1 epitopes was verified by aligning their three-dimensional struc-
tures (PDB code: H3 = 1HGF and H1 = 1RU7). The RMSD values of alpha carbons 
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in five epitopes between H3 and H1 are 2.18, 0.63, 1.19, 2.43 and 1.90 A, respectively. 
The HA alignment of A/California/04/2009 with A/PR/8/1934 and of A/California/ 
04/2009 with A/ Aichi/2/1968 shows that neither A/PR/8/1934 nor A/ Aichi/2/1968 
has a gap-free alignment with A/California/04/2009. Thus, a new numbering scheme 
is required for the 2009 H1N1 ('swine flu') hemagglutinin. The new numbering starts 
at the same amino acid position as the H1 numbering [142, 143]. Amino acid 130 in 
A/California/04/2009 corresponds to a gap in A/PR/8/1934, indicating that amino 
acid position > 130 in A/California/ 04/2009 has the number equal to 1 plus the 
corresponding number of the amino acid in A/PR/8/1934. In Table 4.1, we use 
the A/California/04/2009 numbering scheme. HA alignment of swine flu strains de-
posited in NCBI and GISAID up until18 May 2009 shows that no mutation occurred 
in amino acid 130. By examining the three-dimensional structure of A/PR/8/1934 
(PDB code: 1RU7), we find that amino acid 129 (A/PR/8/1934 numbering) is ex-
posed and position 130 is partially buried inside the molecule. Consequently, although 
amino acid 130 (A/California/04/2009 numbering) in swine flu HA may or may not 
be significant to antibody binding, we have no evidence that it is in the epitope. 
4.2.2 Extension of mapped epitope using entropy method 
The definition of information entropy of site k is 
20 
S(k) =-"" ni ln ni ~N N 
i=l 
where ni is the number of times that amino acid i (i = 1-20) is found in site k of the 
aligned full-length strains. N is the number of those full-length sequences, equal to 
2294. 
The threshold of the information entropy values to identify epitopes is determined 
adaptively. Amino acids in epitopes are under immune pressure selection and evolve 
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to avoid recognition by antibodies, yielding large information entropy values for amino 
acids in epitopes among all H1 strains. Additionally, classical epitopes are defined 
to be on the surface of the three-dimensional structure of the hemagglutinin. We 
decreased the entropy threshold until amino acids inside the structure constitute a 
significant proportion of those amino acids newly incorporated into the epitopes. 
Here, we select 0.075 as the threshold. 
4.2.3 Phylogenetic Tree and Its Root 
Three hundred and twenty H1N1 swine flu protein sequences as of 18 May 2009 
were downloaded from the NCBI and GISAID databases. ClustalW is applied to 
align these strains. Two hundred and sixty-six sequences containing residues 27324 
(A/California/04/2009 numbering, modified from [3]) were used to create the phylo-
genie tree with PHYLIP [144]. Two hundred and sixty-six subsequences that included 
residues 27-324 were extracted, and duplicated subsequences were removed. The 23 
unique aligned subsequences were then used as the input of the program PHYLIP. 
The distance matrix from protein sequences (protdist) and the Fitch-Margoliash and 
least squares methods with evolutionary clock (kitsch) [144] were sequentially applied 
to generate the phylogenie tree in Figure 4.1. The output of protdist is the input of 
kitsch. In the phylogenetic tree, the strain A/California/07/2009 (FJ966974) is one 
of the outgroups, which are closest to the root. 
4.2.4 Calculation of Pepitope 
The antigenic distance between two strains is calculated from the amino acid sequence 
in five epitopes of hemagglutinin. For each epitope, the P-value is defined as the 
proportion of different amino acids between these two strains. The largest of the 
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Figure 4.1 : Phylogenetic tree of swine flu hemagglutinins deposited in NCB! and 
GISAID until 18 May 2009. For each tip containing over two strains, representative 
strains are marked. 
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five P-values is defined as Pepitope, and the corresponding epitope is defined as the 
dominant epitope [2, 31]. 
4.3 Results 
4.3.1 Antigenic Distance 
As of 18 May 2009, there are 320 HlNl swine flu strains in the NCB! and GISAID 
databases, and we focus on the interval covering residues 27-324 (A/California/04/2009 
numbering, modified from [3]) in 266 of 320 sequences covering this interval. Among 
these 266 sequences, the closest strain to the root of a phylogenetic reconstruction 
[144] is A/California/07/2009 (FJ966974) (Figure 4.1). There are 20 mutations in 
the population of sequences, referenced to this strain, with a maximum Hamming 
distance of 4. Using the Pepitope method, we find the largest Pepitope value is 0.059 
(dominant epitope = E). A/California/04/2009 {FJ966082) is a candidate for vac-
cine design. There are 20 mutations in the population of sequences, referenced to 
A/California/04/2009, with a maximum Hamming distance of 5. The largest Pepitope 
value between this candidate strain and all sequences deposited to date is 0.059 (dom-
inant epitope = E), suggesting a worst-case vaccine efficacy against strains deposited 
to date of 69.1% of that of a perfect-match, Pepitope = 0, vaccine. 
4.3.2 Epitope Identification 
To construct Pepitope for HlNl, the identities of the epitope regions in Hl are needed. 
An early antibody mapping experiment on the PR/8 strain of HlNl identified 9, 
6, 6, 5 and 6 amino acids belonging to the five epitopes Sa, Sb, Cal, Ca2 and Cb, 
respectively [3]. These Hl epitopes map by sequence homology to the H3 epitopes 
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B+D, B, C+D, A+D and E, respectively. Interestingly, for those H1 epitopes that 
map to multiple H3 epitopes, individual antibodies bound to all H1 epitopes mapping 
to the same set of H3 epitopes, suggesting that the identification of the H1 epitopes 
may be subject to refinement. The number of amino acids determined by antibody 
mapping to be in the five epitope residues of H1 is about one-third of the number of 
amino acids identified in the five epitopes of H3 influenza A [29, 30]. 
We determined the likely remaining members of the five epitope regions in H1 by 
information entropy methods. On 5 May 2009, we downloaded all 2735 H1 human 
influenza A strains from NCBI. We retained the 2294 full-length sequences. We 
constructed a sequence entropy diagram (Figure 4.2) from these data. The refined 
H1 epitopes were constructed by (i) mapping the known H3 epitopes [29, 30] to the H1 
sequence, in rough agreement with the skeleton of sites identified by early antibody 
mapping experiments [3] (sequence mapping determined by ClustalW alignment of 
A/PR/8/1934 to A/ Aichi/2/1968), and (ii) 31 additional sites identified as being 
under selective immune pressure, on the surface of the hemagglutinin protein, and 
with information entropy values> 0.075. 
Interestingly, eight amino acids were identified with information entropy > 0.075 
that were outside the conventional definition of epitopes. Three of these were in the 
tail region of the hemagglutinin (positions 3, 314 and 320, numbering as in [3]). The 
other five were not surface residues ( positions 61, 174, 233, 248 and 249) (Figure 
4.3). Although these residues can affect the geometry at the surface, and so can be 
under selective pressure, they are not available for presentation to antibodies and so 
cannot be within a classically defined antibody epitope. 
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Figure 4.2 : Sequence entropy for the human strains of Hl (A/PR/8/1934 numbering, 
as in [3]). Positions belonging to predicted epitopes are color coded by the epitope 
identity. 
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Figure 4.3 : Color-coded epitopes in the Hl structure (PDB code: 1RU7) . 
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Table 4.1 : Amino acids in epitopes A, B, C, D and E of HI (A/California/04/2009 
numbering, modified from [3]). For A/PR/8/1934 numbering, amino acid numbers 
above 130 would have 1 subtracted from them. 
Epitope Amino acids 
A 118 120 121 122 126 127 128 129 132 133 134 
135 137 139 140 141 142 143 146 147 149 165 
252 253 
B 124125152153154155156157160162183 
184 185 186 187 189 190 191 193 194 195 196 
c 34 35 36 37 38 40 41 43 44 45 269 270 271 272 
273 27 4 276 277 278 283 288 292 295 297 298 
302 303 305 306 307 308 309 310 
D 89 94 95 96 113 117 163 164 166 167 168 169 
170 171172 173 174 176 179 198 200 202 204 
205 206 207 208 209 210 211 212 213 214 215 
216 222 223 224 225 226 227 235 237 239 241 
243 244 245 
E 47 48 50 51 53 54 56 57 58 66 68 69 70 71 72 73 
74 75 78 79 80 82 83 84 85 86 102 257 258 259 
260 261 263 267 
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4.4 Discussion 
With the epitopes in H1 identified, Pepitope can be constructed for H1 influenza A. 
The parameter Pepitope provides a quantitative definition of antigenic distance. With 
this measure of antigenic distance, vaccine strains as 'close' as possible to potential 
circulating strains can be identified. This capability should be useful in the design of 
the H1N1 component of the annual influenza vaccine. This capability should also be 
useful for special situation H1N1 vaccines, such as a vaccine for the recently emerged 
swine flu. 
The Pepitope measure of antigenic distance can be used to estimate vaccine efficacy. 
Vaccine efficacy is (u- v) ju, where u is the probability (or rate) that unvaccinated 
people are infected and v the probability (or rate) that vaccinated people are infected. 
By analogy with the H3N2 study [2, 31], we expect vaccine efficacy will be well 
predicted by the equation E = 0.47- 2.47 x pepitope. This equation predicts, for 
example, that a single mutation in dominant epitope B would lead to a vaccine efficacy 
that is 76.1% of that of a perfect match between vaccine and virus. This equation 
also predicts that vaccine efficacy is no longer positive for Pepitope > 0.19. 
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Chapter 5 
Quantifying Selection and Diversity in Viruses by 
Entropy Methods, with Application to the 
Hemagglutinin of H3N2 Influenza 
Many viruses evolve rapidly. For example, hemagglutinin of the H3N2 influenza A 
virus evolves to escape antibody binding. This evolution of the H3N2 virus means 
that people who have previously been exposed to an influenza strain may be infected 
by a newly emerged virus. In this chapter, we use Shannon entropy and relative 
entropy to measure the diversity and selection pressure by antibody in each amino acid 
site of H3 hemagglutinin between the 1992-1993 season and the 2009-2010 season. 
Shannon entropy and relative entropy are two independent state variables that we 
use to characterize H3N2 evolution. The entropy method estimates future H3N2 
evolution and migration using currently available H3 hemagglutinin sequences. First, 
we show that the rate of evolution increases with the virus diversity in the current 
season. The Shannon entropy of the sequence in the current season predicts relative 
entropy between sequences in the current season and those in the next season. Second, 
a global migration pattern of H3N2 is assembled by comparing the relative entropy 
flows of sequences sampled in China, Japan, the USA, and Europe. We verify this 
entropy method by describing two aspects of historical H3N2 evolution. First, we 
identify 54 amino acid sites in hemagglutinin that have evolved in the past to evade 
the immune system. Second, the entropy method shows that epitopes A and B in 
the top of hemagglutinin evolve most vigorously to escape antibody binding. Our 
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work provides a novel entropy-based method to predict and quantify future H3N2 
evolution and to describe the evolutionary history of H3N2. 
5.1 Introduction 
A common strategy by which viruses evade pressure from the immune system is to 
evolve and change their antigenic profile. Viruses with a low evolutionary rate that 
infect only humans, such as the small pox virus [35], can be effectively controlled 
by vaccinating the human population. By contrast, viruses with a high evolutionary 
rate, such as HIV, hepatitis B, and influenza A, resist being eliminated by the immune 
system by generating a plethora of mutated virus particles and causing chronic or 
repeated infection. In this study, we take subtype H3N2 influenza A virus as a model 
evolving virus. Influenza A virus circulates in the human population every year, 
typically causing 3-5 million severe illnesses and 250,00Q-500,000 fatalities all over 
the world [14]. Hemagglutinin (HA) and neuraminidase (NA) are two kinds of virus 
surface glycoproteins encoded by the influenza genome. The subtype of influenza is 
jointly determined by the type of hemagglutinin ranging from Hl to Hl6, and that 
of neuraminidase ranging from Nl to N9. On the surface of the virus membrane, 
HA exists as a cylindrical trimer containing three HA monomers, and each monomer 
comprises two domains, HAl and HA2. Hemagglutinin is also a key factor in virus 
evolution, because it is the major target of antibodies, and HA escape mutation 
changes the antigenic character of the virus presented to the immune system. The 
H3N2 virus causes the largest fraction of influenza illness. H3 hemagglutinin is under 
selection by the immune response mainly on the five epitope regions in the HAl 
domain [36], labeled epitopes A toE, as shown in Figure 5.1. The immune pressure 
and the escape mutation drive the evolution of the H3N2 virus. The underlying 
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mutation rate of the HA gene is 1.6 x w-5 /amino acid position/ day [37], measured 
using the method modified from that in an earlier study on the HA mutation rate [38]. 
Note that the mutation rate does not necessarily equal to the evolution rate, or the 
fixation rate. The mutation rate equals to the evolutionary rate only if the evolution 
is neutral. The non-neutrality of the HA evolution is shown in the Results section. 
Evolution of the hemagglutinin viral protein causes occasional mismatch between the 
virus and the vaccine and decreases vaccine effectiveness [2, 34]. As more amino acid 
substitutions are introduced into influenza sequences, the antigenic characteristics of 
influenza strains drift away [39], and influenza epidemic severity of subtype H1N1 [40] 
and subtype H3N2 [41] increases. 
The H3N2 virus has a distinguished evolutionary history, largely affected by the 
immune pressure. The H3N2 virus emerged in the human population in 1968 and has 
been circulating in the population since 1968. The phylogenetic tree of H3 hemag-
glutinin since 1968 has a linear topology in which most sequences are close to the 
single trunk of the tree, and the lengths of the branches are short [42, 30, 43]. His-
torical hemagglutinin sequences fall into a series of clusters, each of which has similar 
genetic or antigenic features and circulates for 2-8 years before being replaced by 
the next cluster [44, 30]. The evolution of different amino acid positions of hemag-
glutinin shows a remarkable heterogeneity: a subset of positions undergo frequent 
change, while some positions are conserved [4]. This heterogeneity is quantified by 
the Shannon entropy at each position of the amino acid sequence of hemagglutinin [1]. 
Shannon entropy has been used to locate protein regions with high diversity, such as 
the antigen binding sites ofT-cell receptors [45]. Shannon entropy has been used to 
identify antibody binding sites, or epitopes, which are under immune pressure and so 
are rapidly evolving [1]. The heterogeneity of amino acid substitution suggests that 
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Figure 5.1 : The tertiary structure of the HAl domain of H3 hemagglutinin (PDB 
code: lHGF). The surface of HAl facing outward is the exposed surface when the 
hemagglutinin trimer is formed. The other two HAl domains (not shown) in the 
HA trimer are located at the back of the structure displayed here. The solid balls 
represent five epitopes. Color code: blue is epitope A, red is epitope B, cyan is epitope 
C, yellow is epitope D, and green is epitope E. 
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point mutations randomly occurring in distinct positions have different contributions 
to the virus fitness. 
The selection pressure on the H3N2 virus to evolve is reflected in the difference 
between the H3 hemagglutinin sequences in two consecutive seasons. We consider 
Northern hemisphere strains. When the epidemic initiates in a new season, we assume 
that each position of an HA sequence inherits the amino acid from a sequence of the 
previous season or has a different amino acid due to random mutation and selection. 
This assumption comes from the fact that the H3N2 virus circulating in each influenza 
season migrates from a certain geographic region in which the virus is preserved 
between two influenza seasons [43, 32]. In the absence of selection, the histogram of 
the 20 amino acid usage in one position in the current season is similar to that in 
the same position in the previous season except for changes due to the small random 
mutation rate. The difference between the two histograms beyond that expected due 
to mutation quantifies selection. 
Synthesizing these factors, we introduce an entropy method to describe the evolu-
tion of influenza. The entropy method extracts an evolutionary pattern from aligned 
sequences. Shannon entropy quantifies the amount of sequence information in each 
position of aligned sequences [46, 47]. The sequence information reflects the varia-
tion, which is equivalently diversity, in each position, and so Shannon entropy has 
been used to measure the diversity in each position [48, 49, 50]. Shannon entropy 
has also been used to measure the structural conservation in the protein folding dy-
namics [51, 52]. See [53] for a detailed review of the applications of Shannon entropy. 
On the other hand, relative entropy measures gain of sequence information at each 
position and requires a background amino acid frequency distribution [54]. Relative 
entropy was also used as a sequence conservation measure to detect functional pro-
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tein sites [55, 56]. Further, a dimension reduction technique using relative entropy 
has identified sectors in proteins [57, 56]. As an extension of these previous works, 
we apply Shannon entropy and relative entropy to jointly measure two quantities in 
each position: sequence information in one season and gain of sequence information 
from one season to the next season. Simultaneous analysis of Shannon entropy and 
relative entropy sheds light on the evolutionary pattern of the H3N2 virus evolution 
when data from multiple seasons are available. In the HAl domain, positions in the 
epitope regions have increased Shannon entropy, and this feature was applied to lo-
cate the epitopes of Hl hemagglutinin [1]. We here use Shannon entropy to quantify 
the virus diversity in each amino acid position in each season. The entropy relative 
to the previous season [58] is also used to analyze the evolution of the HAl domain 
in one single season and to quantify the selection pressure on the virus in each amino 
acid position in each season. The selection and the virus diversity are two significant 
state variables determining the dynamics of evolution. 
The chapter is organized as follows. The Materials and Methods section presents 
the data used in this work and details of the entropy model. The Results section uses 
Shannon entropy of the sequence in one season to predict the evolution quantified 
by relative entropy from this season to the next season. Results are also presented 
for the flow of virus migration between the four geographic regions of China, Japan, 
the USA, and Europe. In the Result section, we demonstrate the entropy method in 
two applications, the results of which agree with prior knowledge on H3N2 evolution. 
Finally, we discuss our results and present our conclusions. 
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5.2 Materials and Methods 
5.2.1 Sequence Data 
The hemagglutinin sequences considered in this work are the amino acid sequences 
of the hemagglutinin of human influenza A H3N2 virus. We only use Northern Hemi-
sphere sequences because 90% of the world population lives in Northern Hemisphere. 
The influenza season in Northern Hemisphere is defined as the time interval from 
October in one year to September in the next year. We downloaded 5309 North-
ern Hemisphere sequences labeled with month of collection from the NCBI Influenza 
Virus Resource on 16 January 2011. Sequences too short to cover residues 1-329 of 
hemagglutinin were removed, and the remaining sequences were trimmed to only keep 
residues 1-329 in the HAl domain. Any sequence with an undefined amino acid in 
residues 1-329 was removed. We consider 18 seasons from 1992-1993 to 2009-2010 
during which most available sequences were collected. In total, we preserved and 
aligned 4292 sequences in these 18 seasons containing amino acids 1-329. 
5.2.2 Histograms of 20 Amino Acids 
The first step is to quantify the alignment of the amino acid sequences. The aligned 
historical H3 hemagglutinin sequences form a matrix A with 4292 rows and 329 
columns. The element A 1,j denotes the identity of the amino acid in sequence l 
and position j. The 4292 sequences were clustered into 18 groups by the seasons 
of sampling from the 1992-1993 season to the 2009-2010 season. Note that most of 
the sequences before the 1992-1993 season were not labeled with month of collection 
and are excluded from this study. We denote by i = 0, 1, ... , 17 the seasons between 
1992-1993 and 2009-2010. For position j in season i, the relative frequency of each 
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amino acid k, f (k, i, j), k = 1, ... , 20, was calculated from the vector Aiti),j where 
the index array l( i) holds the indices of sequences sampled in season i. 
5.2.3 Shannon Entropy as Diversity 
The Shannon entropy is one useful quantification of the diversity in single position. 
Large Shannon entropy has the physical meaning that the amino acid in the given 
position is prone to be substituted. This physical meaning was also applied in [1]. 
The diversity at a single position takes the format of Shannon entropy because of the 
sensitivity of Shannon entropy to diversity. 
This physical meaning of the Shannon entropy does not necessarily involve the 
joint frequency distributions for two and more positions, and we do not consider the 
joint frequency in the manuscript. Rather, we define the diversity only in the level 
of single amino acid position. Consequently, the defined diversity is additive for a 
number of positions. The idea of adding diversity in each position of the sequence 
comes from classic works such as [46], which added the Shannon entropy in each 
position to measure the total diversity in an aligned binding site. 
Therefore, diversity of the virus in each position in each season is represented by 
the Shannon entropy that quantifies the amount of information in the histogram or 
distribution under study. For the sequences sampled in all the seasons, positions with 
high evolutionary rate have a higher Shannon entropy compared to the conserved 
positions [1]. The sequences in each season are assumed to be collected concurrently. 
The Shannon entropy is a quantification of diversity of amino acids in one position, 
and so the diversity in position j in season i is calculated from the histogram f ( i, j) = 
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[f (1, i, j), ... , f (20, i, j)]T by Shannon entropy 
20 
Di,j =- Lf(k,i,j)logf(k,i,j) (5.1) 
k=l 
in which k = 1, ... , 20 is the identity of the amino acid in position j in season i. 
5.2.4 Relative Entropy as Selection Pressure 
Selection in each position j in season i is reflected by the significant difference between 
the 20-bin histogram in the current season f (i,j) and that in the previous season 
f (i- 1, j). In the absence of selection, random mutation and genetic drift are the 
dominant forces generating f (i,j) from f (i- 1, j). In each position, random mutation 
creates a slightly modified histogram, from which amino acids are randomly chosen 
to appear in season i by the effect of genetic drift. 
The source of random mutation is the spontaneous error of the RNA polymerase 
replicating the influenza virus RNA. The random mutation rate in different regions 
of hemagglutinin is thought to be homogeneous, regardless whether the regions are 
in antigenic sites or not [145]. Therefore random mutation is modeled as a Poisson 
process M (f..l, g ( k)) equally affecting all the positions. Here f..l is the mutation rate of 
influenza A virus that equals to 5.8x 10-3 /residue/season [37], and g (k), k = 1, ... , 20 
is the relative frequency of each amino acid in the whole alignment A. The probability 
that the original amino acid t mutates to amino acid u is 
f..l9 (u) 
Mu,t(f..l,g) = 1 _ g (t)" (5.2) 
So after mutating for one season, the histogram in position j in season i -1 is obtained 
by 
f (i,j) = M (J.L,g) f (i- 1,j). (5.3) 
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This histogram serves as the background distribution for season i from which the 
sequences in season i are built. 
If selection is absent, the effect of genetic drift is to create sequences in the current 
season by randomly choosing amino acids in each position from a background distri-
bution f (i,j). We denote by Ni the number of sequence in season i. The probability 
that Ni amino acids in position j have the histogram f (i,j) is [56] 
(5.4) 
where 
s - ~f(k. ")1 f(k,i,j) i,j - L..J , t, J og fA (k . .) 
k=l 't, J 
(5.5) 
is the relative entropy between the observed histogram, f (k, i, j), and the background 
histogram, j (k, i, j) [58]. 
The null hypothesis that selection is absent in the evolution is rejected if the 
relative entropy Si,j is great enough such that the probability in Equation 5.4 is less 
than 0.05, that is, the relative entropy Si,j is greater than -log (0.05) /Ni in season 
i. Note that the majority of residues were stable in most of the seasons, and in this 
case the relative entropy is Si,j = log (1/ (1- J.L)) ~ f..L· To avoid classifying these 
stable residues erroneously as positions under selection, a proper threshold of relative 
entropy needs to be larger than the mutation rate J.L. Additionally, a fraction >. of the 
circulating HAl sequences were not deposited in the database because of the sampling 
bias of the HAl sequences. In an extreme case, in a stable position j with the real 
histogram of 20 amino acids [1- >., >., ... , O]T in all the seasons, the histograms of the 
sequences sampled in two consecutive seasons i-1 and i are f (i- l,j) = [1, 0, ... , O]T 
and f ( i, j) = [1 - >., >., ... , O]T, respectively, and so the relative entropy introduced 
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by the sampling bias is 
. 1- >. >. 
sblas ~ (1- >.)log--+ >.log /19 
l-JL J.l 
(5.6) 
in spite of the absence of selection in position j in season i. The relative entropy Sbias 
equals to 0.1 if a sampling bias >. = 2.5% exists in the HAl database sequences. We 
fix the threshold of the relative entropy in season i to 
{ 1->. >. } s:hres = max -log (0.05) I Ni, (1 - >.)log 1 - J.l + A log JL/19 ~ max {3/ Ni, 0.1} . 
(5.7) 
The numbers of collected HAl sequences Ni were fewer than 30 only in the 1995-1996 
season (i = 3) with N3 = 25. The thresholds S~hres = 0.12 > 0.1 in the 1995-1996 
season due to the small numbers of HAl sequences. In all the other 17 seasons, the 
numbers of sequences Ni were greater than 30, and so the thresholds s;hres = 0.1. 
5.3 Results 
In this section, we show the positive correlation between the Shannon entropy in sea-
son i and the relative entropy from season i to season i + 1. This correlation means 
that the larger the virus diversity in one season, the higher the virus evolutionary 
rate from this season to the next season. We draw the H3N2 migration pattern by 
comparing the relative entropy. The migration pattern reveals a novel migration path 
from the USA to Europe and shows that the virus evolutionary rate is higher in the 
epicenter, China, than in the migration paths. We also demonstrate the entropy 
method in two applications. First, we compute average Shannon entropy and relative 
entropy in each position over the past 17 seasons to identify positions under selection 
pressure. Second, we compare Shannon entropy and relative entropy in epitope re-
gions to find the contribution of each epitope to the H3N2 evolution. Results of these 
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two applications agree with previous studies and additionally show the heterogeneity 
of the selection pressure over different amino acid positions of hemagglutinin, with 
increased pressure in the epitopes, as well as the dominance of epitopes A and B. 
5.3.1 Correlation between Shannon entropy and relative entropy 
Relative entropy Si+l,J in amino acid position j from season i to season i+ !linearly in-
creases with Shannon entropy Di,j in position j in season i. For the sequences sampled 
from the 1992-1993 season (i = 0) to the 2008-2009 season (i = 16), 329 x 17 = 5593 
ordered pairs (Di,j, Si+l,J) are calculated. All except two pairs fall into 8 bins in which 
the values of Di,j belong to 8 intervals [0, 0.1), [0.1, 0.2), ... , [0.7, 0.8), respectively. 
The first bin with Di,j in [0, 0.1) is discarded because it contains numerous conserved 
amino acid positions. The values of Si+l,J are averaged respectively in each of the 
7 remaining bins. As described in Figure 5.2, average relative entropy in each bin 
shows positive correlation with midpoints of the Di,J interval, R2 = 0. 70. An amino 
acid position j with high Shannon entropy Di,J in season i is expected to present high 
relative entropy Si+l,i from season i to i + 1. The evolution in position j from season 
i to i + 1 quantified by relative entropy is therefore predicted using the mean and· 
standard error of Si+l,J in the bin chosen by Di,J in season i. 
Positive correlation is also observed between the mean values of Di,J and Si+l,J in 
a variety of positions j in each season i. In each season between 1992-1993 (i = 0) 
and 2008-2009 (i = 16), we average the Shannon entropy Di,J and relative entropy 
Si+l.i over the positions j with Di.i > 0.1. The data point with i = 1, (0.22, 1.38), 
has a large standard error of the relative entropy Si+l,J and is excluded in the analysis 
below. The remaining average Shannon entropy (D)i (i = 0, 2, ... , 16) correlates with 
average relative entropy (S)i+1 ( i = 0, 2, ... , 16) with R2 = 0.50, as shown in Figure 
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5.3. A least squares fit gives (S)i+1 = 1.82(D)i - 0.23. Thus, the expected average 
relative entropy from the current season i to the next season i + 1 can be calculated 
from the average Shannon entropy (D)i in the current season i. 
The above relationships between Shannon entropy and relative entropy cannot be 
generated by a neutral evolution model. To demonstrate this result, we create an 
ensemble of 1000 identical sequences with 50 amino acid positions. Each iteration of 
the model simulates H3N2 evolution during one season. In each iteration, the number 
of mutated amino acids Nmut in each sequence follows a Poisson distribution with 
mean 1-L = 2.0, which is the annual substitution rate in history. The Nmut mutated 
positions are then randomly assigned in the corresponding sequence. We randomly 
select Pcut = 10% of the sequences to build the sequence ensemble in the next iteration. 
The Shannon entropy Di,J and relative entropy Si+l,J generated in iteration i = 51-
100 are processed using the same method as for H3 sequences in history. First, as 
shown in Figure 5.2, no increasing trend appears in the means of Si+l,J in the 7 bins 
from [0.1, 0.2) to [0.7, 0.8). Second, no correlation (R2 = 0.003) is observed between 
(D)i and (S)i+b see Figure 5.3. When we change the parameters 1-L between 1.0 and 
10 and Pcut between 1% and 100% in the algorithm, the simulation still does not yield 
the visible increasing trend in Figure 5.2 or the correlation observed in Figure 5.3. As 
a result, we conclude that neutral evolution alone is not able to generate the pattern 
between Shannon entropy and relation entropy of H3 sequences. It was previously 
shown that the fixation rate of H3N2 evolution cannot be explained only by neutral 
evolution [4]. In this study, the monotonically increasing linear relationship between 
relative entropy and Shannon entropy in Figure 5.2 and 5.3 suggests that selection 
pressure substantially contributes to H3N2 evolution. 
1rr=~==~==~==~--P-----~--. 
c::: 
::0 
.s::. 0.8 
~ 
CD 0 7 
.5 . 
~0.6 
e 
-!5 0.5 
~ 0.4 
~ 
CD 0.3 
~ ~ 0.2 
c( 
0.1 
00 
---;:r- H3 data 
- * - Neutral evolution model 
, , i ---r- --! - - -I 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 
Bins of Shannon entropy 
87 
Figure 5.2 : Mean and standard error of relative entropy Si+l,i in each bin of Shannon 
entropy. Shannon entropy and relative entropy in each of the 329 positions and in 
each of the 17 seasons between 1992-1993 ( i = 0) and 2008-2009 ( i = 16) fall into one 
of the eight bins. The first bin with Shannon entropy less than 0.1 is discarded. Bins 
with larger Shannon entropy Di,i also have larger relative entropy Si+l,i· Shannon 
entropy Did and relative entropy Si+l,i in iteration i = 51-100 of the neutral evolution 
model are used to calculate mean and standard error of relative entropy in each bin 
of Shannon entropy distribution in the same way. No increasing trend is found. Error 
bar is one standard error. 
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Figure 5.3 : Average Shannon entropy (D)i versus average relative entropy (S)i+1 for 
each season between 1992-1993 (i = 0) and 2008-2009 (i = 16). For each season i, a 
set of amino acid positions j with Shannon entropy Di,j greater than 0.1 are chosen. 
For all the j in this set of positions, (D)i is the average of the Shannon entropy 
Di,j values and (S)i+I is the average of relative entropy Si+l,j values. Horizontal and 
vertical error bars are the standard errors of Shannon entropy and relative entropy, 
respectively. The solid line, (S)i+I = 1.82(D)i- 0.23, is a least squares fit of (D)i to 
(S)i+1 (i = 0, 2, ... , 16). A strong correlation with R2 = 0.50 exists between (D)i and 
(S)i+I excluding the point (0.22, 1.38) with Ni = 1, which has a large standard error 
of the relative entropy Si+l,j· Using the same method, (D)i and (S)i+1 are calculated 
from a neutral evolution model, i = 51-100, and plotted. No visible correlation exists 
between (D)i and (S)i+I from the neutral evolution model. 
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5.3.2 Annual Virus Migration 
The entropy method is also used to analyze the global migration pattern of the virus. 
Most of the Northern Hemisphere H3 sequences were collected in East-Southeast 
Asia, the USA, and Europe. East-Southeast Asia is suggested to be the reservoir 
of the annual H3N2 epidemic [43]. To increase the geographic resolution in East-
Southeast Asia,. we use two regions, China and Japan, as the representative of East-
Southeast Asia, because each of these regions has a population over 50 million and 
has a consistent time series of H3 sequence data from the 2001-2002 to the 2007-2008 
season. 
We select the sequences in four geographic regions that are China, Japan, the USA, 
and Europe in seven seasons from 2001-2002 to 2007-2008. In all the six pairs of 
consecutive seasons, we calculate for each region four average relative entropy values 
of the whole sequence. These four average relative entropy values are calculated using 
the sequences in each of the four regions in the previous season as the reference. The 
results are shown in Table 5.1. Sequences collected in China in the previous season 
yield the minimum relative entropy to the sequences in the current season collected 
in China (p < 2.1 x 10-5 , Wilcoxon signed-rank test), Japan (p < 0.0049, Wilcoxon 
signed-rank test), and the USA (p < 0.0012, Wilcoxon signed-rank test). Sequences in 
the USA in the previous season have the minimum relative entropy to the sequences in 
Europe in the current season (p < 0.15, Wilcoxon signed-rank test). Relative entropy 
data in Table 5.1 imply the virus migration from China, as the geographic reservoir, 
to Japan and the USA and suggest a migration from the USA to Europe. The result 
in Table 5.1 also implies that the H3N2 virus circulating in China seed the virus in 
China, Japan, and the USA in the next season, and the virus in the USA probably 
seed the virus in Europe in the next season. 
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Table 5.1 : The relative entropy between hemagglutinin sequences in the different 
regions in the current influenza season and sequences in these regions in the previous 
season. The minimum relative entropy in each column is marked in bold. The p values 
of the Wilcoxon signed-rank test between the minimum relative entropy and other 
relative entropy values in the same column are in the parentheses. Hemagglutinin 
sequences were collected from four geographic regions: China, Japan, the USA, and 
Europe. Seven seasons from 2001-2002 to 2007-2008 are used here. The relative 
entropy values listed in this table are averaged for all the sites and all the six pairs of 
consecutive seasons. These results imply that the H3N2 viruses in China, Japan, and 
the USA migrate from China, while the H3N2 virus in Europe migrates from USA. 
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Comparison of the relative entropy data in Table 5.1 in the H3N2 reservoir and 
migration paths also reveals the H3N2 virus migration pattern. Using the Wilcoxon 
sign-rank test, the relative entropy data of the H3 hemagglu~inin in China in two 
consecutive seasons is significantly greater than those in the three migration paths: 
from China to Japan (p = 0.035), from China to the USA (p = 0.0030), and from the 
USA to Europe (p = 0.0017). The relative entropy data, therefore, confirms China as 
the H3N2 reservoir and implies that novel H3N2 viruses are emerging in China, not 
during the migration process. 
5.3.3 Positions under Selection 
The values of diversity as Shannon entropy Di,J and selection as relative entropy Si,J 
are available for the sequences collected from the 1993-1994 season to the 2009-2010 
season. First we apply the mean field approximation to remove the variation of selec-
tion and diversity over the time, and only consider the variation of Shannon entropy 
and relative entropy in different positions and regions over the past 17 seasons. A 
profile of the pattern of Shannon entropy and relative entropy in position j comprises 
the average selection, the number of seasons under selection, and the average diver-
sity. The average selection 83 is expressed by the mean of relative entropy in each 
position over the 17 seasons 
- 1 17 
sj = 17 2:: si,j (5.8) 
i=1 
and is displayed in Figure 5.4 (a). The number of seasons under selection in each 
position j is calculated by 
17 
Nj = L H (Si,j- s;hres) (5.9) 
i=1 
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where H is the Heaviside step function. The numbers are shown in Figure 5.4 (b). 
The average diversity D i in each position is calculated by averaging the Shannon 
entropy over the 17 seasons from 1993-1994 to 2009-2010 
- 1 17 
Dj = 17 LDi,j 
i=l 
(5.10) 
and is displayed in Figure 5 .4 (c) . 
Figure 5.4 (d) presents the distribution of the selection. Around 76% of the amino 
acid positions 1-329 of hemagglutinin have an average selection close to zero and fall 
into the leftmost bin. The numbers of seasons when selection Si,j in these positions 
were greater than the threshold level Sjhres are shown in Figure 5.4 (e). The average 
diversities Di,j in all the positions are shown in Figure 5.4 (f). If position j is under 
selection with Si,i > Sfhres in greater than two of the 17 seasons between 1993-1994 
and 2009-2010, or Ni > 2, this position j is classified as a position under selection in 
the evolutionary history of H3N2 virus. The 54 positions with Si,i > Sjhres in greater 
than two seasons are listed in Table 5.2. 
Patterns of selection and diversity similar to those observed in historical sequences 
in Figure 5.4 are generated by a Monte Carlo simulation model, as displayed in Figure 
S 1. The basis of the Monte Carlo simulation is that antibody binds to one of two 
epitope regions on the surface of the HAl domain [2], and the dominant epitope 
bound by antibody is under immune pressure and undergoes a higher substitution 
rate [42]. The detailed description and discussion of the Monte Carlo model is in the 
Appendix. 
5.3.4 Comparison of Different Regions 
A human antibody binds to five epitopes in the H3 hemagglutinin [36]. The five 
epitopes are located in different parts of the HAl domain of the cylinder-like structure 
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Figure 5.4 : (a) Average selection in each position quantified by relative entropy dur-
- 17 ing the past 17 seasons from 1993- 1994 to 2009- 2010, calculated by Sj = I:i=1 Si,j /17. 
The colors represent positions in epitopes A to E and positions outside the epitopes, 
as in Figure 5.1. (b) Number of seasons for each position when the relative entropy 
was greater than the threshold S{hres , i.e. the position was under selection. (c) A v-
erage diversity in each position quantified by Shannon entropy in the seasons from 
1993- 1994 to 2009- 2010, calculated by Dj = '2:~~ 1 Di,j/17. (d) Distribution of the 
average selection in each position displayed in (a). (e) Distribution of the numbers of 
seasons under selection displayed in (b). (f) Distribution of the average diversity in 
each position shown in (c). 
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Table 5.2 : Amino acid positions j under selection. To be included, the positions 
must be under selection, Si,i > ,S:hres, in greater than two seasons. · 
Region 
Epitope A 
Epitope B 
Epitope C 
Epitope D 
Epitope E 
Amino acid positions 
122 124 126 131 133 137 140 142 144 145 
128 155 156 157 158 159 189 192 193 197 
45 50 273 275 278 312 
121 172 173 201 207 219 226 227 229 246 
57 62 75 78 83 92 260 262 
Out of epitopes 3 5 25 33 49 106 202 222 225 271 
of the H3 hemagglutinin. Epitopes A and B are on the top of the HAl structure and 
are exposed in the HA trimer. Epitope Dis on the top of HAl structure and is partly 
buried inside the HA trimer. Epitopes C and E are at the central area of the exposed 
surface of the HAl domain as shown in Figure 5:1. Using the entropy method, we 
will show that epitopes A and B are under the highest average selection over all the 
seasons. These results can be interpreted as the antibody binds mostly to the top 
exposed part of the structure of hemagglutinin trimer defined by epitopes A and B, 
and so the selection in these two epitopes is with higher intensity. 
We divide the HAl domain of the H3N2 hemagglutinin into six regions, namely 
epitopes A to E, and positions not in any of the epitopes. These regions show signif-
icantly distinct patterns of evolution. In each seasons from 1993-1994 to 2009-2010, 
we averaged selection and diversity in each epitope and the positions not in any of the 
epitopes. The fraction of positions j under selection defined by Si.i > ,S:hres was also 
calculated. The averages for 17 seasons are listed in Table 5.3. It is evident that the 
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Table 5.3 : Annual selection, fraction of positions under selection, and diversity in 
epitopes A to E, positions not in any of the epitopes, and the whole HAl sequence. 
Region Selection Fraction of positions Diversity 
under selection 
Epitope A 0.187 0.152 0.077 
Epitope B 0.157 0.134 0.062 
Epitope C 0.077 0.087 0.048 
Epitope D 0.100 0.072 0.037 
Epitope E 0.111 0.094 0.049 
Out of epitopes 0.021 0.019 0.013 
The whole sequence 0.060 0.051 0.028 
values in Table 5.3 vary across the epitopes. The selection and diversity in epitopes 
A and Bare greater than those in epitopes C, D, and E for each of selection, fraction 
of positions under selection, and diversity. The fraction of positions under selection 
is significantly greater than those in epitopes C, D, and E (p < 0.038, using Wilcoxon 
signed rank test). The values in epitopes C, D, and E are significantly greater than 
those not in any of the epitopes (p < 0.0019 for selection, p < 0.0011 for fraction 
of positions under selection, and p < 6.0 x 10-4 for diversity, using Wilcoxon signed 
rank test). Consequently, epitopes A and B display the highest level of selection and 
diversity. 
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5.4 Discussion 
The Shannon entropy and the relative entropy are here introduced to quantify the 
diversity and the selection pressure of the evolving H3N2 virus. The foundation 
of the entropy calculation is the assumption that the virus sequences used in the 
entropy calculation are from a random unbiased sampling of the virus circulating 
in the human population. However, sampling density of the H3N2 virus varies in 
different geographic regions, hence creating a sampling bias. 
We have addressed this issue at the continent level by analyzing data from different 
regions separately. We now additionally study the effect of sampling bias within one 
country. For example, among the H3 hemagglutinin sequences labeled with month 
of collection in the NCBI Influenza Virus Resource Database, the New York state 
sequences account for about one third of the USA sequences. In the contrast, New 
York state has only about 6.5% of the USA population. We chose eight seasons from 
2001-2002 to 2008-2009 with abundant USA sequences collected in and out of New 
York state during this period of time available in the database. Using the procedure 
in the Materials and Methods section, we calculated the histogram of 20 amino acids 
in each amino acid position in each season for the New York state sequences, and that 
for the non-New York state sequences. Each of the 329 x 8 = 2632 pairs of histograms 
in and out of New York state were compared using the x2 test for homogeneity. The 
p values of 2581 pairs are greater than 0.05. That is, 98.1% of the pairs are not 
significantly different. The high sampling density in New York state does not affect 
the histograms of 20 amino acids in each position, implying that the sampling bias of 
the H3N2 virus is uncorrelated to the amino acid usage patterns. 
By applying Shannon entropy and relative entropy to the aligned hemagglutinin 
sequences labeled with month of collection, we obtain the evolution and migration 
97 
pattern of the H3N2 virus in the Results section. First, Shannon entropy and relative 
entropy quantify diversity of and selection pressure over the virus, relatively. Relative 
entropy from the current season i to the next season i + 1 linearly increased with the 
Shannon entropy in the current season i. See Figure 5.2 and 5.3. Second, relative 
entropy quantifies the similarity of two groups of virus and implies the migration path 
of the H3N2 virus. See Table 5.1. In the following text we compare our methods and 
results to the literature. 
The relative entropy reveals the H3N2 migration pattern. Previous studies applied 
phylogenetic methods in an attempt to locate the epicenter of the H3N2 epidemic in 
each season. [32] studied the dynamic of influenza sequence diversity in the tem-
perate regions in both hemispheres to imply that the H3N2 virus originates in the 
tropics and migrates to the temperate regions in both hemispheres. [43] obtained the 
antigenic and genetic evolution rate in each region and distances of the H3N2 strains 
to the trunk of the phylogenie tree. This information indicated East and Southeast 
Asia as the epicenter, from which the H3N2 virus spreads to North America, Europe, 
and Oceania in each season [43]. Recently, [146] suggested the center of the H3N2 
migration network being China, Southeast Asia, and the USA by estimating the mi-
gration rate between different regions in the world. Here the relative entropy, the 
gain of sequence information, is used as a novel measure of the sequence similarity. 
The H3N2 migration path is the directed graph in which each path has the minimum 
relative entropy, or the maximum sequence similarity. These studies reach a consen-
sus that South China is located in the epicenter of influenza epidemics. Here, we 
additionally identify a novel migration path from the USA to Europe and show that 
virus evolutionary rate is higher in the epicenter than in the migration paths. 
Previous studies have identified positions that have led to the immune escape of in-
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of the dN IdS ratio method. The second category operates at the amino acid level. 
[4] identified the positions with amino acid switch occurring in history to be under 
selection. Our entropy method recognizes the positions with relative entropy higher 
than the threshold, S:hres, in greater than two seasons. A large dN IdS of a codon does 
not necessarily mean an amino acid switch in the same position because the amino 
acid substitution could be unfixed. Methods at the amino acid level, such as the amino 
acid switch [4] and our entropy method, can identify positions with low dNidS to 
be under selection because these methods do not consider nucleotide substitutions. 
Positive selection does not necessarily lead to a fixed amino acid switch, and in this 
case the entropy method can still detect positive selection. Unlike the amino acid 
switch method [4], the entropy method applied in this study is able to detect unfixed 
amino acid substitutions arising from selection. Our entropy method releases the 
requirement of fixed amino acid substitution in [4] but adds one requirement: the 
positions under selection need to present large relative entropy in greater than two 
seasons. Consequently, these methods identify slightly different sets of positions to 
be under selection. 
5. 5 Conclusion 
We use Shannon entropy and relative entropy as two state variables of H3N2 evolu-
tion. The entropy method is able to predict H3N2 evolution and migration in the next 
season. First, we show that the rate of evolution increases with the virus diversity 
in the current season. The Shannon entropy data in one season strongly correlate 
with the relative entropy data from that season to the next season. If higher Shan-
non entropy of the virus is observed in one season, higher virus evolutionary rate is 
expected from this season to the next season. Second, the relative entropy values 
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between virus sequences from China, Japan, the USA, and Europe indicate that the 
H3N2 virus migration from China to Japan and the USA, and identify a novel migra-
tion path from the USA and Europe. The relative entropy values in and out of China, 
the epicenter, show that evolutionary rate is higher in China than in the migration 
paths. Moreover, the entropy method was demonstrated on two applications. First, 
selection pressure of the H3 hemagglutinin is mainly in 54 amino acid positions. Sec-
ond, the top exposed part in the three-dimensional structure of HA trimer covered by 
epitopes A and B is under the highest level of selection. These results substantiate 
current thinking on H3N2 evolution, and show that the selection pressure is focused 
in a subset of amino acid positions in the epitopes, with epitopes A and B on the top 
of hemagglutinin being dominant and making the largest contribution to the H3N2 
evolution. These predictions and applications show that the entropy method is not 
only predictive but also descriptive. 
5.6 Appendix: Monte Carlo Simulation of the Patterns of 
Selection and Diversity 
We introduce a Monte Carlo model aiming to regenerate the patterns of selection and 
diversity shown in Figure 4 in the main text. In this model, the sequence of the HAl 
domain contains a dominant epitope bound by the antibody and possessing a high evo-
lutionary rate f..L1 = 0.12 amino acid substitution/site/season, with the other amino 
acid positions with a low evolutionary rate f..L2 = 0.0034 amino acid substitution/site/season 
[42]. In each season, the numbers of positions in and out of the dominant epitope 
were defined as £ 1 and £ 2 , respectively. An ensemble of 1000 HAl sequences was cre-
ated with identical amino acid identity in each of the 329 positions, and was simulated 
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from the 1969-1970 season to the 2009-2010 season. The historical dominant epitopes 
of H3 hemagglutinin were epitopes A and B, each of which was dominant for about 
seven seasons [2]. Therefore, the dominant epitope in the model was initialized as epi-
tope A, and shifted between epitopes A and B every seven seasons. In each season, 
the numbers of amino acid substitutions in and out of the dominant epitope were 
randomly determined from two Poisson distributions with mean values >.1 = 111£ 1 
and >.2 = 112£2, respectively. The positions of amino acid substitutions and the new 
amino acid identities were then randomly assigned. This process was repeated for all 
the 1000 sequences in each season. Following this procedure, we calculated for each 
position j the average relative entropy SJ, the number of seasons under selection NJ, 
and the average diversity D J, using the simulated sequences between the 1993-1994 
season and the 2009-2010 season. We also present the histograms of SJ, NJ, and DJ· 
The results of these calculations are shown in Figure 5.5. 
The general picture depicted by this Monte Carlo simulation model reflects natural 
influenza evolution. The similarity between the results from the historical sequences 
in Figure 4 and those from the Monte Carlo simulation model in Figure 5.5 sug-
gests that the Monte Carlo simulation model captures a major part of the picture of 
influenza evolution. The Monte Carlo simulation model also suggests that the bind-
ing of antibody and the increased substitution rate in the dominant epitope are the 
significant features of influenza evolution. 
The annual evolution in the dominant epitope bound by the antibody decreases 
the affinity between virus and antibody and enables the virus to escape the immune 
memory of the virus circulating in the previous seasons. The evolutionary rate in the 
dominant epitope is 111 = 0.12 amino acid substitution/site/season [42]. Both the 
historical sequences of the HAl domain [4] and the Monte Carlo simulation model 
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suggest that substitutions of amino acid identities have occurred randomly across 
the dominant epitope. The relative frequency f (k, i, j) of each amino acid k in each 
position j in each season i shows that the amino acid substitutions were in random 
positions in each sea.Son and displayed few visible correlation between two positions 
[4]. The Monte Carlo simulation model randomly selects the positions in which the 
amino acid is mutated, and generates similar patterns of selection and diversity to 
the historical data. 
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Figure 5.5 : The results of the Monte Carlo simulation model containing epitopes 
A (blue) and B (red), and all the other positions. The model was simulated for 
41 seasons. (a) Average selection in each position quantified by relative entropy 
calculated by SJ = I:i~ 1 Si,J/17 in the last 17 seasons. The colors represent positions 
in epitopes A and B and positions outside the epitopes. (b) Number of seasons for 
each position when the relative entropy was greater than the threshold SJhres , i.e. 
the position was under selection. (c) Average diversity in each position quantified by 
Shannon entropy in the 17 seasons, calculated by DJ = "L:i~ 1 Di,J/17. (d) Distribution 
of the average selection in each position displayed in (a). (e) Distribution of the 
numbers of seasons under selection displayed in (b) . (f) Distribution of the average 
diversity in each position shown in (c). 
Chapter 6 
Selective Pressure to Increase Charge in 
Immunodominant Epitopes of the H3 
Hemagglutinin Influenza Protein 
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The evolutionary speed and the consequent immune escape of H3N2 influenza A virus 
make it an interesting evolutionary system. Charged amino acid residues are often 
significant contributors to the free energy of binding for protein-protein interactions, 
including antibody-antigen binding and ligand-receptor binding. We used Markov 
chain theory and maximum likelihood estimation to model the evolution of the num-
ber of charged amino acids on the dominant epitope in the hemagglutinin protein of 
circulating H3N2 virus strains. The number of charged amino acids increased in the 
dominant epitope B of the H3N2 virus since introduction in humans in 1968. When 
epitope A became dominant in 1989, the number of charged amino acids increased in 
epitope A and decreased in epitope B. Interestingly, the number of charged residues 
in the dominant epitope of the dominant circulating strain is never fewer than that 
in the vaccine strain. We propose these results indicate selective pressure for charged 
amino acids that increase the affinity of the virus epitope for water and decrease the 
affinity for host antibodies. The standard PAM model of generic protein evolution is 
unable to capture these trends. The reduced alphabet Markov model (RAMM) model 
we introduce captures the increased selective pressure for charged amino acids in the 
dominant epitope of hemagglutinin of H3N2 influenza (R2 > 0.98 between 1968 and 
1988). The RAMM model calibrated to historical H3N2 influenza virus evolution in 
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humans fit well to the H3N2/Wyoming virus evolution data from Guinea pig animal 
model studies. 
6.1 Introduction 
Influenza A virus causes annual global epidemics resulting in severe morbidity and 
mortality. The dominant circulating virus today is the H3N2 virus, which emerged 
in 1968 and is defined by two kinds of surface glycoproteins: H3 hemagglutinin and 
N2 neuraminidase. It is currently believed that hemagglutinin is relevant to virus 
attachment and entry into the cell, while neuraminidase facilitates virus release [20]. 
Hemagglutinin also plays a central role in the process of immuno escape, in which 
the antibodies mainly attack five epitopes, denoted as epitopes A-E, on the surface 
of the hemagglutinin protein [59, 28]. Because of antigenic changes through time, 
influenza vaccines are redesigned each year to provide improved protection against 
evolved circulating strains. The efficacy of the annual vaccine is variable due to the 
escape mutation of the influenza virus [29], especially mutation at the five epitopes 
on the hemagglutinin [2]. 
By analyzing the results of over 50 epidemiological studies of H3N2 influenza 
during the period 1968 - 2004, [2, 60, 31, 33] showed that the escape mutation of 
influenza A virus can be measured by Pepitope, the proportion of mutated amino acids 
in the dominant epitope of hemagglutinin, where the dominant epitope is defined as 
the epitope with the largest such proportion among the five epitopes. Compared with 
Psequence, the proportion of mutated amino acids in the whole sequence of hemagglu-
tinin, and the ferret antisera assays, Pepitope between vaccine strains and dominant 
circulating strains in the same flu season correlated better with the vaccine effica-
cies in the northern hemisphere [2]. Therefore Pepitope is an appropriate measurement 
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for the antigenic distances between vaccine strains and dominant circulating strains. 
With the definition of the dominant epitope, the escape mutation at the dominant 
epitope induces the largest antigenic distance between vaccine strains and dominant 
strains, and endows the dominant epitope with the immunodominance. 
In Gupta et al. 's model [2), which correlates well with vaccine efficacy in humans, 
every mutated amino acid is assigned the same weight. However, free energy calcu-
lations suggest that different amino acid substitutions have different contributions to 
the escape from the immune pressure. In general, the calculated differences in bind-
ing free energy l:l.l:l.G = l:l.Gmutated - l:l.Gwildtype are different for different mutations, 
where l:l.Gmutated and l:l.Gwildtype denote binding free energy between two proteins one 
of which has and does not have a point mutation, respectively. For the experimen-
tally measured difference in binding free energy l:l.l:l.G between human growth hor-
mone (hGH) and its first bound receptor (hGHbp), individual alanine substitutions 
of hydrophobic amino acids on the epitope of hGHbp induced the largest increase in 
l:l.l:l.G, followed by charged amino acids [8). Nevertheless, we show that charged amino 
acids correlate more strongly with viral evolution (Table 6.3 and 6.4 in this chapter). 
Nakajima [9) found that the majority of escape mutations of H3 hemagglutinin of the 
strain A/Kamata/14/91 were the mutations that introduce charged amino acids, and 
that the frequency of selected mutations to charged residues· was significantly higher 
than that expected by random chance. A related study by Smith [30) found a similar 
over-representation of mutations to charged amino acids in the evolution of influenza. 
We here consider the effect of different physical properties on the escape from 
immune pressure. We focus on the charged amino acids in the epitopes. These amino 
acids are strongly hydrophilic, and they reduce the tendency of antibodies to bind to 
hemagglutinin. Charged amino acids play a critical role in protein-protein interaction 
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by creating salt bridges and salt bridge networks. Charged amino acids introduce 
specificity in binding [10]. Amino acid substitutions involving charged residues in the 
vicinity of receptor-binding region of HA affect the binding affinity between HA and 
its receptor [11]. The evolution of charged amino acids, therefore, may provide useful 
information on viral escape from antibody pressure. A discussion of charge evolution 
in proteins has been given by Leunissen [12], who observed a large variance in the 
evolutionary trends among different protein families. Here we use stochastic methods 
to model the evolution of charged amino acids on the epitopes of H3 hemagglutinin 
strains collected from humans since 1968. 
The metaanalysis of 50 epidemiological human vaccine efficacy studies shows that 
the single dominant epitope is the critical region that determines the epidemiological 
vaccine efficacy [2]. There are five non-overlapping epitopes on the surface of H3 
HA molecule, namely epitope A-E, to which different sets of antibodies bind. In 
each epitope, the p value is defined as the fraction of mutated amino acids [2]. The 
dominant epitope is defined as the epitope with the greatest p value. The greatest 
p value is Pepitope· Epidemiological data on the vaccine efficacies in 18 previous flu 
seasons when H3N2 subtype was dominant were collected from approximately 50 
studies [2]. The identities of the vaccine strains and dominant circulating strains 
were also obtained to calculate Pepitope· H3N2 vaccine efficacy correlates with Pepitope 
with R2 = 0.81. This strong correlation shows that Pepitope defined by the single 
dominant epitope is a quantitative definition of antigenic distance. Importantly, the 
Pepitope calculated from the dominant epitope correlated better with vaccine efficacy 
than did antigenic distance including all HA amino acids [2]. 
The results of [61] show that subdominant epitopes are not the critical regions 
for vaccine efficacy. In an effort to improve the definition of antigenic distance, four 
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modifications of the definition of antigenic distance were tested for their ability to 
improve the correlation with vaccine efficacy: 1) incorporating p values from sub-
dominant epitopes, 2) distinguishing conservative and non-conservative amino acids 
mutations, 3) mutations in amino acids adjacent to the epitopes, and 4) the calcula-
tion of mutations in neuraminidase [61]. These four modifications of the definition of 
antigenic distance, including use of subdominant epitope p values, all failed to sub-
stantially improve the correlation with vaccine efficacy data in the years 1971-2004. 
These results motivate our focus on the dominant epitiope in the present analysis. 
The reduced alphabet Markov model (RAMM) described in this chapter is an 
amino acid substitution model. It is built from the H3 hemagglutinin strains circu-
lating in 1972 - 1987 when epitope B was the dominant epitope. This time span 
is shortly after the emergence of H3N2 virus in 1968, and this newly emerged virus 
subtype needed some time to adapt to host immune system, because emergence of 
new subtypes such as H2N2 in 1957 and H3N2 in 1968 went with Asian flu and Hong 
Kong flu outbreaks, indicating that subtypes like H3N2 were more virulent in the 
beginning and less adaptive to human. Further, the phylogenetic tree of H3N2 also 
shows that H3N2 evolved faster at the very beginning than in the later stage (30]. So 
the pattern of evolution illustrates the escape mutation of the virus before substantial 
adaptation to host immune system was developed. Because the sequence database 
has been derived from patient samples and categorized by antigenic strain and date 
of collection, the human data do not necessarily reflect fixed variants, but, rather, 
snapshots along an evolutionary continuum. 
Mutations of amino acids in different positions in the epitope are viewed as in-
dependent and identical Markov chains, whose parameters are the transition matrix 
P or the instantaneous rate matrix Q. Markov models of protein evolution include 
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the point accepted mutation (PAM) model [62) and the block substitution matrix 
(BLOSUM) model [63). These models are derived by counting mutations in aligned 
amino acid sequences, and this approach provides the transition matrices P (t) of 
a Markov chain in a period of evolutionary time t. [64] introduced the maximum 
likelihood method to estimate the elements of the transition matrix, and maximum 
likelihood was also employed to estimate the evolutionary time t when fixing the 
transition matrix P (t) [65). The instantaneous rate matrix Q was calculated from 
the Laplace transform of P (t) [65, 66). For a review of applications to 2000, see [67]. 
Some recent studies estimated the effect of possible multiple mutations at the same 
position within evolutionary time t [68, 69]. The instantaneous rate matrix has been 
estimated from observed frequencies of 20 amino acids [70]. 
The transition matrices P and the instantaneous rate matrices Q of most previous 
models are 20 x 20 matrices trained by analyzing databases with numerous alleles 
in many taxa. In the present case, the training data are limited, which can cause 
overfitting and introduce large errors to the fit model. One way to circumvent this 
difficulty is to decrease the number of parameters: 20 amino acids may be classified 
into several groups with similar biophysical properties. Here we grouped 20 amino 
acids as 5 charged amino acids and 15 uncharged amino acids. 
To test whether the mathematical models. can be applied to data outside of the 
existing human data, we investigated their relevance to animal models of influenza 
infection. Guinea pigs have been shown to be infected with unadapted H3N2 strains. 
In most cases, the infection is limited to the upper respiratory tract, causes little 
apparent morbidity, and can be spread to cage mates via aerosol [71 J. As part of our 
analysis of the Pepitope calculations, we developed additional evolutionary data derived 
through analysis of progeny viruses in animal model systems. Interestingly, the pat-
110 
tern of variations in the Guinea pig infection correlated well with the predictions of 
the model and with the human evolutionary data. 
6.2 Materials and Methods 
We defined the charged amino acids as {Asp, Glu, Arg, Lys, His}. Historical se-
quence data indicated that the number of charged residues increased continually on 
the dominant epitope of the hemagglutinin of the circulating H3N2 strains in Figure 
6.1, except for the data in the year 1996-1997 which was presumably a continuation 
of the decreasing trend in the charge of epitope B since 1993. The vaccine strains in 
Figure 6.2 also had increasing numbers of charged amino acids in a period of time 
without epitope shift. The charge in the dominant epitope sometimes stopped in-
creasing, which means the existing of the steady state for the charge and will be 
discussed later. Moreover, since the observed dominant epitope in a given year was 
either epitope A or epitope B, we defined the subdominant epitope as the epitope in 
the set {epitope A, epitope B} other than the dominant one. Figure 6.1 and Figure 
6.2 also shows that the number of charged residues decreased in the subdominant 
epitope in both the circulating strains and the vaccine strains. For vaccine strains 
and circulating strains collected in 19 years, vaccine efficacies in each year had a 
strong correlation (R2 = 0.81) with the Pepitope in that year [2), but R2 decreased 
quickly if we use the weighted sum of Pepitope and Pepitope in previous years (Pan and 
Deem, unpublished data). Therefore we treated the immune escape of the virus as a 
Markov process [149). Additionally, since there is limited information on the correla-
tion between different positions on a given epitope, we assumed that the mutations at 
different positions on the epitope followed identical and independent Markov chains. 
The epitope A and epitope B of the circulating strains and the strains deposited 
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Figure 6.1 : Number of charged amino acids for each year on the epitope A and 
epitope B of the dominant circulating strains from 1971 to 2003. 
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Figure 6.2 : Number of charged amino acids for each year on the epitope A and 
epitope B of the vaccine strains from 1971 to 2003. There were four consecutive 
intervals where epitope A or epitope B was dominant. 
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·in the GenBank database were collected in 18 years between 1968 and 2003 and listed 
in Table 6.1, where the numbers of charged amino acids are presented as number for 
the dominant circulating strain and the average number for the circulating strains in 
GenBank database in the same year [2]. These data were also plotted (Figure 6.1 
and Figure 6.3). The dominant epitope was epitope A in the 1971 strain, epitope B 
in the {1972, 1973, 1975, 1984, 1985, 1987} strains, epitope A in the {1989, 1992, 
1993, 1994, 1995} strains, and epitope Bin the {1996, 1997, 1998, 1999, 2001, 2003} 
strains. All the strains except the 1971 strain fell into three multi-year time intervals 
defined by unchanged dominant epitopes. The numbers of charged amino acids on 
the dominant epitopes of each strain were counted and utilized. The total number of 
charged amino acid on a certain epitope, Nc, was modeled by a binomial distribution 
with probability 
(6.1) 
with the mean number of amino acids in the epitope equal toN Pc (t I t:, 61), where N 
was the total number of amino acids on the epitope. 
Table 6.1 : Epitope A and B of dominant circulating strains. Two numbers of charged amino acids in each epitope in 
each year are presented; the first one is calculated from the dominant circulating strain, and the second one is the simple 
arithmetic average of all strains collected in that year and deposited in GenBank. 
...... 
...... 
~ 
Year Dominant circulating strain Dominant 
epitope 
1971-1972 HongKong/1/68 (AF201874) A 
1972-1973 England/42/72 (AF201875) B 
1973-1974 PortChalmers/1/73 (AF092062) B 
1975-1976 Victoria/3/75 (ISDNV1C75) B 
1984-1985 Mississippi/1/85 (AF008893) B 
1985-1986 Mississippi/1/85 (AF008893) B 
1987-1988 Shanghai/11/87 (AF008886) B 
1989-1990 England/427 /88 (AF204238) A 
1992-1993 Beijing/32/92 (AF008812) A 
1993-1994 Beijing/32/92 (AF008812) A 
1994-1995 Johannesburg/33/94 (AF008774) A 
1995-1996 Johannesburg/33/94 (AF008774) A 
1996-1997 Wuhan/359/95 (AF008722) B 
1997-1998 Sydney/5/97 (AJ311466) B 
1998-1999 Sydney/5/97 (AJ311466) B 
1999-2000 Sydney/5/97 (AJ311466) B 
2001-2002 Panama/2007 /99 (ISDNCDA001) B 
2003-2004 Fujian/411/2002 (ISDN38157) B 
Number of Sequence of epitope A 
charged of the dominant 
amino acids circulating strain 
in epitope A 
5/2.22 TGTVTQDGNAKGPGKIIRNM 
3/2.95 NGTVTQNGNAKGPDSSRNM 
3/3.00 NGTVTQNGNAKGPDSGRNM 
3/3.18 NGNVTQNGSAKGPDNGRNM 
2/2.00 NGNVTQSGYAKGSVNSRNM 
2/2.13 NGNVTQSGYAKGSVNSRNM 
3/3.20 NDNVTQSGYAKGSVNSRNM 
3/3.42 NDNVAQSGCAKGSVNSRNM 
4/4.64 NDNVAQDGYAKGSVNSRNM 
4/4.77 NDNVAQDGYAKGSVNSRNM 
4/4.71 NNNVAQDKYAKGSVNSRNM 
4/4.35 NNNVAQDKYAKGSVNSRNM 
4/4.01 NGNVAQDTYAKGSVKSRNM 
3/4.07 NSNVAQNTYAKSSIKSRNM 
3/4.03 NSNVAQNTYAKSSIKSRNM 
3/3.95 NSNVAQNTYAKSSIKSRNM 
4/4.70 NSNVAQNTSAKRSNKSRNM 
4/4.53 NSNVTQNTSAKRSNKSRNM 
Number of 
charged 
amino acids 
in epitope B 
2/2.78 
2/3.00 
3/3.00 
5/4.18 
7/6.88 
7/7.03 
8/8.20 
8/8.20 
8/7.79 
8/7.02 
7/6.94 
7/6.36 
6/6.01 
5/5.53 
5/5.18 
5/5.01 
5/5.02 
5/4.98 
Sequence of Epitope B 
of the dominant 
circulating strain 
TGTKSGSTVNSTNQETSLVQA 
TGYKSECTVNSTNQVTSLVQA 
TGYKSGSAVNSTDQETNLVQA 
TGYKLGSTVNSTDKETDLVQA 
TGYKSESKANSTDKETNLVRA 
TGYKSESKANSTDKETNLVRA 
TGBESEYKANSTDRETNLVRA 
TGBESEYKANSTDRETNLVRA 
TGBKSEYKANSTDRDTSLVRA 
TGBKSEYKANSTDRDTSLVRA 
TGBKLEYKANSTDSDTSLVRA 
TGBKLEYKANSTDSDTSLVRA 
TGBKLEYKANSTDSDTSIVQA 
TGHQLKYKANSTDSDTSIAQA 
TGHQLKYKANSTDSDTSIAQA 
TGHQLKYKANSTDSDTSIAQA 
TGHQLKYKANSTDSDISLAQA 
TGTHLKYKANGTDSDISLAQA 
...... 
...... 
C1l 
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6.2.1 Discrete-Time Markov Chain 
We first applied a discrete-time Markov chain using one year as the time unit be-
cause the available data are the st~ains deposited in databases with one-year time 
resolution. The probability distribution was defined as 1r (t) = (Pc (t), Pu (t)) = 
(Pc (t), 1- Pc (t)) with the initial value (Pco, 1- Pco), where Pc and Pu were the 
probabilities that a charged amino acid and an uncharged amino acid existed in a 
given position on the dominant epitope. Following this definition, the transition ma-
trix is a 2-by-2 matrix, taking parameters that describes the evolutionary process. 
We chose the mutation probability for each position, €, and the bias for mutation 
to charged amino acids from charged or uncharged amino acids, 81 and 82 , respec-
tively, to characterize the virus evolution model discussed in this chapter. Thus the 
transition matrix is 
(6.2) 
with 
where € is the amino acid substitution rate (the new amino acid could be identical to 
the original amino acid); and O!cc, O!cu 1 O!uc 1 and O!uu are the conditional probabilities 
that a charged residue mutated to a charged residue, a charged residue mutated to 
an uncharged residue, an uncharged residue mutated to a charged residue, and an 
uncharged residue mutated to an uncharged residue, respectively, if the substitution 
occurred. The parameters 81 and 82 were the bias for the probability that a charged 
amino acid mutated to a charged amino acid, an uncharged amino acid mutated to 
a charged amino acid, respectively. Under the further assumption that 81 = 82 =a, 
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Figure 6.3 : Average number of charged amino acids for each year on the epitope A 
and epitope B of the strains deposited in the GenBank database from 1971 to 2003. 
The curves in this figure were smoother than those in Figure 6.1 due to the averaging 
over database strains. The difference in the numbers of charged amino acids between 
this figure and Figure 6.1 is smaller than one for most years. 
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the probability distribution in year t is 
(Pc(t!€,8),Pu(t!€,8)) = (Pco,1-Pco)pt 
= (Pco,1-Pco)Q-lDtQ 
= ( ~ (1 + 48- (1 - €)t (1 + 48- 4Pco)) , 1 - Pc (t I €(613) 
where the matrix Q was invertible, the matrix D was diagonal. 
6.2.2 Continuous-Time Markov Chain 
Besides the discrete-time Markov chain, the continuous-time Markov chain was also 
commonly employed in several bio-related fields including the estimation of residue 
mutation rates [150]. In the continuous-time Markov chain, the transition rate matrix 
Q is first defined describing the evolution of probability distribution in a infinitesimal 
time interval, with Ql = 0 where 1 is a column vector with all the elements equal to 
unity. The transition matrix is 
p (t) = (Pee (t) Pcu (t)) = exp (Qt) 
Puc (t) Puu (t) 
(6.4) 
with the probabilitydistribution at year twas again defined as 1r (t) = (Pc (t), Pu (t)) = 
"7r (0) P (t) with the initial probability distribution 1f' (0) = (Pco, 1 - Pco). And if the 
Markov chain contains finite states, the Kolmogorov backward equation (KBE) 
!p (t) = QP (t) (KBE) (6.5) 
holds. 
For the evolution process of charged amino acid, the Q matrix was defined as 
(6.6) 
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The solution for the transition matrix exp (Qt) was 
Pcu (t) = 
Puc (t) = 
Puu (t) -
The term Pc is given by 
(6.7) 
6.2.3 Maximum Likelihood Estimation 
The maximum likelihood estimation method optimizes the parameters in a given para-
metric form by maximizing the log-likelihood function with the definition l ( 8 I x) = 
lnP (x 18). The observed data x = (x1,x2 , ••• ,Xm) are usually independent, there-
fore the maximum likelihood function is l (8 I x) = L:;=1 ln P (xk I 8). In our model, 
the data xk = (n, t) in different years were assumed to be independent, where n was 
the number of charged amino acids, t was the time in years, and the parameter set 
was 8 = (t:, 5, Pc0 ). From the relationship between the total number of charged amino 
acids and the probability distribution at each position (6.1), the maximum likelihood 
equation was written as 
m 
+ L (N- n) ln [1- Pc (tk I € 1 5, Pco)] (6.8) 
k=l 
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with the expression of Pc in (6.3). 
The maximum likelihood function was maximized by solving the following equa-
tions 
f) 
aE l (E, 8, Pco I x) = 0 
f) (6.9) 88 z (€, 8, Pco I x) = 0 
f) 
aPo l (E, 8, Pco I x) - 0 
The numerical solution was identical to that of the least square fit to the first two 
significant figures. We note that solutions of (6.9) were not ill-conditioned while the 
nonlinear fitting algorithm for (6.3) led to ill-conditioned Jacobians. 
6.2.4 Guinea Pig Animal Model 
The Guinea pig model of human influenza infection was adopted to model the process 
of infection and reinfection [71]. A sample of A/Wyoming/2003 (H3N2) was obtained 
from the Centers for Disease Control and Prevention (CDC). Sequence analysis of 
multiple plaque isolates from the CDC virus demonstrated that the sample contained 
a mixture of viruses with several hemagglutinin (HA) sequences, all in close agreement 
with the A/Wyoming/03/2003 sequence reposited in GenBank (accession number 
AAT08000). An isolate (WyB4) representing the dominant HA sequence contained 
within the CDC virus mixture was purified and propagated. 
In the first infection experiment, four immunologically na'ive Guinea pigs were 
inoculated with the CDC virus mixture to model virus evolution in the absence of 
robust immunity. Three days following inoculation, progeny virus were purified from 
nasal washes for sequence analysis of the HA genes. After a recovery period of 28 
days, two of the animals were reinfected with the CDC virus mixture to model virus 
escape in the presence of increased immune pressure. Nasal washes were collected 
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after 3 days, progeny virus isolated, and HA gene sequences analyzed. In a second 
infection experiment, six na1ve Guinea pigs were inoculated with the purified WyB4 
isolate. Again, virus progeny were purified from nasal wash samples for HA sequence 
analysis. In a third infection experiment, Guinea pigs were inoculated with three 
immunizations of recombinant Wyoming HA protein having the same sequence as 
the WyB4 isolate. After the animals had mounted robust immune responses, they 
were challenged with either WyB4 or the CDC virus mixture. Progeny virus were 
isolated from nasal washes for HA gene sequence analyses. 
6.3 Results 
6.3.1 Charge Increases in the Dominant Epitope 
The parameters obtained by the fitting algorithm for the first time interval ( epitope 
B was dominant, from 1972 to 1987) were (JT = (E, 8, Pco) = (0.207, O.l13, 0.0937) 
with the square of the correlation coefficient between observations and the model 
R2 = 0.98. The mathematical details are shown in Supplementary Material. Here 
the transition matrix was 
- (0.868 0.132) p_ . 
0.075 0.925 
(6.10) 
We plotted the observed data and the data predicted by the model with the 
parameters fixed by maximum likelihood estimation in Figure 6.4. We fit E and 8 to 
the data in the range 1972-1987 and used these values for all years. We fit the value 
of Pco in the range 1972-1987 and found it equal to the data point at 1972. For other 
intervals we used the observed initial values. 
The model parameters here yielded the average number of point mutations in 
epitope B = 19NE/20 = 4.07, and the observed numbers of point mutation in epitope 
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Figure 6.4: Number of charged amino acids for each year on the dominant epitopes of 
the circulating strains. Both the observed data from 1971 to 2003 and the predicted 
data from 1972 to 2003 are plotted. Since the estimated Pco was close to the observed 
number,· we used the observed numbers of charged amino acids in the first year of the 
interval to calculate Pco. 
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B during one year were: 1971-1972, 4; 1972-1973, 6; 1984-1985, 0. Those are all 
the available one-year time spans in the training data,. and this model falls inside the 
standard error of the actual annual mutation rates on the dominant epitopes. That 
8 = 0.11 showed that the conditional probability that a charged residue mutated to 
a charged residue was 0.36 while the probability that an uncharged residue mutated 
to an uncharged residue was 0.64. The observed number of charged amino acids on 
epitope B in 1972 was 2, and corresponding Pco = 2/21 ~ 0.095, which agrees well 
with the fit value Pco = 0.094. 
We also obtained all the strains deposited in the GenBank database that were 
collected in the same year as a circulating strain existed. The numbers of charged 
amino acids Nc = NPc (t I €, 8, Pco) were counted for each year as the mean value of 
the numbers of charged amino acid on the dominant epitope of the strains collected 
in that year. The standard deviations of the numbers of charged amino acid on the 
dominant epitope were also calculated for each year. Again, there is. no assurance 
that any of these mutations can be considered end-point or fixed variants as the 
evolutionary process continued from year to year. By using these Pc (t I €, 8, Pco) to 
fit the parameters 8 = {€, 8, Pco), € approached to zero when the number of iterations 
of the fitting algorithm increased to infinity, while the product €8 approached to 
0.016 compared with the product €8 = 0.023 in the case with only circulating strains. 
Both the calculated and observed Pco equal to 0.14. The model fit well with all the 
datapoints in this time span with R2 = 0.99. We note that the Markov model is 
not able to reproduce convex and rising data, and this is the reason for € -+ 0 for 
these data. In fact the data in Figure 6.5 are convex probably because the simple 
arithmetic averaging is only a rough approximation, and we expect concave and rising 
data, which the Markov model can represent, from a properly weighted population 
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Figure 6.5: Number of charged amino acids for each year on the dominant epitopes of 
the average of all the database strains in the same year. Both the observed data from 
1971 to 2003 and the predicted data from 1972 to 2003 were plotted. We used the 
observed numbers of charged amino acids in the first year of the interval to calculate 
Pco. Error bars for the circulating strains are one standard deviation calculated from 
all NCBI strains collected in that year. 
average. The maximum likelihood method estimated the same parameter values to 
within two significant figures as the least square fitting method. 
The continuous-time Markov chain possessed the similar parameter set 8 = 
().1 , >.2 , Pco) to the discrete-time Markov chain. For the circulating strains in 1972-
1987, the nonlinear least-squares fitting yielded the parameters ..\1 = 0.15, ..\2 = 
0.084, Pco = 0.094 with R2 = 0.98. For the database strains, there were ,\1 = 
-0.031, ,\2 = 0.011, Pco = 0.14 with R2 = 0.99. As before, simple arithmetic av-
eraging produces convex and rising data, which the Markov model is not able to 
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represent, and which is not expected from a population average. 
The RAMM model fit well the data in circulating strains and those in the GenBank 
database in the first time interval (1972-1987). This model had a larger discrepancy 
in the prediction versus both groups of data in the second (1989-1995) and third time 
interval (1996-2003). 
6.3.2 Evolution of Amino Acids in Epitopes of Hemagglutinin is Non-
universal: Comparison with PAM Matrix 
To compare with the RAMM model, we also employed the conventional PAM matrix 
[62] to predict the evolution of charged amino acids. We first calculated the PAM1 
matrix M = { Mii} describing the evolution of one amino acid position during a time 
unit in which the probability that a point mutation occurred in this position was 
fixed by Dayhoff et al. [62] to 0.01 (the meaning of the suffix 1). Evolution during 
n time units was depicted by PAMn matrix with PAMn = PAM1n = Mn = {Mfi}. 
The probability for a point mutation occur was then 
20 
p = L (1 - M:i) 11"i· (6.11) 
i=l 
We let this probability equal to the annual mutation rate calculated by the RAMM 
model and verified by the historical data, 19€/20 = 0.196, and so PAM22 should be 
selected to calculate the mutations during one year. The more frequently used PAM20 
matrix, however, underpredicts the annual mutation rate and generates larger errors. 
While the PAM22 matrix reproduces the observed number of total mutations in the 
dominant epitope, as we shall see, it underpredicts the number of charged mutations 
per year. This means there is an additional selective force for charged amino acids in 
the epitopes of hemagglutinin relative to protein evolution in general. To calculate 
the 2 x 2 transition matrix with the definition 
p = (Pee Pcu) 
· Puc Puu 
there were 
Pcu = P {charged -+ uncharged I charged} 
= 
L:i=charged ( L:j=uncharged Mfj) 1ri 
L:i=charged 1ri 
Puc = 
L:i=uncharged ( L:j=charged Mfj) 1ri 
L:i=uncharged 1ri 
Pee 1- Pcu 
Puu 1- Puc· 
yielding the solution of the transition matrix P based on PAM22 matrix 
p = (0.883 0.117) 
0.040 0.960 
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(6.12) 
(6.13) 
(6.14) 
(6.15) 
(6.16) 
which is slightly different from RAMM matrix (6.10). The evolution predicted by 
PAM22 matrix for the circulating strains and equally weighted database strains is 
plotted in Figure 6.6 and Figure 6.7, respectively. 
6.3.3 Guinea Pig Animal Model Verifies the Increase in Charge 
To buttress our analyses of the evolution of charged amino acids in historical virus 
sequences, we examined the frequency of charge changes in the HA sequences derived 
from the progeny virus using the Guinea pig animal infection model. The animals 
were divided into two groups, na:ive and immune. The immune animals were either 
previously infected or immunized with HA protein. The animals were given either 
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Figure 6.6 : Number of charged amino acids for each year on the dominant epitopes of 
the circulating strains. Both the observed data from 1971 to 2003 and the predicted 
data from 1972 to 2003 with PAM22 matrix were plotted. Pco was fixed to the 
observed numbers of charged amino acids in the first year of the interval. The PAM22 
matrix cannot reproduce the data. 
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Figure 6.7: Number of charged amino acids for each year on the dominant epitopes 
of the average of all the database strains in the same year. Both the observed data 
from 1971 to 2003 and the predicted data from 1972 to 2003 with PAM22 matrix were 
plotted. Pco was fixed to the observed numbers of charged amino acids in the first 
year of the interval. The PAM22 matrix cannot reproduce the data. Error bars for 
the circulating strains are one standard deviation calculated from all NCBI strains 
collected in that year. 
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an inoculum of a dominate strain with the frequency 64.3%, as well as three closely-
related variants with the frequencies 14.3%, 14.3%, and 7.1% respectively, totaling 
35.7%, denoted CDC, or an inoculum of the dominant plaque-purified strain of the 
CDC stock mentioned above, denoted WyB4. The HA genes from replicated virus 
were sequenced from nasal washing samples at three days following intra-nasal inoc-
ulation. As observed in Table 6.2, na1ve animals given the CDC inoculum resulted in 
an increase in the frequency of variants in the nasal wash virus. The WT:mutant ra-
tio of 64.3%:35.7% in the CDC inoculum was reduced to 48.3%:51.7% in the progeny 
virus, indicating that the dominant viral strain in the starting material was reduced 
16.0% while new HA mutants increased 16.0%. Moreover, most of the progeny vari-
ants characterized in the nasal wash samples were not previously detected in the CDC 
stock virus suggesting that the progeny variants arose during infection in the Guinea 
pig. The Guinea pig animal model also yielded new strains with multiple mutations 
as well as new strains which fundamentally changed the biochemical character of the 
mutated amino acid. Although many of the new variants may came from neutral 
mutation, the scenario that some of the new variants increased the replicative fitness 
cannot be precluded. Thus, it seems likely that the egg-adapted variants in the CDC 
stock had reduced replicative fitness relative to the WyB4 strain. Unexpectedly, rein-
fection of the same Guinea pigs with the CDC stock resulted in an increase of 11.3% 
in the frequency of the wildtype HA sequence and a concomitant equal decrease in 
the frequency of progeny strains having mutated HA genes. 
In the second set of experiments in which na1ve Guinea pigs were infected with the 
WyB4 plaque-purified clone of the dominant strain in the CDC stock, progeny virus 
had a 69.4%:30.6% WT:mutant HA gene ratio relatively close to that seen with the 
CDC stock in naYve animals. In the third experiments in which immunized animals 
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were infected with the WyB4 virus, the ratio of WT:mutant HA genes increased 
to 75.7%:24.3%, similar to the result observed in infections with the CDC stock. 
Taken together, infection of naive animals resulted in a frequency of WT HA genes 
of approximately 65-70% while infection of immune animals produced an increase 
in the WT frequency to rv76% regardless of whether the CDC stock or WyB4 virus 
was used. By comparing the percentages of mutants listed in Table 6.2, three pairs 
of numbers are statistically significantly different (p < 0.02), which are CDC naive 
vs. CDC reinfected, CDC na'ive vs. WyB4 na'ive, and CDC na'ive vs. WyB4 HA-
immunized, respectively. The null hypothesis cannot be rejected for the other three 
pairs when testing the statistically significant difference (p > 0.3). That is, only the 
low WT ratio in CDC na'ive is statistically significant. Presumably the immunized 
animals eliminated the virus more quickly, and so fewer mutations were formed. 
Figure 6.8 compares the number of charged residues predicted by both the PAM22 
model and the reduced alphabet Markov model (RAMM), with those observed in the 
progeny of Guinea pigs infected with the A/Wyoming/2003 mixture obtained from the 
CDC. Because epitope B was the dominant epitope in the Wyoming virus circulating 
in 2003, we focused our analysis on the residues contained within this epitope. Five 
charged residues were present in the 21 amino acid B epitope in the initial Wyoming 
inoculum. The mean number of charged residues increased to 5.09 in the progeny 
from na'ive animals and 5.09 in the progeny of reinfected animals. 
The evolutionary times between the strains from the original inocula, the progeny 
of na'ive Guinea pigs, and the progeny of reinfected animals are estimated by the 
mean number of mutations in the whole sequence of strains collected from Guinea 
pigs, divided by the approximate annual historical number of mutations in the whole 
HAl sequences (mean historical mutations during the years 1971-2003 = 5.2 amino 
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acids/HAl sequence/year). Note that regardless of whether charged amino acids are 
involved, the numbers of mutations in the whole sequence instead of epitope B are 
used to calibrate the evolutionary times. The strains from the na'ive Guinea pig 
experiments were characterized, and the total number of point mutations in these 
strains was then divided by the number of strains to calculate the population average 
number of point mutations in the progeny strains. This average number was divided 
by 5.2, the mean number of historical mutations per year in the whole HAl sequences, 
to obtain the evolutionary time fl.t for the na'ive Guinea pig experiment. The fl.t for 
the reinfection experiment was calculated following the same method. The number 
of charged amino acids in epitope B, the dominant epitope for the Wyoming strain, 
increased in a trajectory that closely followed the path predicted by the RAMM 
model. In contrast the generic protein evolution PAM22 model predicted no such 
increase in charged residues. The evolutionary times and the numbers of charged 
amino acids in epitope B are calculated respectively by different approaches, therefore 
the evolutionary time is independent of the increase of charged amino acids. Thus, 
the agreement between RAMM model and the experiment is nontrivial. 
Figure 6.9 shows a similar plot of charged residues observed from the experimen-
tal infection of na'ive and immune Guinea pigs with the WyB4 isolate compared to 
predicted values. The methods used in the analysis shown in Figure 6.8 were applied 
to the data derived from infection with the homogenous virus. The WyB4 appeared 
to accumulate charged residues in the epitope B somewhat more rapidly than the 
Wyoming mixture obtained from the CDC. These data suggest either that the WyB4 
strain has a replicative advantage in Guinea pigs and therefore evolves faster, or that 
accumulation of charged residues, especially in immune animals, represents a selective 
advantage. 
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Figure 6.8 : Comparison of charged residue changes between theoretical models and 
sequence data derived from Guinea pigs inoculated with the CDC A/Wyoming/2003 
virus mixture. The RAMM and the PAM theoretical models were considered, as 
well as three data points from the Guinea pig infections: First point: Wyoming 
inoculum; Second point: progeny strains from infection of na'ive Guinea pigs; and 
Third point: progeny strains from infection of previously infected Guinea pigs. The 
time of na'ive and reinfection strains was estimated from the average number of amino 
acid mutations, counting both wild type and mutated strains, in the whole HAl 
sequence. With the assumption derived from historical data that the annual mutation 
rate was 5.2 amino acids/HAl sequence/year, we divided those average numbers of 
mutations by 5.2 to obtain the times. Error bars are one standard error. 
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Figure 6.9 : Comparison of charged residue changes between theoretical models and 
sequence data derived from progeny virus isolated from Guinea pigs inoculated with 
the homogeneous WyB4 virus isolate. The number of predicted and observed charged 
residues were analyzed with the method used for the data in Figure 6.8. Error bars 
are one standard error. 
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Table 6.2 : Sequence analysis of progeny virus isolated from nasal washes of infected 
Guinea pigs. CDC virus designates mixture of Wyoming HA sequence variants con-
tained in initial virus stock. WyB4 virus designates purified stock from predominant 
isolate of CDC virus. Immune status refers to whether the animals were nai've, i.e. 
neither previously infected nor immunized with purified HA protein, or immune. 
Number of sequences refers to the number of HA genes examined in progeny virus 
isolated from nasal washes. 
Virus Immune status Number of sequences Wild type Mutants 
CDC nai've 58 28 (48.3%) 30 (51.7%) 
CDC reinfected 82 62 (75.6%) 20 (24.4%) 
WyB4 nai've 62 43 (69.4%) 19 (30.6%) 
WyB4 HA-immunized 210 159 (75.7%) 51 (24.3%) 
Comparing Figure 6.8 and Figure 6.9, the WyB4 isolate appeared to evolve more 
in na'ive animals than did the mixed CDC stock. A greater number of mutations 
per mutant strain were observed in na'ive animals receiving the WyB4 isolate virus 
than the nai've animals receiving the CDC swarm. Among the 30 collected mutants 
of CDC na'ive, the numbers of mutants with 1-4 point mutations were 22, 3, 4, and 1, 
respectively, with the average number of mutations per mutant equaled 1.47 (standard 
error: 0.16), and 15 of 44 (34.1%) mutations occurred in epitopes A-E. Among the 19 
collected mutants of WyB4 na'ive, the number of mutants with 1-4 point mutations 
were 6, 10, 2, and 1, respectively, with the average number of mutations per mutant 
equaled 1.89 (standard error: 0.19), and 21 of 36 (58.3%) mutations occurred in 
epitopes A-E. The difference of the average number of mutations per mutant of CDC 
nai've and WyB4 na'ive is hence significant (p = 0.039). Again, the mechanisms 
behind these data are not clear, but they suggest the appearance of some form of 
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heterotypic immunity in the CDC stock virus. That is, the immune system of the 
Guinea pig either put more pressure on the WyB4 strain to evolve or took longer to 
clear the WyB4 and so allowed it to evolve longer relative to the CDC stock virus. 
An estimation of evolutionary time from the total number of mutations in the HA 
protein suggests the explanation is more likely the former. 
6.3.4 Partitioning the Amino Acids by Charge is Optimal 
The RAMM model discussed in this chapter deals with the numbers of amino acids 
belonging to a certain category in different years. Besides the charged-uncharged 
categorization of the 20 amino acids, we considered 6 different categories, which 
were polar (Arg, Asn, Asp, Cyc, Glu, Gln, His, Lys, Ser, Thr, Tyr), hydrophobic 
(Ala, Gly, Ile, Leu, Met, Phe, Pro, 'frp, Val), basic (Arg, Lys, His), acidic (Asp, 
Glu), amides (Asn), aliphatic (Gly, Ala, Val, Leu, Ile), to generate different data sets 
for the RAMM model. Four combinations among these seven categories were also 
introduced with the amino acids in each category being counted once, which were 
charged+basic, charged+acidic, charged+polar, hydrophobic+aliphatic, respectively. 
To further generalize the R2 value given by the RAMM model, different combinations 
of epitopes were focused on. Here the sequence of H3 hemagglutinin (HAl) between 
position 44 and 312 was split into six subsets: epitope A-E, and the amino acids 
outside any epitope, defined as 0. Table 6.3 shows that charged amino acids are 
among the categories best fit by the RAMM model. Table 6.4 lists the R2 values of 
the RAMM model for 7 categories of amino acids that are counted in 6 combinations 
of epitopes containing epitope B, the dominant epitope in the year of 1972-1987. 
Compared with Table 6.3, Table 6.4 indicates that focusing on the dominant epitope 
leads to the approximately optimal fitting. 
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Table 6.3 : R2 values for amino acid categories and epitope B, the dominant epitope, 
using dominant circulating strains in 1972-1987 from which the model is trained. 
Seven categories and four combinations of categories are presented here. These 
four combinations involving charged and hydrophobic amino acids are chosen as 
the supplement to the seven categories, because charged and hydrophobic amino 
acids, especially charged ones, are critical in protein-protein interaction and evolu-
tion [8, 9, 10, 11, 12]. 
Categories R2 Categories R2 
Charged 0.9810 Charged+ Basic 0.9932 
Polar 0.9620 Charged+ Acidic 0.9567 
Hydrophobic 0.9586 Charged+ Polar 0.9568 
Basic 0.9872 Hydrophobic+ Aliphatic 0.8528 
Acidic 0.8743 
Ami des 0.6217 
Aliphatic 0.7698 
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Table 6.4 : R2 values for· amino acid categories and combinations of epitopes involving 
epitope B, the dominant epitope, using dominant circulating strains in 1972-1987 
from which the model is trained. Residues outside an epitope are denoted by 0. 
The dominant circulating strains in the time span of 1972-1987 have epitope B as 
the dominant epitope. The H3N2 virus emerged in 1968, therefore less adaptation to 
host immune system was developed compared with other time span. The previous 
discuss indicates that epitope B had the immunodominance in this period of time, 
and this table shows the limited contribution of amino acids outside the dominant 
epitope to the pattern of evolution. 
Epitopes AB BC BD BE BO ABCDEO 
Charged 0.8928 0.9782 0.9431 0.9913 0.9810 0.8935 
Polar 0.8187 0.9620 0.7780 0.8528 0.9766 0.7656 
Hydrophobic 0.9586 0.9771 0.7928 0.9580 0.9884 0.9766 
Basic 0.9872 0.9872 0.9913 0.9456 0.9872 0.9917 
Acidic 0.4730 0.9210 0.6337 0.7245 0.6838 0.3916 
Ami des 0.9771 0.7922 0.9834 0.2171 0.8443 0.9326 
Aliphatic 0.4976 0.9009 0.7648 0.3787 0.7895 0.6129 
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6.4 Discussion 
6.4.1 Data Fitting and Verifying the RAMM Model 
For the historical data, our analysis was based on both the dominant circulating strain 
and the average of all circulating strains deposited in NCBI database. The frequency 
of database strains is not currently available. In addition, because clear sequential 
and temporal relationships between the sequences are unavailable, the fixation of 
mutations is unknown. Although some trends in the mutations have emerged (such 
as increased numbers of both charged residues in defined epitopes and total numbers 
of glycosylation sites throughout the HA ectodomain), the majority of the sequences 
do not appear to be fixed. 
For the Guinea pig animal model, the frequency of both wildtype and variants 
were collected and tabulated. These data allowed us to calculate a population average 
of all the strains with no loss of frequency information when counting the average 
number of mutations and the increase of charged amino acids. For the Guinea pig 
experiment, we have sequences for all the strains characterized in all animals, and can 
thus calculate the true population average. However, at this time we do not have firm 
data on fixation rates of variants in the Guinea pig infection. Some of the observed 
variants could have been fixed over the 4-6 rounds of replication that occurred in 
the three-day infection, but a serial transmission experiment performed in immune 
animals would be required to provide quantitative data on mutations have become 
immunologically fixed. Thus, the quality of the Guinea pig data and the human 
database with respect to fixation of mutations is comparably similar. 
Note the RAMM model calibrated to years of human epidemiological data fit well 
the Guinea pig experimental data. Figure 6.8 and Figure 6.9 compare the observed 
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evolution of the HA envelope in the CDC Wyoming mixed ·stock and the purified 
WyB4 isolate with the evolution predicted by the two models. As shown above, the 
model fit the in vivo data well for the CDC stock but underestimated the accumula-
tion of charged residues observed in progeny from the WyB4 infections. CDC stock 
was an ensemble of a dominant and three closely-related variants while WyB4, the 
plaque-purified isolate and the dominant member of the CDC stock was the virus 
that appeared to have greater replicative capacity in Guinea pigs as compared to the 
variants in the CDC stock. The CDC stock infection of nai"ve animals more closely 
represents a cross-section of a transmitting quasi-species related to all the circulating 
strains existing in one year, while the WyB4 infection of nai"ve animals may model 
the dominant circulating strain. 
Table 6.4 provides further support to the hypothesis of a single dominant epitope. 
These data show the R2 values of the correlations between observations and the model 
using numbers of charged amino acids in a variety of combinations of epitopes as well 
as a general null model using the whole sequence of H3 HA. Different amino acid 
categories are also incorporated in Table 6.4 to show the R2 values of the correlation 
between observations and the model. Thus, as in previous studies [61], Table 6.4 
confirms that calculations using the single dominant epitope lead to the approximately 
optimal fitting between the observations and the model. None of the inclusions of 
subdominant epitopes yields R2 values much greater than that of focusing on the 
single dominant epitope. 
The results obtained from the discrete-time and continuous-time Markov chains 
were essentially identical. By comparing expressions (6.3) and (6.7), the parameter set 
of the discrete-time Markov chain (€, o, Pco) and that of the continuous-time Markov 
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{: = 
1 - e-(.xl +-X2) 
.X2 1 
.X1 + .X2 4 
{6.17) 
The discrete-ti:rne Markov chain was appropriate for the case in this chapter because 
the time unit for the data was year. Currently there is limited time resolution avail-
able, hence using discrete-time model with one-year time resolution did not lose any 
information. The virus evolves continuously in different geographic regions, however, 
and spreads among these regions by the migration of humans and birds. Further-
more, the global virus strains in a given time point constitutes an ensemble where 
the population of different strains varies. Available data are the dominant circulating 
strains in each year, as well as the database strains. Therefore, the average numbers 
of charged amino acids should be the weighted sum of all the database strains in each 
year, rather than their simple arithmetic means. It will be of significant help to know 
the frequency of each database strain so that a population average can be calculated. 
6.4.2 Model Reversibility 
Most previous models assumed the reversibility of the Markov chain, whose transition 
matrices P = {Pij} and equilibrium probability distributions 1r = {7ri} satisfied the 
detailed balance equation 
{6.18) 
Such models were mainly designed to describe the evolution of bacteria,· archaea, and 
eukaryota living in a relative constant environment. The evolution of these species 
is probably dominated by a stable and loose natural selection that is tolerant to 
mildly deleterious polymorphism [151]. Viruses, on the other hand, perform their 
biological function in other organisms, and usually their surface protein antigens are 
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targeted by the immune systems in the antigen sequence space that makes the virus 
evolution under strong, directed, and changing selection. This arrow of time due 
to directed selection invalidates the reversibility assumption, because 1r is changing, 
and this higher degree of freedom must be accounted for when formulating the model. 
In the data shown here, the detailed balance condition (6.18) was not established, 
because the immune pressure and selection are constantly changing. In other words, 
when starting from a non-steady state initial condition, the system will first converge 
toward the steady state before fluctuating about that steady state until the immune 
pressure changes again. We studied the non-equilibrium dynamics of the evolution: 
the evolution of the probability distribution was dominated by a changing proportion 
of charged amino acids. 
Compared with Figure 6.4 and Figure 6.5, PAM22 fit better with both the cir-
culating strains and the database in later years than in early years partly because 
the equilibrium probability distribution of PAM22 model (6.16) solved by (6.18) was 
Pc = 0.25, Pu = 0. 75, hence the expected numbers of charged amino acid in epitope 
A and epitope B were 5.31 and 4.81, close to the numbers in later years depicted in 
Figure 6.1 and Figure 6.3. On the other hand, PAM22 drifted away from both the 
circulating strains and the database strains in the early stage after the emergence of 
H3N2 virus, when the immune escape was underway most strongly. This phenom-
ena showed that H3N2 virus did not follow the general law of protein evolution in a 
constant environment in the early years, while its evolution returned to steady state 
about twenty years after its emergence in 1968. The higher fixation rate of charged 
residues determined by the RAMM model versus the general PAM model is due to 
immune pressure. 
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6.4.3 Fluctuation and Spatial Distribution of Charge 
The dominant epitopes [2] in history were epitope A and epitope B, so in a certain year 
one of them was dominant while the other was subdominant. As a common trend, 
the number of charged amino acids on the dominant epitope increased and that on 
the subdominant epitope decreased. The explanation is likely that an increase in 
number of charged amino acids reduces the free energy of binding of antibodies to 
the epitope, by increasing the affinity of the epitope for water. Although the number 
of charged amino acid on the subdominant epitope decreased almost monotonically, 
it never decreased to the initial level. 
[9] pointed out that the epitopes of A/ Aichi/2/1968 and A/Kamata/14/1991 share 
similar shapes, hence the spatial distribution of charged amino acids on the epitopes 
could be estimated from the available structure of Aichi strains in 1968 (PDB entry: 
!KEN). We plotted such figures for epitope A and B for each circulating strain. 
The number and position of hydrophobic amino acids were relatively conservative: 
hydrophobic amino acids existed at position (130, 138, 168) on epitope A and position 
(163, 194, 196, 198) on epitope B in each circulating strain. Positions (130, 138, 168) 
located in three corners of epitope A while positions (163, 194, 196, 198) constituted 
a continuous region on the center of epitope B. The hydrophobic center on epitope 
B was gradually surrounded by charged amino acids during the virus evolution in 
1972-1987, so in the epitope shift year of 1989, epitope B contained a hydrophobic 
center surrounded by charged amino acid, a structure found in other protein-protein 
interaction cases [8]. This arrangement of amino acids was preserved in epitope B 
in later years, which may be the reason that the number of charged amino acids 
stayed in a high level in epitope B. Epitope A, however, did not evolve into the stable 
structure with a hydrophobic center surrounded by charged residues; thus the number 
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of charged amino acids fell to a lower level when epitope A was subdominant than 
when epitope B was subdominant. We also repeated the same analysis on the recently 
emerged H5Nl strains, using as epitopes the residues aligned to H3N2 epitopes. We 
did not observe a significant change in the number of charged amino acids, perhaps 
since the H5Nl virus has not evolved substantially in human. 
6.5 Conclusion 
Mutation of the H3 hemagglutinin on the surface of the the influenza virus decreases 
the ability of the immune system to recognize the flu and decreases the efficacy of the 
annual vaccine. We show that influenza tends to increase the number of charged amino 
acids in the regions of hemagglutinin that the immune system recognizes, probably 
because this reduces ability of antibodies to bind hemagglutinin. An interesting 
corollary of this selection is that the number of charges in the dominant epitope of the 
dominant circulating virus strain is never fewer than that in the vaccine strain, chosen 
early in the season. We developed a model of the evolution of charge iri hemagglutinin 
by partitioning 20 amino acids into two categories: charged and uncharged, calibrated 
this model on virus evolution data in humans, and demonstrated the model on Guinea 
pig animal model studies. 
Protein evolution models such as PAM model and BLOSUM model typically apply 
to the evolution of bacteria, archaea, and eukaryota. For influenza virus, the harsh 
and changing environment due to immune pressure on the virus, makes its evolution a 
non-equilibrium dynamics, especially in the time period after its initial emergence in 
humans. The RAMM model supports the hypothesis that the rate of charge evolution 
is greater in regions of hemagglutinin recognized by the immune system than in 
proteins in general. Such temporal and spatial heterogeneity requires a method such 
144 
as we have presented here for modeling the virus evolution. 
6.6 Supplementary Material 
6.6.1 Fitting the Markov Models 
Two methods were applied to fix the parameters: a non-linear least square fitting 
and the maximum likelihood estimation. To fix the data points for the least square 
fitting, the observed numbers of charged amino acids Nc were asserted to be equal 
to the means of the binomial distribution each year. The parameters 8 = (€, 8, Pco) 
in the discrete-time Markov chain were fit by non-linear least squares in each time 
interval based on the observed values Pc (t I €, 8, Pco) = Nc/N, using the parametric 
form (6.3). 
The estimated number of annually mutated residues on epitope B in this interval 
was 
number of mutated residues - Nc€ ( 1 - ~ace)+ Nu€ ( 1 - 115 auu) 
= 19N€+€8 (Nu _ Nc) 
20 15 5 
19 ~ 20N€ (6.19) 
where Nc and Nu were the numbers of charged and uncharged amino acid residues in 
the dominant epitope, respectively. 
When €t is small, the original model of Pc (t I €, 8) reduced to 
Pc(tl€,8) = ~(1+48-(1-€)t(1+48-4Pco)) 
1( ~ 4 1 + 48 - {1 - €t) {1 + 48 - 4Pco)) 
= Pco + €8t (6.20) 
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which meant that when € -+ 0 and €8 -+ const, €8 was the rate of increase of the 
probability that a charged amino acid exists at a certain position on the dominant 
epitope. 
Chapter 7 
Predicting Fixation Tendencies of the H3N2 
Influenza Virus by Free Energy Calculation 
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Influenza virus evolves to escape from immune system antibodies that bind to it. We 
used free energy calculations with Einstein crystals as reference states to calculate the 
difference of antibody binding free energy (~~G) induced by amino acid substitution 
at each position in epitope B of the H3N2 influenza hemagglutinin, the key target for 
antibody. A substitution with positive ~~G value decreases the antibody binding 
constant. On average an uncharged to charged amino acid substitution generates 
the highest ~~G values. Also on average, substitutions between small amino acids 
generate ~~G values near to zero. The 21 sites in epitope B have varying expected 
free energy differences for a random substitution. Historical amino acid substitutions 
in epitope B for the A/ Aichi/2/1968 strain of influenza A show that most fixed and 
temporarily circulating substitutions generate positive ~~G values. We propose that 
the observed pattern of H3N2 virus evolution is affected by the free energy landscape, 
the mapping from the free energy landscape to virus fitness landscape, and random 
genetic drift of the virus. Monte Carlo simulations of virus evolution are presented 
to support this view. 
7.1 Introduction 
Influenza A virus causes annual global epidemics resulting in 5-15% of the population 
being infected, 3-5 million severe cases, and 250,00Q--500,000 fatalities [14]. The 
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subtype of influenza A is determined by two surface glycoproteins-hemagglutinin (H) 
and neuraminidase (N). The H3N2 virus has been one of the dominant circulating 
subtypes since its emergence in 1968. The antibodies IgG and IgA are the major 
components of the immune system that control influenza infection, binding to the 
influenza hemagglutinin [72]. There are five epitopes at the antibody binding sites 
on the top of H3 hemagglutinin, namely epitopes A-E. The epitope bound most 
prolifically by antibody is defined as the dominant epitope, and it is central to the 
process of virus neutralization by antibody and virus escape substitution [2]. The 
cellular immune system, on the other hand, plays a relatively less recognized role 
in handling the invasive influenza virus [72]. The cellular system along with the 
innate immune system exerts a somewhat more homogeneous immune reaction against 
genetically distinct influenza strains [73, 72]. 
Vaccination is currently the primary method to prevent and control an influenza 
epidemic in the human population [14]. Influenza vaccination raises the level of 
antibody specific for hemagglutinin and significantly enhances the binding affinity 
between antibody and hemagglutinin. Vaccine effectiveness depends on the antigenic 
distance between the hemagglutinin of the administered vaccine strain and that of 
the dominant circulating strain in the same season [2, 74]. Memory immune response 
from virus in previous seasons as well as vaccination in the current and previous 
seasons impose selective pressure on the current circulating virus to force it to evolve 
away from the virus strains recognized by memory antibodies that selectively bind to 
hemagglutinin. 
As a result of the immune pressure and the escape evolution of the influenza virus, 
which is largely substitution in the dominant epitope of hemagglutinin, the influenza 
vaccine must be redesigned and administered each year, and the vaccine effectiveness 
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has been suboptimal in some flu seasons [2, 33]. The escape evolution in the dominant 
epitope is at a higher rate than that in the amino acid sites outside the dominant 
epitope [42]. Sites in the dominant epitope also show higher Shannon entropy of the 
20 amino acids than do those outside the dominant epitope [1 J. High substitution 
rate and Shannon entropy in the dominant epitope of hemagglutinin suggest that 
the dominant epitope is under the strongest positive selection by human antibodies. 
The immune pressure against each genotype of the dominant epitope can be at least 
partially quantified by the binding constant between antibody and hemagglutinin. 
The H3N2 virus and human immune system in this work are simplified to be a 
system consisting of the H3 hemagglutinin and the corresponding human antibody. 
Exposure by infection or vaccination produces an affinity-matured antibody with the 
binding constant to the corresponding hemagglutinin equal to 106-107 M-1 , while 
the binding constant of an antibody uncorrelated to the hemagglutinin is below 102 
M-1 [72]. Escape substitutions may decrease the binding constant by changing the 
antibody binding free energy t::..G. Some substitutions decrease the antibody binding 
constant more than others and have higher probabilities to be fixed, because decrease 
in the antibody binding constant is favorable to the virus. Here we define the differ-
ence of antibody binding free energy as t::..t::..G = t::..G42 - b..G31 in which b..G31 and 
t::..G42 are antibody-wildtype hemagglutinin binding free energy and antibody-evolved 
hemagglutinin binding free energy, respectively, as shown in Figure 7.1. The fixation 
tendency of each substitution is a function of the difference of the antibody binding 
free energy [75] of the escape substitution. 
Epitope A or B of the H3N2 virus was dominant in most influenza seasons [2]. 
Epitope B of the H3N2 virus was the dominant epitope presenting more substitutions 
than any other epitope in the recent years. Epitope B was also dominant in 1968 
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when H3N2 virus emerged. Thus during these periods of time, the substitutions in 
epitope B directly affect the antibody binding constant and reflect the direction of 
the virus escape substitution. To attain a global view of the effects of substitutions in 
epitope B, it is necessary to compute a matrix containing the differences of antibody 
binding free energy caused by each possible single substitution in epitope B. There 
are 21 amino acid sites in epitope B, and each residue in the wild type strain may 
substitute to any of the 19 different types to amino acid residues, hence we need 
to calculate a 19 x 21 matrix with 399 elements. Such a matrix is a free energy 
landscape quantifying the immune selection over each evolved influenza strain. In 
this free energy landscape, the virus tends to evolve to a position with low binding 
affinity of antibody to evade antibodies and reduce the immune pressure. Calculation 
of this landscape will enable us to study the mechanism of immune escape from a 
quantitative viewpoint, providing a criterion to describe and foresee the evolution of 
influenza virus. 
This chapter is organized as follows: In Materials and Methods section, we de-
scribe the protocol for the free energy calculation and the system of hemagglutinin 
and antibody. In Results section, we present and analyze the calculated free energy 
landscape. The substitutions observed in history are also compared with the results 
of the calculation. In the Discussion section, a general picture of H3N2 virus evolu-
tion under the selection pressure of the immune system is discussed and simulation 
results are discussed. Finally, our work is summarized in the Conclusion section. 
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7. 2 Materials and Methods 
7.2.1 Scheme of the Free Energy Calculation 
The expression of the binding constant K depends on the antibody binding free energy 
!::l.G, K = exp(-!::l.G/RT). The Boltzmann constant R = 1.987 x 10-3 kcaljmol/K. 
The temperature is fixed to the normal human body temperature T = 310 K. Shown 
in Figure 7.1, one substitution in hemagglutinin changes the antibody binding free 
energy from !::l.G31 to !::l.G42 . The first and second subscripts define the end state 
and the starting state of the binding process, respectively. The ratio of the antibody 
binding constant after and before substitution is written as 
K1 Ko = exp (-!::l.!::l.GjRT) (7.1) 
where K 1 and K 0 are the antibody binding constant to substituted and wildtype 
hemagglutinin, respectively. 
The difference of the antibody binding free energy !::l.!::l.G = !::l.G42 - !::l.G31 = 
!::l.G43 - !::l.G21 is calculated by applying the Hess' Law to the thermodynamic cycle 
defined by State 1-4 in Figure 7 .1. The processes corresponding to !::l.G 43 and !::l.G21 
are unphysical but more convenient to simulate. We calculated !::l.G21 and !::l.G43 for 
each amino acid substitution in the unbound hemagglutinin and hemagglutinin bound 
by antibody, respectively. On the surface of the virus particle, hemagglutinin exists 
in the form of a trimer in which three monomers are encoded by the same virus gene. 
Thus we simultaneously substituted the amino acids in three hemagglutinin monomers 
in the trimer. The antibody has a Y-shaped structure with two heavy chains and two 
light chains. In the resolved structure (PDB code: 1KEN), the hemagglutinin trimer 
is bound by two Fab fragments. Thus, we incorporated the Fab dimer into the system 
for MD simulation. 
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Using the software CHARMM [152], we calculated each of b.G21 and b.G43 using 
thermodynamic integration [153]. We used molecular dynamics (MD) simulation to 
obtain the ensemble averages of the integrand from which each of b.G21 and b.G43 is 
calculated. The potential energy for the MD algorithm to sample the conformation 
space of the system is 
U (r, >.) = (1- >.) Ureac (r) + >.Uprod (r) (7.2) 
in which r is the coordinates of all the atoms, >. is the variable of integration, Ureac is 
the potential energy of the system corresponding to wild type hemagglutinin, and Uprod 
is the potential energy of the system corresponding to substituted hemagglutinin. The 
value of b.G21 or b.G43 is 
fl I au (r, >.)) fl 
b.G = Jo \ 8>. ,\d).= Jo (Uprod (r)- Ureac (r)),x d>.. (7.3) 
The integrand (Uprod ( r) - Ureac ( r)) ,x is the ensemble average with fixed >. of potential 
energy difference between the system after and before substitution. The interval of 
integration>. E (0, 1) was equally divided into four subintervals in each of which a 16-
point Gauss-Legendre quadrature was applied to numerically integrate the ensemble 
averages. The ensemble averages with 64 distinct >. E (0, 1) were calculated by MD 
simulation with the potential energy defined in equation 7.2. 
7.2.2 Einstein Crystal 
We introduce the Einstein crystals to calculate the free energy of the reference state in 
the dual topology at both endpoints of the thermodynamic integration. To illustrate 
the function of the Einstein crystals, we analyze the free energy of the dual topology 
without Einstein crystals when>.= 0 as an example. We denoted by n 1 , n 2 , and n0 
numbers of the reactant atoms, product atoms, and all the remaining atoms in the 
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State 1: Separated Slate 2: Separated 
antibody and ~G,. Slate 1a 6G,b State 1b 6Gz,b State 2b t.G,. State2a t.G,. antibody and wjldtype evolved 
hemagglutinin hemagglutinin 
6Ga1 6G42 
Stale 3: Complex State 4: Complex 
of antibody and t.G,. State 3a t.G,. Slate 3b b.G43b Slate4b t.G .. State 4a t.G., of anUbody and 
wlldtype evolved 
hemagglutinin hemagglutinin 
t.G., 
Figure 7.1 : The scheme of the free energy calculation. The free energy difference of 
one substitution is calculated by !:l.!:l.G = !:l.G43 - !:l.G21 . Staten, n = 1-4, is the real 
system. State na has the same configuration of atoms as state n except that all the 
hydrogen atoms have mass 16.000 amu. Compared to state na, state nb contains one 
additional Einstein crystal of product atoms (n = 1, 3) or reactant atoms (n = 2, 4). 
The mass of hydrogen atoms in state nb is also 16.000 amu. Free energy !:l.G21b and 
!:l.G43b are obtained by thermodynamic integration. 
system, respectively. We denoted by r, r product, and x the coordinates of the reactant 
atoms, product atoms, and all the remaining atoms in the system. The momenta of 
reactant atoms, product atoms, and the remaining atoms are denoted by Pr,i• Pp,i, 
and Px,i· The masses are similarly denoted by mr,i• mp,i• and mx,i· The Hamiltonian 
of the system with .A= 0 is 
~ 2 ~ 2 ~ 2 
H = L 2Px,i. + L 2Pr,i. + L 2Pp,i. +Uno (x)+(1- .A) Uno+nl (x, r)+.AUno+n2 (x, Tproduct). 
i=l mx,. i=l mr,• i=l mp,• 
(7.4) 
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The partition function is 
no ( 2 ) 3/2 nt ( 2 . ) 3/2 n2 ( 21rm . ) 3/2 
Q =II ~~;·i II :;·· P h2 ;·· 
i=l i=l . •=1 J dx dr exp [-.BUno (x)- ,BUno+n1 (x, r)] X J drproduct 1 
n2 [(2 )3/2 l 
=Qreal X  ;;,i V 
=Qreal X Qproduct· (7.5) 
When .>.. = 0, this partition function is the product of Qreal, the partition function 
of the real system without product atoms, and Qproduct' the partition function of the 
product atoms when.>..= 0. 
The free energy is given by -1/ .B times the logarithm of the above partition 
function. The free energy is 
(7.6) 
As shown in the above equation, the effect on the translational entropy from the 
product atoms is proportional to the logarithm of system size V. It diverges in the 
thermodynamic limit. This divergence exists, no matter what.>.. scaling is performed. 
Note that we do not use the Einstein crystals to handle the translational entropy a 
ligand loses or gains when binding a flexible biomolecular receptor, which is taken 
into account by the thermodynamic cycle in Figure 7.1. The translational entropy, 
proportional to log V in equation 7.6, is that of the dummy product atoms, not that 
of the bound or unbound complex. 
The value of G depends on the identity of the product atoms. Thus, the con-
tribution to the thermodynamic integration is different at the two endpoints, i.e. 
-kT log Qreactant =f -kT log Qproduct, in which Qreactant is the partition function of the 
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reactant atoms when >. = 1. Note also that the expression of the partition function 
contains the factor Qproduct for the product atoms. Relating the conventional expres-
sion for thermodynamic integration, equation 7.3, to b..b..G of equation 7.1 requires 
one to account for this term. This term arises from the use of a dual topology in 
CHARMM, and this term is typically ignored. While the contribution from the de-
coupled atoms is not constant, it can be exactly calculated if the restricted partition 
function over the decoupled atoms can be calculated. This calculation is what the 
Einstein crystal performs, using an Einstein crystal for the reference state rather the 
ideal gas in equation 7.4. 
In four 16-window thermodynamic integrations, the smallest variable of integra-
tion is >. = 1.32 x 10-3 . Since >. is close to zero, product atoms in the system have 
potential energy near zero and behave as ideal gas atoms, with translational entropy 
proportional to the logarithm of system size, see equation 7.6. Exact calculation of 
the translational entropy terms of product atoms at >. = 0 by explicit dynamics seems 
difficult, because the translational entropy of the product atoms grows as the loga-
rithm of the system size. These relatively free product atoms destabilize the system. 
This entropy divergence is a fundamental feature of the statistical mechanics, not a 
numerical artifact. Unrestrained product atoms induce large fluctuation of the Hamil-
tonian in the MD algorithm. These fluctuations increase the standard error of the 
quantity Uprod (r) - Ureac (r), which is defined in equation 7.3 and is computed from 
the trajectory of the MD simulation. These fluctuations often cause the numerical 
integration algorithm in the MD simulation to be unstable [154]. IIi this case, the en-
ergy of the simulated system increases rapidly. This phenomenon causes CHARMM 
to terminate abnormally. The translational entropy introduced by the free atoms at 
>. = 0 and 1 affects the result. Reactant atoms cause the same problem near >. = 1. 
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We noticed that the non-linear scaling, i.e. using a high power of>. such as the 
fourth power of>., in equation 7.2 [155, 156] did not work. The high power of the 
smallest >. is extremely close to zero and the product atoms are almost free, which 
cause the MD simulation to terminate abnormally at several windows with small 
>.. Additionally, the issue of translational entropy of reactant and product atoms 
needs to be addressed. Even when the MD algorithm with the non-linear scaling 
of >. [155, 156] terminates and appears to have generated a converged simulation 
trajectory, this does not necessarily imply that the translational entropy of reactant 
or product atoms has been properly controlled. In fact, the >.scaling approach may 
hide the entropy divergence at >. = 0 or >. = 1 by letting the algorithm terminate 
due to numerical roundoff error, rather than building statistical mechanical reference 
states for each of >. = 0 and >. = 1 to account for or control the effect of translational 
entropy. 
An alternative to >. scaling introduces the soft-core potential as a way to turn off 
the potential [157, 158]. The soft-core approach, like the lambda-scaling approach, 
does not address the translation entropy of the atoms at >. = 0 or >. = 1. Previous 
studies with non-constrained atoms at both endpoints have been performed [159, 160, 
161, 162, 163, 164, 165]. Besides the classical molecular dynamics with a non-ideal-
gas reference state introduced into the dual topology, quantum molecular dynamics 
via metadynamics has been used to analyze a deamidation process [166]. Other 
applications of quantum molecular dynamics based free energy calculation include 
chorismate conversion to prephenate [167], isomerization of glycine [168], and histone 
lysine methylation [169]. As illustrated in equation 7.6, the translational entropy of 
the uncoupled atoms causes error in the final free energy results if it is not accounted 
for. 
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One way to calculate the free energy change exactly is to use a non-ideal-gas 
reference state. This is quite natural, since the protein is not composed of ideal gas 
atoms. Deng and Raux introduced restraint potentials to confine the translational 
and rotational motion of a bound ligand to accelerate convergence of the simulation 
[170). We use this idea to exactly include the contribution from the restrained states 
and built two Einstein crystals as the reference states for reactant and product atoms, 
respectively. Our calculation allows a theoretically exact determination of the free 
energy due to amino acid substitution. 
To handle these two difficulties at both endpoints of the integration in a theo-
retically exact way, we use two Einstein crystals as the reference states for reactant 
and product atoms, respectively. The Einstein crystal has been used as a reference 
state for free energy calculations. Frenkel and Ladd computed free energy of solids 
by building a path connecting the real solid and the reference Einstein crystal [171]. 
N oya et al. showed that a restrained Einstein crystal is a suitable reference in the free 
energy calculation of biomolecules [172). The Einstein crystal, a solid state model, 
is consistent with the nature of antibody binding process in liquid phase. First, al-
though the importance of biomolecular flexibility in protein-protein binding process 
is well-accepted, and is fully and exactly included in our calculation, we simply need 
to localize the product atorris when A = 0 and the reactant atoms when A = 1. 
Moreover, we· need to calculate the contribution to the free energy of these localized 
atoms. 
The choice of Einstein crystals as the reference states removes the singularity in 
thermodynamicintegrationin equation 7.3. As an example, an Einstein crystal was 
used as the reference state for the free energy calculation of hard-sphere fluid in order 
to remove the singularity in equation 7.3 at the end point A= 0 [173). In this example, 
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the reference Einstein crystal was achieved by harmonically coupling the particles to 
their equilibrium positions and removing all interactions between particles [17 4]. 
We here use Einstein crystals as the reference states to calculate the binding free 
energy change due to amino acid substitution. The Einstein crystal is a model for 
localized atoms. The free energy of the Einstein crystal can be exactly calculated. One 
Einstein crystal contains distinguishable and non-interacting atoms under harmonic 
constraints around reference positions fixed in space. In the Einstein crystal, the 
atom i with coordinates r i has potential energy 
(7.7) 
in which r i and riO are the actual and reference position of the atom, respectively, 
and Ki is the force constant of the harmonic constraint. We denote by mi the mass 
of atom i. The canonical partition function of an Einstein crystal is 
_1 j (~ -{3p~) (~ -f3Ki iiri- rwll 2 ) d d QE (N, V, T) = h3N exp {;;: 2mi exp {;;: 2 p r 
(211')3N N (mi)3/2 h/3 g Ki (7.8) 
The spatial fluctuation of atom i in the Einstein crystal is 
(7.9) 
In our system, we let the potential energy for MD simulation defined by equation 
7.2 become 
U (r, >.) = (1- >.) Ureoc; (r) + >.Uprod (r) + >.Uein,reac (r) + (1- >.) Uein,prod (r). (7.10) 
Therefore reactant and product atoms are localized at both >. = 0 and >. = 1. The 
reference positions of atoms in Einstein crystals are the equilibrium positions of cor-
responding reactant and product atoms. To minimize the numerical error during 
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the thermodynamic integration calculation, we minimized the fluctuation of the in-
tegrand of thermodynamic integration (au ( r' >.) I a>.) A = ( Uein,reac ( r) - Ureac ( r)) A + 
(U prod ( r) - Uein,prod ( r)) A. Minimization of the terms on the right hand size is approx-
imately achieved by letting the average spatial fluctuation of each atom in Einstein 
crystals equal to that of the corresponding reactant or product atom, i.e. 
( 2) ( 2) 3 8r· = 8r· = ( ') reac ( ') ein,reac (3 K[eac (7.11) 
. 3 ((8r·)2 ) = ((8r·)2) = -~ 
' prod ' ein,prod (3 Kfrod (7.12) 
For each atom in the Einstein crystal, the force constant of harmonic constraint, 
K[eac or Krod, was calculated from the monitored fluctuations of the corresponding 
reactant or product atom with equation 7.11 or equation 7.12. In the scheme in 
Figure 7.1, the states with Einstein crystals are states 1b, 2b, 3b, and 4b. 
7 .2.3 Modified Hydrogen Atoms 
The frequency of atom vibration depends on its mass. Hydrogen atoms generaliy have 
the highest vibration frequencies in the system. Such high frequencies require short 
time step in MD simulation and increase computational load. To limit vibration 
frequencies and allow a longer time step, one can apply the SHAKE algorithm to 
fix the length of any bond involving hydrogen atoms [175]. The SHAKE algorithm 
decreases the degrees of freedom in the system by introducing additional constraints 
between atoms. Instead, we artificially changed the mass of hydrogen atoms from 
1.008 to 16.000 amu in order to preserve degree of freedom in the system following 
the suggestion by Bennett [176]. A larger mass of hydrogen atoms allows a longer 
time step in the MD algorithm. Pomes and McCammon showed that changing the 
hydrogen mass to 10 amu allow using a 0.01 ps time step to simulate a system which 
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consists of 215 TIP3P water molecules, smaller than our system [177]. Feenstra et al. 
change the mass of hydrogen atoms to 4 amu to increase the simulation stability of a 
system which contains protein and water molecules and resembles our system [178]. 
We set the time step as 0.001 ps, a value widely used in simulations with physical 
masses for all atoms, to gain higher stability in the simulation of our large system 
with a hemagglutinin trimer, a Fab dimer, and water molecules. As with the Einstein 
crystals, we exactly calculated and subtracted off the contribution of the change to the 
hydrogen mass to l:l.l:l.G. Note that the modification of hydrogen mass is independent 
to the reference states in the simulation, which is selected to be Einstein crystals in 
this project. In fact, most of the hydrogen atoms in the system are neither reactant 
nor product atoms. In Figure 7.1, the states with Einstein crystals and modified 
hydrogen atoms are states 1a, 2a, 3a, 4a, 1b, 2b, 3b, and 4b. 
7.2.4 Expressions of Free Energies 
Introducing two Einstein crystals and heavier hydrogen atoms changes the potential 
energy in the system, as well as the canonical partition functions. After modification 
of hydrogen atoms, the mass of atoms changed from mr,i to m~,i' from mp,i to m~,i' 
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or from mx,i to m~,i. Canonical partition functions of the states in Figure 7.1 are: 
X z3 (no+ nb v, T) (7.14) 
1 no ( 21rm' . ) 3/2 n1 ( 21rm' . ) 3/2 
Q3b (no+ nl + n2, v, T) = h3(no+nl) n f3 x,t n T 
X z3 (no+ n, v, T) G; r fi ( ;j.::. r (7.15) 
Q, (no+ n,, V, T) h3(~+n,) fi C'?';) 3/2 fi C'';'·;) 3/2 
X z4 (no+ n2, v, T) (7.16) 
Q4a (no+ n2, V, T) 1 no ( 21rm' . ) 3/2 n2 ( 21rm' . ) 3/2 -=-~ IT x,t IT p,t h3(no+n2) -/3- f3 
i=l i=l 
xZ4(n0 +n2,V,T) (7.17) 
Q4b (no+ n1 + n2, V, T) 1 no ( 21rm' ·)3/2 n2 ( 21rm' ··)3/2 --.-----:- IT x,t IT p,t h3(no+n2) f3 f3 
i=l i=l 
X Z,(n.,+n2, V,T) G;tfi (;:i~ r (7.18) 
in which the states are denoted by the subscripts. Contribution of the potential 
energy part of the Hamiltonian to the partition function is 
Z3(no+n1,V,T) = jexp(-f3Uno+n1 (r))dr 
Z4 (no+ n2, V, T) = J exp ( -f3Uno+n2 (r)) dr 
(7.19) 
(7.20) 
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From the partition functions, free energies defined in Figure 7.1 are calculated: 
!:l.Gaa = (7.21) 
!:l.G4a = (7.22) 
!:l.Gab = (7.23) 
!:l.G4b = (7.24) 
(7.25) 
in which QE1 and QE2 are the partition functions of the Einstein crystals for product 
atoms and reactant atoms, respectively. The free energy !:l.G43b was calculated by 
thermodynamic integration while !:l.G43 was used to calculate the free energy differ-
ence of one substitution. Note that the correction term between !:l.G43b and !:l.G43 
is independent of the masses of atoms. Canonical partition functions as well as free 
energies of the state 1, 1a, 1b, 2, 2a, and 2b are calculated in a similar way. 
7 .2.5 Implementation of Free Energy Calculation Algorithm 
The above discussion is the theoretical basis for the implementation of our free energy 
calculation algorithm. The free energy calculation protocol consists of four steps. 
First, we built the dual topology with reactant and product atoms in the amino acid 
substitution site in separated antibody and hemagglutinin or antibody-hemagglutinin 
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complex. We then solvated the protein system and modified the mass of hydrogen 
atoms. Second, two Einstein crystals were introduced as the reference states for the 
reactant and product atoms, respectively. Third, the MD simulation was run at 64 
windows. The thermodynamic integration algorithm obtained the free energy values 
!::..G21 for separated antibody and hemagglutinin or t::..G43 for antibody-hemagglutinin 
complex, as in Figure 7.1. This step gave the t::..t::..G value. Fourth, we calculated 
the error bar of the t::..t::..G value obtained in the last step. The technical details of 
these four steps are illustrated in the text below. Also described are the verification 
of the free energy calculation protocol, the software and hardware information, and 
the CPU hours consumed by the protocol. 
The hemagglutinin trimer of H3N2 virus strain A/ Aichi/2/1968 with bound dimer 
antibody HC63 (PDB code: 1KEN) was used in our calculation. For each amino acid 
substitution, we built the dual topology with side chains of both amino acids prior to 
the simulation. Reactant and product atoms were defined as the side chains in the 
original and substituting amino acid, respectively. All the covalent and non-bonded 
interactions between reactant and product atoms were removed. The protein was in 
an explicit water box with periodic boundary condition. The mass of hydrogen atoms 
was changed from 1.008 to 16.000 amu. 
All the simulations were performed by CHARMM c33b2 with CHARMM22 force 
field [152]. We first fixed the positions of hemagglutinin trimer except reactant atoms 
and minimized the system with 200 steps of steepest descent (SD) algorithm and 
5000 steps of adopted basis Newton-Raphson (ABNR) algorithm. We ran a 5 ps 
MD simulation of the system, the trajectory of which gave the spatial fluctuation 
((6ri)2 ) of each reactant atom .. Then we fixed reactant atoms, released product 
atoms, and ran a 5 ps MD simulation to obtain the spatial fluctuation of each product 
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atom. Final positions of both reactant and product were adopted as the reference 
positions of the corresponding Einstein crystal. The force constant Ki of each atom 
in Einstein crystals was obtained from ((8ri)2 ) by equation 7.11 and equation 7.12. 
With modified hydrogen atoms and two Einstein crystals as the reference states of 
reactant and product atoms, state lb, 2b, 3b, and 4b in Figure 7.1 were generated 
for thermodynamic integration. 
In thermodynamic integration, MD simulations were run at 64 windows with dis-
tinct .X. In each window, pressure of the system was first calibrated with a 10 ps 
MD simulation in an isothermal-isobaric (NPT) ensemble. The duration of 10 ps is 
appropriate because it is long enough to equilibrate the pressure and short enough to 
prevent the protein from drifting away from the original location. We fixed coordi-
nates of the residues and water molecules except for those within 15 A from the three 
alpha carbons. Then we removed amino acid residues and water molecules other than 
those within 27.5 A from the three alpha carbons of substituted residues in the hemag-
glutinin trimer to reduce the system size, because the fixed atoms are not included 
in the topology of movable atoms and the cutoff of the non-bonded forces is 12 A. 
The Ewald sum was used to calculate charge interactions. Note that this substantial 
reduction of the system relies on the assumption that the free energy change due to 
the amino acid substitution is mostly affected by atoms near the binding site after the 
system reaches equilibrium. This assumption is based on two facts: the conformations 
of hemagglutinin and antibody are stable once the system reaches equilibrium, and all 
the removed or fixed atoms have invariant interactions with the substituting amino 
acid residues. The stable protein conformation means amino acid residues far away 
from the substituting residue do not move during the amino acid substitution process. 
In the CHARMM22 force field used in this project, the cutoff of non-bonded force is 
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12 A and less than the 15 A threshold for system reduction. The system reduction 
does not directly affect the force on the substituted residue because of absence of 
the long-range non-bonded force between the substituted residue and atoms removed 
from the system. This system reduction method was also applied to compute binding 
free energy of subtilisin [179], of tripsin [163], and of Src SH2 domain [164]. Robust 
results were obtained in all of these applications. Generally, this system reduction 
strategy can produce reliable result if the reduced system contains the residues and 
molecules critical to the binding process [163]. We note that the system reduction 
method could be a limitation of the free energy calculation model. The fixing of amino 
acid residues and water molecules described in section 2.5 substantially reduced the 
CPU time needed, but is an approximation to the real system containing the whole 
proteins. This limitation reflects the tradeoff between model accuracy and required 
computational resource. In the canonical ensemble, the new system was equilibrated 
for 200 ps and simulated for another 900 ps as the data production phase. The inte-
grand of thermodynamic integration is the ensemble average of the sampled trajec-
tory (8U (r, .X) /8-Xh = (Uein,reac (r)- Ureac·(r)- Uein,prod (r) + Uprod (r)),x· The free 
energy ~G21 and ~G43 between the real states was calculated by adding a correction 
term of the Einstein crystals in equation 7.26. Finally, the difference of antibody 
binding free energy is ~~G = ~G43- ~G21· 
Error bars of ~~G are also given. The convergence behavior of the simulation 
was analyzed using the block average method developed by Flyvbjerg and Petersen 
[180]. As mentioned above, the MD simulation for either the unbound hemagglutinin 
or the hemagglutinin-antibody complex contains 64 windows with distinct .X. The 
900 ps data production phase contains 9 x 105 simulation steps. The values A = 
Uprod (r)- Ureac (r), as in equation equation 7.3, computed in consecutive simulation 
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steps were grouped into bins, and consecutive bins were merged progressively. The 
quantity a 2 (A) 1 (n- 1), in which a 2 (A) is the variance of the average of each bin 
A1 , A2 , .•• , An and n is the number of bins, increases with the bin size and reaches a 
plateau when the bin size is 1 x 104 steps. We fixed the bin size to 1 x 104 steps and 
estimate the variance of ensemble average (A) as a 2 (A) I (n- 1), following Flyvbjerg 
and Petersen's method [180]. 
This protocol, without the Einstein crystal contribution, was verified by recalcu-
lating published free energy differences of amino acid substitution T1311 [75]. With-
out the Einstein crystal contribution, our protocol gave the ~~G = 5.69 ± 0.07 
kcallmol, compared to the ~~G = 5.20 ± 0.94 kcallmol in the published work [75]. 
Theoretically exact results presented here include the Einstein crystal contribution. 
We note that the theoretically exact ~~G for T131I, including the Einstein crystal 
contribution, is 3. 71 ± 0.07 kcallmol. 
The simulation was performed using CHARMM22 force field at three clusters: tg-
steele.purdue.teragrid.org (Intel Xeon E5410, 2.33 GHz), sugar.rice.edu (Intel Xeon 
E5440, 2.83 GHz), and biou.rice.edu (IBM POWER7, 3.55 GHz), as well as at the 
condor pool tg-condor.rcac.purdue.edu at Purdue University. Simulation of each sub-
stitution took approximately 7.5 thousand CPU hours on average, and so this work 
consumed about three million CPU hours. 
7.3 Results 
7.3.1 Free Energy Landscape 
For each of the 21 amino acid sites in epitope B, we substituted from alanine to each 
one of the 19 other amino acids, in which we used the neutral histidine (CHARMM 
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code: Hse) as the model of histidine. The free energy difference and standard error of 
each substitution were calculated by the MD simulation (see Materials and Methods). 
The wildtype amino acid in each site of epitope B was extracted from the hemagglu-
tinin sequence of the H3N2 strain A/ Aichi/2/1968. The free energy difference and 
standard error of the substitution from the wildtype amino acid in each site were then 
calculated from the values for the change from the wildtype amino acid to alanine 
and from alanine to the new amino acid. The values are listed in Table 7.1. 
Table 7.1 : Summary of the calculated free energy differences b.b.G in each amino 
acid site in epitope B from the wildtype amino acid to all 20 amino acids. The 
standard errors are also listed. The free energy difference and its standard error of 
the substitution from the wildtype amino acid to itself are both zero. The units of 
free energy differences and their standard errors are kcal/mol. 
Positions 128 129 155 156 157 158 159 
Ala -13.12 ± 0.27 3.33 ± 0.29 2.78 ± 0.20 1.19 ± 0.33 2.48 ± 0.21 4.27 ± 0.31 5.18 ± 0.21 
Arg 22.57 ± 0.46 2.31 ± 0.45 16.98 ± 0.37 0.08 ± 0.50 -4.19 ± 0.44 -1.61 ± 0.48 7.07 ± 0.42 
Asn -4.80 ± 0.36 5.83 ± 0.42 -7.83 ± 0.30 10.72 ± 0.40 5.64 ± 0.34 3.41 ± 0.42 10.97 ± 0.35 
Asp 4.52 ± 0.38 19.12 ± 0.42 16.28 ± 0.32 11.06 ± 0.42 9.95 ± 0.37 18.37 ± 0.40 15.34 ± 0.36 
Cys -11.83 ± 0.34 12.64 ± 0.37 -2.37 ± 0.30 5.32 ± 0.38 -2.72 ± 0.29 -7.88 ± 0.40 7.92 ± 0.32 
Gln -12.37 ± 0.40 7.34 ± 0.42 -4.29 ± 0.36 13.14 ± 0.41 -0.45 ± 0.36 11.47 ± 0.43 6.54 ± 0.40 
Glu 11.15 ± 0.38 10.50 ± 0.42 17.77 ± 0.34 26.54 ± 0.43 4.68 ± 0.36 8.58 ± 0.48 5.19 ± 0.39 
Gly -9.93 ± 0.39 o.oo ± o.oo 17.00 ± 0.34 0.11 ± 0.44 0.21 ± 0.36 o.oo ± 0.00 -4.19 ± 0.41 
Hse 4.43 ± 0.42 0.15 ± 0.43 2.47 ± 0.36 -6.89 ± 0.43 12.18 ± 0.38 5.54 ± 0.46 1.06 ± 0.39 
lle -16.03 ± 0.41 0.54 ± 0.40 1.55 ± 0.33 8.33 ± 0.42 11.22 ± 0.37 8.09 ± 0.43 18.96 ± 0.39 
Leu -23.58 ± 0.41 -4.27 ± 0.43 -8.92 ± 0.33 2.64 ± 0.45 -6.26 ± 0.39 1.61 ± 0.45 4.08 ± 0.38 
Lys 3.57 ± 0.45 11.18 ± 0.46 14.58 ± 0.37 o.oo ± 0.00 6.24 ± 0.40 -1.60 ± 0.48 5.39 ± 0.46 
Met -13.38 ± 0.39 ~2.59 ± 0.39 1.23 ± 0.35 10.11 ± 0.43 16.15 ± 0.36 14.49 ± 0.44 -6.38 ± 0.37 
Phe -10.21 ± 0.45 6.12 ± 0.43 9.39 ± 0.35 0.30 ± 0.45 10.28 ± 0.40 5.17 ± 0.48 12.33 ± 0.42 
Pro -9.36 ± 0.36 -2.43 ± 0.42 -1.86 ± 0.31 2.32 ± 0.43 5.69 ± 0.30 17.09 ± 0.40 6.08 ± 0.36 
Ser -14.55 ± 0.34 3.36 ± 0.37 -1.09 ± 0.29 -1.45 ± 0.38 0.00 ± o.oo 2.76 ± 0.39 0.00 ± 0.00 
Thr 0.00 ± 0.00 7.35 ± 0.36 0.00 ± 0.00 -1.08 ± 0.41 6.34 ± 0.32 8.36 ± 0.41 15.32 ± 0.32 
Trp 9.82 ± 0.47 4.81 ± 0.47 19.84 ± 0.43 23.26 ± 0.48 16.14 ± 0.45 3.52 ± 0.62 -1.35 ± 0.45 
Tyr -14.83 ± 0.43 2.72 ± 0.42 7.25 ± 0.36 -2.18 ± 0.46 -8.37 ± 0.44 18.42 ± 0.51 5.95 ± 0.43 
Val -19.13 ± 0.37 3.56 ± 0.38 8.57 ± 0.31 -3.01 ± 0.39 7.63 ± 0.32 3.77 ± 0.42 6.45 ± 0.32 
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Positions 160 163 165 186 187 188 189 
Ala 4.16 ± 0.22 -0.24 ± 0.22 4.15 ± 0.24 -3.19 ± 0.19 -4.03 ± 0.23 3.45 ± 0.25 9.01 ± 0.28 
Arg 9.70 ± 0.44 5.97 ± 0.39 14.58 ± 0.41 21.01 ± 0.38 8.12 ± 0.42 -0.06 ± 0.45 0.39 ± 0.48 
Asn 2.07 ± 0.34 2.32 ± 0.32 0.00 ± 0.00 4.67 ± 0.30 -10.07 ± 0.34 0.00 ± 0.00 -3.18 ± 0.37 
Asp 13.50 ± 0.32 12.64 ± 0.32 25.01 ± 0.31 24.54 ± 0.28 7.78 ± 0.35 19.77 ± 0.37 6.77 ± 0.35 
Cys 15.82 ± 0.31 1.84 ± 0.30 1.93 ± 0.29 -2.30 ± 0.25 -11.09 ± 0.32 4.07 ± 0.34 6.23 ± 0.33 
Gin 3.04 ± 0.39 -8.29 ± 0.35 4.27 ± 0.36 5.16 ± 0.33 -2.87 ± 0.37 12.36 ± 0.39 0.00 ± 0.00 
Glu 15.48 ± 0.36 2.17 ± 0.35 15.74 ± 0.34 33.29 ± 0.31 14.41 ± 0.35 10.10 ± 0.37 12.16 ± 0.39 
Gly 1.22 ± 0.39 -5.83 ± 0.38 9.11 ± 0.37 0.13 ± 0.27 -0.60 ± 0.30 -5.06 ± 0.32 -5.69 ± 0.32 
Hse 0.52 ± 0.38 6.31 ± 0.33 7.44 ± 0.33 18.15 ± 0.30 3.69 ± 0.39 -1.95 ± 0.40 -8.53 ± 0.40 
lie 1.51 ± 0.34 10.62 ± 0.36 3.85 ± 0.33 -1.85 ± 0.30 -2.51 ± 0.33 -4.77 ± 0.37 3.65 ± 0.37 
Leu -1.39 ± 0.40 3.85 ± 0.35 -9.20 ± 0.37 1.07 ± 0.30 -0.40 ± 0.38 -1.30 ± 0.37 -6.91 ± 0.39 
Lys 5.91 ± 0.44 10.37 ± 0.38 1.93 ± 0.41 -1.15 ± 0.39 24.91 ± 0.41 8.42 ± 0.44 9.48 ± 0.64 
Met 10.78 ± 0.38 7.22 ± 0.35 1.63 ± 0.36 13.06 ± 0.33 -5.11 ± 0.36 6.97 ± 0.38 6.86 ± 0.40 
Phe 7.90 ± 0.41 -0.86 ± 0.36 13.87 ± 0.38 6.94 ± 0.33 -7.23 ± 0.39 2.05 ± 0.39 4.37 ± 0.43 
Pro 4.51 ± 0.32 12.50 ± 0.34 18.96 ± 0.33 11.82 ± 0.29 10.69 ± 0.32 -10.24 ± 0.35 -8.98 ± 0.36 
Ser 7.13 ± 0.29 9.07 ± 0.30 -0.92 ± 0.28 0.00 ± 0.00 -4.88 ± 0.31 8.09 ± 0.33 -5.09 ± 0.34 
Thr 0.00 ± 0.00 9.18 ± 0.30 10.35 ± 0.31 -14.79 ± 0.27 0.00 ± 0.00 3.53 ± 0.38 9.30 ± 0.35 
Trp 0.86 ± 0.44 12.34 ± 0.35 19.02 ± 0.43 -7.69 ± 0.38 -11.04 ± 0.48 7.20 ± 0.40 -9.19 ± 0.45 
Tyr -5.43 ± 0.39 1.06 ± 0.34 14.76 ± 0.37 11.90 ± 0.33 5.29 ± 0.42 1.57 ± 0.40 4.81 ± 0.41 
Val 7.99 ± 0.34 0.00 ± 0.00 9.79 ± 0.32 2.97 ± 0.29 3.08 ± 0.33 3.73 ± 0.34 -7.89 ± 0.36 
Positions 190 192 193 194 196 197 198 
Ala -18.12 ± 0.24 -0.86 ± 0.23 -5.20 ± 0.20 2.37 ± 0.23 5.95 ± 0.23 -2.40 ± 0.29 0.00 ± 0.00 
Arg 4.97 ± 0.41 23.07 ± 0.44 32.33 ± 0.41 -13.66 ± 0.37 -25.38 ± 0.44 -17.94 ± 0.47 3_.99 ± 0.37 
Asn -16.44 ± 0.30 -2.56 ± 0.32 8.24 ± 0.30 -3.81 ± 0.31 13.27 ± 0.36 -6.58 ± 0.38 0.05 ± 0.28 
Asp. 18.75 ± 0.32 2.92 ± 0.32 15.29 ± 0.29 26.72 ± 0.35 9.25 ± 0.34 5.58 ± 0.39 5.17 ± 0.24 
Cys -20.36 ± 0.32 -1.45 ± 0.32 -9.79 ± 0.26 1.91 ± 0.30 1.30 ± 0.31 6.(0 ± 0.36 5.91 ± 0.22 
Gin -17.37 ± 0.37 -6.00 ± 0.37 4.87 ± 0.34 -0.83 ± 0.32 7.68 ± 0.36 0.00 ± 0.00 1.41 ± 0.31 
Glu 0.00 ± 0.00 1.18 ± 0.35 45.40 ± 0.34 38.35 ± 0.33 3.60 ± 0.36 11.34 ± 0.41 2.37 ± 0.30 
Gly -17.09 ± 0.29 -13.46 ± 0.30 -13.89 ± 0.27 -18.59 ± 0.30 8.08.± 0.31 4.11 ± 0.36 3.65 ± 0.28 
Hs~ -26.26 ± 0.35 -Q.96 ± 0.38 -0.96 ± 0.35 9.95 ± 0.34 i8.42 ± 0.37 -2.62 ± 0.40 -3.27 ± 0.35 
Ile -16.45 ± 0.37 -5.57 ± 0.37 -3.80 ± 0.31 -6.91 ± 0.32 0.77 :j: 0.34 1.23 ± 0.41 0.01 ± 0.32 
Leu -17.27 ± 0.36 -7.97 ± 0.37 10.76 ± 0.34 0.00 ± 0.00 10.07 ± 0.39 -0.03 ± 0.40 -11.18 ± 0.29 
Lys -9.33 ± 0.38 5.67 ± 0.42 39.36 ± 0.39 -16.67 ± 0.38 0.49 ± 0.40 -16.50 ;1: 0.47 1.98 ± 0.37 
Met -26.63 ±0.34 6.82 ± 0.36 -2.91 ± 0.32 7.75 ± 0.35 4.08 ± 0.37 -7.79 ± 0.40 15.57 ± 0.32 
Phe -31.89 ± 0.39 1.56 ± 0.40 16.46 ± 0.59 2.78 ± 0.34 -1.99.± 0.37 l.Ofi ± 0.44 8.73 ± 0.34 
Pro -17.85 ± 0.33 -2.28 ± 0.33 9.84 ± 0.31 8.01 ± 0.31 15.42 :j: 0.35 -5.34 ± 0.40 Q.70 ± 0.29 
Ser -14.75 ± 0.31 -7.79 ± 0.30 0.00 ± 0.00 6.62 ± 0.29 6.91 ± 0.29 1.97 ± 0.36 -2.40 ± 0.22 
Thr -4.17 ± 0.32 0.00 ± 0.00 -2.04 ± 0.27 12.40 ± 0.31 7.81 ± 0.33 -7.91 ± 0.36 6.79 ± 0.24 
Trp -22.93 ± 0.39 2.31 ± 0.44 17.92 ± 0.42 -1.30 ± 0.40 8.17 ± 0.43 -7.73 ± 0.44 -7.23 ± 0.38 
Tyr -13.82 ± 0.38 7.63 ± 0.42 16.16 ± 0.38 9.73 ± 0.36 2.92 ± 0.40 6.10 ± 0.44 -4.82 ± 0.32 
Val, -9.12 ± 0.31 -6.80 ± 0.32 -6.92 ± 0.30 2.59 ± 0.29 0.00 ± 0.00 .4.16 ± 0.39 -4.22 ± 0.24 
As described in equation 7.26, each b..b..G value listed in Table 7.1 contains the 
contribution of two Einstein crystals. The contribution of Einstein crystals to the final 
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A.A.G values was calculated for each of the 399 amino acid substitutions in epitope B. 
The average fraction of the contribution of Einstein crystals in the calculated A.A.G 
values is 44%. The contribution of Einstein crystals is far greater than that of the 
statistical error of our free energy calculation in Table 7.1, which is 4.5% on average. 
Thus, the Einstein crystal contribution is both theoretically exact and practically 
important. In 371 of the 399 substitutions, the absolute values of the contribution of 
Einstein crystals is greater than 1.96 standard errors of the final A.A.G values. That 
is, the contribution of Einstein crystals is significant with p < 0.05 in 93.0% of all 
the amino acid substitutions. Consequently, it is essential to incorporate Einstein 
crystals in the free energy calculation to eliminate the error caused by the methods 
that neglect the unknown effect of the translational entropy of the free atoms in 
thermodynamic integration. The contribution of the translational entropy of ideal 
gas-like atoms ( >. = 0 or >. = 1) needs to be either calculated or removed by a 
theoretically exact method to perform an exact free energy calculation. 
The obtained A.A.G values allow us to analyze the character of each of the 20 
amino acids. We first averaged over all the 21 amino acid sites in epitope B the 
A.A.G value caused by the single substitutions from alanine to the other amino acids. 
The averaged A.A.G values are listed in Table 7.2. The largest A.A.G are caused 
by the negatively charged amino acids (Glu, Asp) and the positively charged amino 
acids (Arg, Lys), indicating that introduction of charged amino acids in the dominant 
epitope decreases the binding affinity between antibody and hemagglutinin. Note that 
amino acid substitutions that change the charge of hemagglutinin significantly affect 
the calculated free energy values [181, 182, 183]. The issue of how to best calculate 
free energy differences when charge changes has been debated over the years. In the 
present paper, we are using the standard Ewald approach with explicit solvent. We 
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note that the evolutionary history of H3 hemagglutinin since 1968 shows an increasing 
trend of the number of charged amino acids in epitope B [132], which agrees with 
the results that introduction of charged amino facilitates virus evasion from antibody, 
as illustrated in Table 7.2. The result that introduction of charged amino acid on 
average increases tltlG is not an artifact, is supported by data from the influenza 
evolution, and is expected on the basis that charge is hydrophilic. In addition to the 
charge, the rank of free energy differences also largely correlated to the size of amino 
acid. By the definition used by RasMol [13], the 16 uncharged amino acids are tagged 
as hydrophobic {Ala, Gly, Ile, Leu, Met, Phe, Pro, Trp, Tyr, Val), large {Gin, Hse, 
Ile, Leu, Met, Phe, Trp, Tyr), medium (Asn, Cys, Pro, Thr, Val), and small {Ala, 
Gly, Ser), as shown in Table 7.2. The ranks of small amino acids are lower than those 
of medium amino acids (p = 0.036, Wilcoxon rank-sum test) and those of large amino 
acids (p = 0.085, Wilcoxon rank-sum test). In contrast, the hydrophobicity of the 
uncharged amino acids is largely uncorrelated to their ranks by tltlG. As a result, 
charged amino acids in the dominant epitope are essential to the immune evasion 
while the virus escape substitution among small amino acids have minimal effect. 
Epitope B comprises 21 amino acid sites in the top ofthe hemagglutinin trimer. 
Taking the probability for one substituting amino acid to exist at each site to be 
proportional to the relative frequency of this amino acid in H3 hemagglutinin, the 
weighted average free energy difference in each of the 21 sites was calculated. The 
relative frequencies of .20 amino acids were obtained from 6896 H3 hemagglutinin 
sequences deposited between 1968 and 2009 in the NCBI database [184] and listed in 
Table 7.2. Also using the tltlG values in Table 7.1, we calculated and tabulated in 
Table 7.3 for each site i the value of (tltlG}i, which is the average tltlG weighted 
by the probability for each different amino acid to be introduced, where probability 
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Table 7.2 : The rank ofthe average binding free energy difference of the single substi-
tution from alanine to another amino acid over all the 21 amino acid sites in epitope 
B of hemagglutinin trimer. The rank correlates with the charge and the size of amino 
acid, and it is relatively uncorrelated to the hydrophobicity. Here we applied clas-
sifications of RasMol for the biochemical properties of the 20 amino acids (13]. The 
relative frequencies of 20 amino acids were counted from the H3 sequences in NCB! 
database from 1968 to 2009. 
Rank Amino Acid t:.t:.G (kcal/mol) Charged Hydrophobic Large Medium Small Relative frequency 
1 Glu 14.612 ± 0.061 X X 0.029 
2 Asp 14.533 ± 0.055 X X 0.051 
3 Arg 6.018 ± 0,078 X X 0.052 
4 Lys 5. 766 ± 0.078 X X 0.057 
5 Trp 4.458 ± 0.081 X X 0.016 
6 Tyr 3.984 ± 0.071 X X 0.035 
7 Thr 3.981 ± 0.050 X 0,078 
8 Pro 3.912 ± 0.054 X X 0.060 
9 Met 3.562 ± 0.062 X X 0.009 
10 Phe 3.522 ± 0.073 X X 0.030 
11 Hse 2.654 ± 0.064 X 0.020 
12 Gin 1.985 ± 0.063 X 0.042 
13 Ile 1.396 ± 0.060 X X 0.070 
14 Asn 1.150 ± 0.054 X 0.085 
15 Val 1.147 ± 0.051 X X 0.055 
16 Cys 0.888 ± 0.046 X 0.028 
17 Ser 0.469 ± 0.044 X 0.096 
(18) (Ala) (0.000 ± 0.000) X X 0.046 
19 Gly 
-1.612 ± 0.055 X X 0.070 
20 Leu -2.273 ± 0.064 X X 0.071 
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is proportional to the relative frequencies of 20 amino acids counted from the H3 
sequences in NCBI database from 1968 to 2009. 
As shown in Table 7.3, there is obvious variation among the expected free energy 
differences (tl.tl.G)i caused by single substitutions at amino acid site i of epitope B. 
This variation is partly due to the wildtype amino acids in the sites. For instance, 
the wildtype amino acid in site 190 is Glu that has the highest rank in Table 7.2. 
As shown in Table 7.3, any amino acid substitution in site 190 tends to have a 
negative tl.tl.G. Another cause of variation in (fl.f}.G)i is that distinct sites affect 
differently the antibody binding process. Epitope B of the wildtype A/ Aichi/2/1968 
hemagglutinin sequence contains five sites with threonine: 128, 155, 160, 187, and 
192. The mathematical expectancies (tl.tl.G)i in these five sites are -7.746, 4.471, 
4.956, 1.182, and -1.737 kcal/mol, respectively. Therefore, each site in epitope B has 
a specific effect on the virus escape substitution. A random substitution in epitope 
B affects the antibody binding free energy differently depending on the site and the 
substituting amino acids. 
The variation of (tl.tl.G)i is also reflected by the tertiary structure of the epitope 
B bound by the antibody. By looking into the structure of epitope B shown in Figure 
7.2. Epitope B resides in two protruding loops from amino acid site 128 to 129, and 
from site 155 to 165, respectively, and in a a-helix from site 186 to 198. Site 128 
has a negative average free energy difference (tl.tl.G) 128 = -7.746 ± 0.098 kcaljmol. 
All the other sites in these two loops show a positive (tl.tl.G)i value of a random 
substitution, with the minimum (tl.tl.G) 157 = 3.944 ± 0.090 kcal/mol in site 157. 
The a-helix is located between hemagglutinin and antibody. In the a-helix, the sites 
facing towards the antibody usually present large positive (fl.f}.G)i values such as site 
193 and 196, while the sites facing towards the hemagglutinin show lower (f}.fl.G)i 
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Table 7.3 : The rank of the average free energy difference (b.b.G)i generated by a 
substitution in each amino acid site i of epitope B. 
Rank Site (b.b.G)i (kcal/mol) 
1 193 8.074 ± 0.081 
2 159 7. 792 ± 0.094 
3 165 7.741 ± 0.086 
4 158 6.128 ± 0.108 
5 196 5.444 ± 0.088 
6 160 4.956 ± 0.090 
7 186 4.754 ± 0.076 
8 163 4.722 ± 0.085 
9 129 4.690 ± 0.103 
10 155 4.471 ± 0.081 
11 156 4.029 ± 0.106 
12 157 3.944 ± 0.090 
13 188 2.945 ± 0.092 
14 194 1.886 ± 0.080 
15 187 1.182 ± 0.087 
16 198 0.531 ± 0.072 
17 189 
-0.631 ± 0.098 
18 192 -1.737 ± 0.087 
19 197 -1.967 ± 0.099 
20 128 -7.746 ± 0.098 
21 190 -12.666 ± 0.084 
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such as site 189, 192, and 197. Thus in the one dimensional sequence from site 186 
to 198, the (~~G)i values oscillate with peaks and valleys corresponding to the sites 
in the a-helix facing alternatingly to the antibody and hemagglutinin. Consequently, 
the variation of the expected free energy changes in distinct sites depends on the 
structure of the hemagglutinin-antibody complex. 
7.3.2 Historical Substitutions in Epitope B 
The simulation results are supported in two aspects by amino acid sequence data of 
H3 hemagglutinin collected since 1968. These historical sequences are downloaded 
from the NCB! Influenza Virus Resource [185] and aligned. First, Pan et al. analyzed 
the number of charged amino acid in epitope B of H3 hemagglutinin in each year 
since 1968, and found an increasing trend of charged amino acids [132]. This finding 
supports the results that amino acid substitution introducing charged residues on 
average facilitates virus escape from antibody, as illustrated in Table 7 .2. Second, 
amino acid substitutions in epitope B between 1968 and 1975 also verified the free 
energy calculation, as shown below. 
With the knowledge of the free energy landscape of the single substitutions, we are 
able to recognize favorable single substitutions in epitope B. Substitutions with large 
positive ~~G values enable the virus to evade the immune pressure and increase 
the virus fitness. Favorable substitutions grow in the virus population. Selection 
for substitutions with large ~~G is part of the evolutionary strategy of the virus. 
The results of free energy calculation can also explain the substituted virus strains 
collected in history. 
We analyzed the hemagglutinin sequence information of H3N2 strains evolving 
from the A/ Aichi/2/1968 strains. H3 hemagglutinin circulating from 1968 to 1971 
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Figure 7.2 : The tertiary structure of the interface between the HAl domain of 
H3 hemagglutinin monomer A/ Aichi/2/1968 (bottom) and the antibody HC63 (top) 
(PDB code: lKEN). Water molecules are not shown. Epitope B of the HAl domain 
is located in two loops and one a-helix with the color scale modulated according to 
the expected free energy difference (~~G)i of each site i in epitope B. The color scale 
ranges from red for the most negative (~!:::.G)i values to blue for the most positive 
(D.D.G)i values. The sites i in epitope B with (~~G)i near zero are colored white. 
The region outside epitope B is colored gray. The red site 128 is far from the antibody 
binding region and the red site 190 possessed the original amino acid .Glu, which is a 
charged amino acid. It may explain why these two sites show negative (D.D.G) i with 
large absolute values. 
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was mainly in the HK68 antigenic cluster while those circulating from 1972 to 1975 
were mainly in the EN72 antigenic cluster [30]. Table 7.4 shows that in the dominant 
epitope B, there were 17 substitutions occurred in 12 sites collected between 1968 to 
1975 [4], which contributed to the immune evasion and corresponding virus evolution 
from the HK68 cluster to the EN72 cluster. Also listed in Table 7.4 are the free energy 
differences of these historical substitutions. The 17 substituting amino acids have 
significantly higher ranks compared to the corresponding wildtype amino acids (p = 
0.0044, Wilcoxon signed-rank test). This significant difference is expected because 15 
of 17 substituting amino acids have ranks between 1 and 10, while 10 of 12 wildtype 
amino acids in the substituted site have ranks between 11 and 20. In all the 21 
sites in epitope B, 15 of 21 wildtype amino acids have ranks between 11 and 20. 
Additionally, the b..b..G values of these 17 substitutions listed in Table 7.4 are greater 
than the expected free energy differences (b..b..G)i in Table 7.3 of random substitutions 
in the 12 substituted sites (p = 0.013, Wilcoxon signed-rank test). 
We also looked into the historical escape substitutions in epitope B evading the 
immune pressure of the vaccine strains. For each influenza season, the amino acids 
in the administered vaccine strain were defined as the wildtype ones and those in the 
dominant cir~ulating strain as the substituting amino acids. In each of the 19 seasons 
in which H3N2 virus was the dominant subtype from 1971 to 2004, the substitutions 
in epitope B were located [2] and their b..b..G values were obtained from Table 7.1. 
As shown in Table 7.5, escape substitutions in epitope B as of 1973 mostly had 
positive b..b..G and generated substituting amino acids with increased rank (p = 0.047, 
Wilcoxon signed-rank test). Such tendency to introduce amino acids with higher ranks 
was not observed after 1973: the ranks of wildtype and substituting amino acids after 
1973 present little significant difference (p = 0.28, Wilcoxon signed-rank test). The 
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Table 7.4 : Substitutions occurred in epitope B of the hemagglutinin A/ Aichi/2/1968 
(H3N2) as of 1975. Also listed are the time when the substitutions were observed, 
and the free energy differences with standard errors. In each site of epitope B, all 
the 20 amino acid were sorted in the descending order by the free energy differences 
introduced by a substitution from the wildtype amino acid to 20 amino acids. The 
ranks of the substituting amino acid and the wildtype amino acid in each substituted 
site are listed in the column Rank (substituting) and Rank (WT), respectively. 
Substitution Year AAG (kcal/mol) Rank (substituting) Rank (WT) 
T128N 1911 -4.796 ± 0.361 8 7 
T1281 1975 -16.026 ± 0.412 18 7 
G129E 1970, 1972 10.500 ± 0.415 4 17 
T155Y 1972-1973, fixed in 1973 7.254 ± 0.358 9 14 
Gl58E 1971-1972 8.584 ± 0.479 6 17 
S159N 1911, 1974-1975 10.969 ± 0.352 5 17 
S159C 1972 7.923 ± 0.324 6 17 
S159R 1972 7.065 ± 0.424 7 17 
T160A 1973 4.160 ± 0.217 11 18 
S186N 1975 4.673 ± 0.298 10 14 
N188D 1971-1973, fixed in 1973 19.767 ± 0.367 1 14 
Q189K 1975 9.484 ± 0.640 2 10 
E190V 1972 -9.115 ± 0.310 5 3 
E190D 1975 18.752 ± 0.324 3 
S193N 1972-1975 8.239 ± 0.301 10 12 
81930 1975 15.285 ± 0.294 7 12 
A198T 1972 6. 793 ± 0.236 3 14 
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hemagglutinin of A/ Aichi/2/1968 used in the free energy calculating is in the HK68 
antigenic cluster. Perhaps after the virus evolved into the next EN72 cluster, change 
in the virus antigenic character stimulates the immune system to produce new types 
of antibody other than the HC63 antibody used in the calculation. A different binding 
antibody changes the free energy landscape of the substitutions in epitope B. Thus 
the application of the present free energy landscape should be limited within the 
HK68 and EN72 clusters. Free energy differences of substitutions in the EN72 cluster 
would need to be calculated using the updated antibody crystal structure. 
7.4 Discussion 
7 .4.1 Fitness of the Virus Strains 
The free energy landscape shown in Table 7.1 gives the change of the antibody binding 
affinity, Kd K0 = exp ( -b..b..G / RT), induced by each possible substitution in epitope 
B of the wildtype hemagglutinin. The majority of the substitutions lead to positive 
b..b..G, and yield a reduced binding affinity K 1 that is smaller than the binding affinity 
of the original mature antibody K 0 • Decreased antibody binding constant grants 
the virus a higher chance of evading the immune pressure and infecting host cells. 
We propose that virus fitness is positively correlated to the free energy difference 
b..b..G. The other factor affecting virus fitness is the capability of the hemagglutinin 
to maintain the normal biochemical functions, such as virus entry. Most sites in 
epitope B changed amino acid identities during 1968 to 2005 as the H3N2 virus kept 
circulating [4]. We therefore postulate that the substitutions in epitope B do not 
greatly interfere with the biochemical function of hemagglutinin, and virus fitness is 
dominantly determined by the free energy difference resulted from substitutions in 
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Table 7.5 : Substitutions occurred in epitope B of H3 hemagglutinin between the 
vaccine strain and the dominant circulating strain in each season in which the H3N2 
subtype was dominant. The free energy difference with standard error of each sub-
stitution is obtained using the free energy landscape in Table 7.1. The ranks of free 
energy differences sorted in the descending order are listed in column Rank (vaccine) 
and in column Rank (circulating) for the amino acids in the vaccine strain and the 
dominant circulating strain, respectively. 
Year Substitution D..D..G (kcal/mol) Rank (vaccine) Rank (circulating) 
1972 T155Y 7.254 ± 0.358 14 9 
1972 G158E 8.584 ± 0.479 17 6 
1972 S159C 7.923 ± 0.324 17 6 
1972 E190V -9.115 ± 0.310 3 5 
1973 T160A 4.160 ± 0.217 18 11 
1973 N188D 19.767 ± 0.367 14 
1973 S193N 8.239 ± 0.301 12 10 
1975 S157L -6.256 ± 0.394 15 19 
1975 A160T -4.160 ± 0.217 11 18 
1975 Q189K 9.484 ± 0.640 10 2 
1975 N193D 7.046 ± 0.317 10 7 
1984 E156K -26.536 ± 0.429 15 
1984 V163A -0.243 ± 0.217 15 16 
1984 D190E -18.752 ± 0.324 3 
1984 1196V -0.768 ± 0.343 16 18 
1987 Y155H -4.782 ± 0.414 9 11 
1987 E188D 9.669 ± 0.382 3 
1987 K189R -9.872 ± 0.697 2 11 
1996 V190D 27.867 ± 0.299 5 
1996 L1941 -6.914 ± 0.324 13 17 
1997 K156Q 13.140 ± 0.413 15 3 
1997 E158K -10.187 ± 0.515 6 18 
1997 V190D 27.867 ± 0.299 5 1 
1997 L1941 -6.914 ± 0.324 13 17 
1997 V196A 5.947 ± 0.229 18 11 
2003 H155T -2.472 ± 0.355 11 14 
2003 Q156H -20.028 ± 0.365 3 20 
2003 S186G 0.132 ± 0.275 14 13 
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epitope B. 
The binding constant between hemagglutinin and antibody after the first round of 
maturation is about 106 M-1 , and the binding constant of an uncorrelated antibody 
is below 102 M-1 [72). On average, four substitutions in epitope B change the substi-
tuted hemagglutinin sufficiently so that the immune response of the original antibody 
binding to epitope B is abrogated [2). Since this is a reduction of the binding constant 
from roughly 106 M-1 to 102 M-1 , one amino acid substitution that contributes to 
immune escape causes on average a 10-fold decrease in antibody binding constant, 
or equivalently ~~Gcrit = 1.42 kcal/mol at 310 K. Assuming the effect of immune 
evasion can be broken into the sum of individual amino acid substitutions in the 
dominant epitope [2), we define the virus fitness w as the sum of the contribution in 
each site of epitope B 
w=Ao+ L 8wi. 
epitope B 
(7.27) 
We denote by ~~Q~'Y the free energy difference to substitute amino acid a to amino 
acid 'Y at site i. We investigated two versions of the virus fitness landscape. The first 
is to define owi as a linear function of the free energy difference of the substitution 
(7.28) 
The second is to define 8wi as a step function 
(7.29) 
in which His the Heaviside step function. Illustrated in the simulation below, either 
definition of fitness is sufficient to explain the observed immune evasion of the H3N2 
virus. 
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7.4.2 Selection in the Epitope 
Evolution of the H3N2 virus is driven jointly by neutral evolution and selection [186]. 
Neutral evolution may be ongoing in sites outside the epitopes. The high substitution 
rate in epitope B suggests that selection is the major factor shaping the pattern of 
evolution in that epitope [4]. Shown in Table 7.4 and Table 7.5 are the historical 
substitutions. The significantly increased ranks of free energy differences suggests the 
existence of selection by the immune pressure for substitutions that have increased 
the free energy difference A.!!J.G and decreased the antibody binding constant. The 
immune selection is directional: certain types of amino acids such as charged ones 
were initially more likely to be added into the epitope B [132] because they maximally 
decreased the antibody binding constant as indicated in Table 7.2. The heterogeneity 
of the expected free energy difference of a random substitution in Table 7.3 shows 
that each site in epitope B has a specific weight with regard to immune escape. 
Table 7.4 also illustrates that the immune selection did not necessarily pick the 
amino acid with the highest rank of !!J.!!J.G as the substituting amino acid. Amino 
acids with moderate rank were introduced into epitope B even for the fixed substitu-
tion T155Y. Therefore the historical evolution did not simply substitute amino acids 
by maximizing the free energy differences in Table 7.1. This phenomenon is possibly 
due to two causes. First, the virus fitness may be insensitive to the l!J.!!J.G values, 
e.g. A1 in equation 7.28 may be small, or amino acid substitutions with large l!J.!!J.G 
values may contribute equivalently to the fitness, as in equation 7.29. Second, only a 
small fraction of virus in one host is shed by the host and infects the next host, so the 
population size of propagated virus from one host is smaller by several· orders of mag-
nitude than the total virus population size in the same host. Additionally, a seasonal 
bottleneck exists in the influenza virus circulation [32]. Both random mutation and 
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small population sizes lead to dramatic randomness in the evolution. Consequently, 
the evolution of H3 hemagglutinin is not solely determined by maximizing the free 
energy differences in Table 7.1 and minimizing the antibody binding constant, even 
if the virus is under immune selection. Instead, randomness plays a key role in the 
H3N2 virus evolution. 
7.4.3 A Picture of the H3N2 Virus Evolution 
Selection depends on the fitness of each virus genotype that is quantified as a non-
decreasing function of the free energy difference /j./j.Q. Moderate selection in epitope 
B requires that fitness improvement is limited when /j./j.G is large. One possibility 
is that the ratio Ad A0 in equation 7.28 is small. Another is that the fitness takes 
the form of equation 7.29 in which all substitutions with /j./j.Q > /j./j.Gcrit have equal 
fitness. 
The virus evolution is also affected by the genetic drift. Genetic drift is a term 
which captures the random component of evolution due to the large size of the phase 
space of possible substitutions relative to the single set of substitutions that lead to 
the highest viral fitness. The effect of genetic drift is quantitatively reflected in the 
fixation process of a new strain, as shown in the simulation below. A narrow bot-
tleneck of virus propagation allows only a small fraction of the progeny to survive, 
imposing a notable probability that a favorable substitution is lost in the next gener-
ation. The effect of genetic drift is to increase the randomness in the virus evolution 
so that observed substitutions are based on chance in addition to the fitness of these 
substitutions. 
To model the H3N2 evolution discussed above, we ran two Monte Carlo simulations 
of the influenza evolution model. A population of N sequences of epitope B with 21 
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sites were created and initialized as the wildtype A/ Aichi/2/1968 sequence. Here N = 
103 to account for a narrow genetic bottleneck of hemagglutinin and for tractability of 
the simulation. We iterated the simulation program for 5,000 generations or about five 
years to recreate a pattern of evolution similar to that in history and shown in Table 
7.4. The random substitution rate of H3 hemagglutinin is roughly 4.5 x 10-6 amino 
acid substitution/site/generation [37]. We let the number of substitutions follow a 
Poisson distribution with mean A = 21 X 4.5 X w-6 N = 9.5 X w-5 N and randomly 
assigned the substitution sites. The substituting amino acid at each substitution 
site was randomly picked from the remaining 19 amino acids proportional to the 
historical frequencies observed in hemagglutinin. The fitness w in the first simulation 
was calculated for each sequence using equation 7.28 with A0 = 100 and A1 = 3 
and that in the second simulation was calculated for each sequence using equation 
7.29 with A0 = 100, A2 = 9, and b..b..Gcrit = 1.42 kcaljmol. Note that by choosing 
A1 = 3 for the first simulation, a random substitution causes the expected fitness 
to change from 100 to 104.9, and by choosing A2 = 9 for the second simulation, a 
random substitution changes the expected fitness from 100 to 105.0. The size of the 
progeny of each sequences equals the fitness w of the sequence if w > 0, and equals 0 
if w ~ 0. The next generation of sequences was initialized by randomly sampling N 
sequences from the progeny sequences. 
The results of both simulations showed remarkable similarity to the observed sub-
stitutions in Table 7.4 with the bottleneck N equal to 103 . See Figure 7.3 and Figure 
7.4. Amino acid substitutions generated in the simulation are usually distinct with 
those in Table 7.4 observed in history. The b..b..G values of each substitution emerging 
in the simulation are nevertheless similar to those of the historical substitutions listed 
in Table 7.4. As was observed in history in Table 7.4, most of the substituted strains 
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in the simulations with relative frequency greater than 1% have positive b.b.G values 
with the ranks of the substituting amino acids ranging from 1 to 10. The fixation of 
a newly emerged substitution takes about 1,000 generations or one year on average. 
Fixed substitutions mostly introduce amino acids with positive b.b.G values in Table 
7.1 and higher ranks in Table 7.2, and several of these fixed substitutions in simula-
tion, such as E190D and N188D, have the highest b.b.G values in the current site. 
However, fixed substitutions in the simulation are not always the substitutions with 
the highest b.b.G values in Table 7.1. These observations suggest that the Monte 
Carlo simulation considering the effect of substitution, selection, and genetic drift is 
able to reproduce the pattern of evolution observed in history. This simulation also 
shows that besides the free energy difference of each substitution, the mapping from 
the free energy landscape to the fitness landscape as well as the random genetic drift 
are dominant factors of the evolution in virus epitopes. 
Shown in Figure 7.3 and Figure 7.4 for both simulations are the trajectories of 
relative frequencies of substituting amino acids. The trajectories are similar to his-
torical observations of human H3N2 virus data [4]. For influenza, 1000 generations 
roughly equal one year. The two substitutions T155Y and N188D were fixed in epi-
tope Bin 1968-1973. As indicated by Figure 7.3 and Figure 7.4, substitution T155Y 
emerged between generation 3000 and 4000, or equivalently between 1971 and 1972 
from the emergence of the H3N2 virus in 1968 [4]. Substitution T155Y was fixed 
between generation 4000 and 5000. Similarly, substitution N188D emerged between 
generation 2000 and 3000 and was fixed between generation 4000 and 5000. The first 
simulation in which virus fitness is calculated using equation 7.28 generated two fixed 
substitution, G 129A that emerged at generation 4000 and was fixed by generation 
5000, and E190D that emerged at generation 3600 and was fixed by generation 3900. 
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The second simulation using equation 7.29 generated one fixed substitutions, V196D 
emerging at generation 2900 and fixed by generation 5000, and one substitution that 
nearly fixed, N188D emerging at generation 4100 and acquiring the relative frequency 
0.84 at generation 5000. The trajectories in both simulations resemble those of sub-
stitutions T155Y and N188D observed in history. From these results, the two Monte 
Carlo simulations appear to capture the main factors of immune selection and genetic 
drift in evolution of the H3N2 virus. 
7.4.4 Multiple Substitutions 
In this work, we calculated the free energy difference for each possible substitution 
in epitope B. The free energy calculation for multiple substitutions is intractable 
using the current technology due to the combinatorially increasing calculation load 
for multiple substitutions. The issue of multiple substitutions is here addressed by 
assuming that the effect of immune evasion is well represented by the sum of the 
contribution in each substituted site in epitope B. Data indicate the independence of 
the immune evasion effect of the sites in epitope B [2]. We may, thus, assume that 
the free energy difference of the multiple substitution is the sum of the individual 
IJ.!J.G values available in Table 7.1 plus a minor correction term. 
7 .4.5 Prediction of Future Virus Evolution 
The result of this work quantifies the reduction of the binding constant of antibody 
to virus for substitutions in epitope B with larger /J./J.G values and higher ranks of 
substituting amino acids. A newly emerging virus strain with larger antibody bind-
ing free energy difference has a greater probability to become the dominant strain in 
the next flu season. Note that due to random fluctuations in the large phase space 
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Figure 7.3 : Two fixed substitutions G129A and E190D generated by Monte Carlo 
simulation of epitope B using equation 7.28. Also plotted are two historical fixed 
substitutions in epitope B: T155Y fixed between 1971 and 1973, and N188D fixed 
between 1970 and 1973. The frequency data of historical substitutions are from Shih 
et al. [4]. The origin of time axis is 1968. One thousand generation of the H3N2 virus 
is approximately one year. Figure 7.3(a) Substitution G129A causing the free energy 
difference f::l.f::l.G = 3.33 ± 0.29 kcal/mol is fixed by the simulation. The rank of the 
free energy difference ofG129A is 12 in 19 possible substitutions in site 129. Figure 
7.3(b) Substitution E190D with !:l.!:l.G = 18.75 ± 0.32 kcaljmol. The rank is 1 in 19 
possible substitutions in site 190. 
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Figure 7.4 : Two fixed substitutions N188D and V196D generated by Monte Carlo 
simulation of epitope Busing equation 7.29. Two historical fixed substitutions T155Y 
and N188D are also plotted, and data are from Shih et al. [4]. Figure 7.4(a) Substitu-
tion N188D causing the free energy difference 6.b.G = 19.77 ± 0.37 kcaljmol is fixed 
by the simulation. The rank of the free energy difference of N188D is 1 in 19 possible 
substitutions in site 188. Figure 7.4(b) Substitution V196D with b.b.G = 9.25 ± 0.34 
kcal/mol. The rank is 5 in 19 possible substitutions in site 196. The proportions of 
substituting amino acids are represented by different line types. 
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of possible substitutions, actual trajectories deviate from the trajectory determined 
by choosing sites and substituting amino acids with greatest free energy differences. 
With a three dimensional structure of hemagglutinin of the current circulating virus 
and binding antibody, one is able to calculate the free energy landscape for all the 
possible single substitutions in the dominant epitope and estimate the a priori escape 
probabilities in the next season. The dominant circulating influenza strain usually 
possesses amino acid substitutions from the vaccine strain against which memory 
antibodies are generated. Usually these substitutions disrupt the antibody binding 
process by decreasing the binding constant, as shown in Table 7.5. Thus one can 
predict vaccine effectiveness by evaluating the antibody binding constant against the 
dominant circulating strain, which is acquired by calculating free energy difference 
of the amino acid substitutions between the vaccine strain and the dominant circu-
lating strain [2]. More accurate predictions of evolutionary pattern of virus as well 
as epidemiological data such as vaccine effectiveness may be obtained by optimally 
mapping the free energy landscape to the fitness landscape and taking into account 
random factors such as genetic drift in the evolution process. 
7.5 Conclusion 
We introduced the Einstein crystal as a technology to improve the results of free 
energy calculation. By calculating the free energy difference of each amino acid sub-
stitution, we obtained the free energy landscape for substitutions in epitope B of 
hemagglutinin. There is notable variation between the values of free energy differ-
ences of different substitutions at different sites, because the identities of original and 
substituting amino acids, as well as the locations of amino acid substitutions, affect to 
differing degrees the antibody binding process. In this free energy landscape, we sug-
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gest that virus tends to evolve to higher ~~G values to escape binding of antibody. 
Counterbalancing this selection is random drift. Historical amino acid substitutions 
in epitope Band Monte Carlo simulations of the virus evolution using the free energy 
based virus fitness, in which random genetic drift of the virus adds statistical noise 
into the virus evolution process, showed that selected substitutions are biased to those 
with positive ~~G values. 
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Chapter 8 
Evidence for Recombination Contributing to the 
Evolution of Extended Spectrum ,8-Lactamases 
(ESBLs) in Clinical Isolates 
In bacteria, the contribution of recombination to mosaic gene structures that facili-
tate the development of antibiotic resistance is well known. The main evolutionary 
mechanism behind the development of extended spectrum ,8-lactamase antibiotic re-
sistance has long been considered to be accumulation of single point mutations, with 
recombination cited as a mechanistic facilitator of increased mutation rates. In this 
study, the presence of recombination was detected in the evolution of antibiotic re-
sistance in clinical bacteria carrying extended spectrum ,8-lactamase genes by several 
bioinformatics methods (DNASP, LDhat, Reticulate, the Max Chi Squared test, the 
Sawyer's Runs Test, PhylPro, the PHI Test, and the filter method). The methods 
of recombination detection were calibrated against data from statistical mechanics 
simulations of evolution, which generated sequences under selection. Since certain 
strong selection pressures can mimic the effects of recombination, which the extended 
spectrum clinical isolates experience due to antibiotic selection at specific active sites, 
detection methods that rely upon silent polymorphic sites to avoid such false positive 
detection were also used. Additionally, linear and logistic regressions were used to 
further test the reliability of the results. Our findings suggest that recombination 
plays an evolutionary role in the development of antibiotic resistance by not only 
facilitating but also combining the mutations. 
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8.1 Introduction 
The world has witnessed a sharp increase in resistant strains of bacteria [187]. Even 
though there are guidelines now in place for administering antibiotics to prevent 
over prescription, many patients, in order to reassure themselves, prefer antibiotic 
treatment as opposed to no treatment [187]. Resistant bacteria are now a significant 
problem confronting the global public health [187]. More worrying are the predictions 
that this problem is only to grow due to decreased research for discovery of novel and 
effective antibiotics [187]. We are now at a point where there are no treatments for 
certain kinds of infections. Factors limiting the introduction of new antibiotics include 
the high cost of development, significant market competition, and demographical 
changes within the United States [187]. 
Among the most frequently used antibiotics are the ,8-lactam drugs, which in-
clude the penicillin and cephalosporin families [188]. The most common method of 
resistance to this type of antibiotic is by bacteria carrying a gene that encodes for 
,8-lactamase, thereby producing an enzyme that hydrolyzes antibiotic by cleaving its 
amide bond [188]. This gene can be on a plasmid, which means it can be acquired 
even from distant strains of bacteria through transformation, transduction, and con-
jugation. The two ,8-lactamase families TEM and SHV are among the most common 
in Gram-negative bacteria. We looked at variants of TEM and SHV ,8-lactamase 
genes from clinical bacterial strains. For these studies all TEM and SHV sequences 
in GenBank were obtained, and then only those that were observed in clinically re-
sistant isolates (as specified by the Lahey Website) were used for the analysis. It is 
presumed that the original ,8-lactamase genes were acquired from soil bacteria [189]. 
The TEM and SHV families of resistance genes were both originally found in E. coli 
and Klebsiella pneumoniae [190]. They are now found in nearly all bacterial species 
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of Enterobacteriaceae [191]. 
TEM is one of the most prevalent plasmid-mediated resistance enzymes in Gram-
negative bacteria (a class A ,8-lactamase) [188]. The TEM-1 enzyme is capable of 
efficient hydrolysis of penicillins and many cephalosporin antibiotics and therefore is 
a widespread cause of resistance. The extended-spectrum cephalosporin antibiotics 
such as cefotaxime and ,8-lactamase inhibitors such as clavulanic acid were devel-
oped to avoid the action of ,8-lactamases such as TEM-1. During the past 20 years, 
however, variants of TEM-1 ,8-lactamase have emerged that are able to hydrolyze 
extended spectrum cephalosporins or avoid the action of inhibitors [192]. There are 
now approximately 180 variants of the TEM-1 enzymes (termed ESBLs, or extended-
spectrum ,8-lactamases) that provide resistance. The sequences of TEM ESBLs have 
been collected at the Lahey clinic ESBL website. 
SHV had been considered a chromosomally encoded species-specific enzyme in 
Klebsiella pneumoniae [193, 194]. As another class A ,8-lactamase, SHV is 60% iden-
tical to TEM in the nucleotide sequence, 67% in the protein sequence, and 81% 
identical at the surface residues. It also has a gene that is 861 base pairs long and 
mutations in the gene for SHV have been discovered that lead to hydrolysis of ex-
tended spectrum cephalosporins [189, 193]. 
Due to the presence of ,8-lactamase genes in bacteria conferring varying degrees 
of resistance to antibiotics, it has been thought that transition from one level of 
resistance to another level comes about by accumulation of single point mutations 
[191]. More recently, it was shown that bacteria under severe stress for survival have 
a mechanism to increase diversity through increased mutation rate also known as 
the SOS response [195]. This mechanism leads to an increase in diversity, which 
in turn makes the population more likely to include mutations that can be selected 
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by the pressures of the new environment. Even though it has been established that 
recombination plays a role in the mechanisms that bring about the higher rates of 
mutation in stressed bacteria [195, 196], other (non-mechanistic) contributions of 
recombination have not been investigated as thoroughly. To our knowledge there 
has been very little recombination characterization of clinical strains carrying the 
.B-lactamase resistant genes [197], and this research extends the work of others on 
recombination. 
One of the requirements for recombination between TEM genes is that the genes be 
present in the same bacterial cell. TEM is one of the most common plasmid encoded 
.8-lactamases in gram negative bacteria and so it is commonly found in clinical isolates 
[198]. The blatrEM gene has been found on many different types of incompatibility 
group plasmids [199] and different plasmid types are often found within the same cell 
[200, 192]. Several studies have shown that multiple blatrEM genes can be found in 
the same bacterial strain and different ESBL alleles can also be found [201, 202, 203]. 
Thus, the co-existence of blatrEM alleles allows the opportunity for recombination to 
take place between genes in gram negative bacterial pathogens. 
Our previous publications have demonstrated the power of recombination to ac-
celerate evolution [86, 85, 204, 205]. In scenarios where the protein used by the 
organism is traveling a short distance in the fitness landscape to overcome the se-
lection pressures, it is presumed that accumulation of single point mutations due to 
DNA replication can happen fast enough that recombination may not play a signif-
icant role in the evolutionary development. However, there are four features that 
suggest recombination may play a role in .8-lactamase evolution. 
First, .8-lactamase mediated resistance has been transferred into infectious bacte-
ria from soil strains by transformation, transduction, and conjugation [206, 207, 208]. 
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These mechanisms all utilize recombination. 
Second, specific mutations in 8 sites, generally resulting in two alleles at each 
site, give rise to about 30 different varieties of TEM (out of. 256 theoretically pos-
sible combinations) and specific mutations in 5 sites, generally resulting in two al-
leles at each site, give rise to about 15 different varieties of SHV ,8-lactamase genes 
(out of 32 theoretically possible combinations). If the evolution of the ,8-lactamase 
genes were by independent random mutations and did not involve recombination, one 
would expect independent evolutionary trajectories. The assumption of independent, 
recombination-free random mutations is incompatible with the observation that a 
few mutations come together in many different combinations. The degeneracy of the 
TEM and SHV sequence space can be explained by the presence of recombination in 
the evolution of both proteins. 
Third, recombination can bring together advantageous mutations in various com-
binations so that evolving into local minima can be avoided. Additionally, gradual 
accumulation of mutations should not create the exhaustive combination of mutations 
that is observed at certain sites in the genes of these clinical ESBL strains. 
Fourth, certain strains of bacteria, which can carry multiple ,8-lactamase genes on 
conjugative plasmids with multiple copy numbers, exchange plasmids in the wild and 
allow for free recombination [207]. In strains of Neisseria meningitidis and Strepto-
coccus pneumoniae, the rate in which alleles are altered by recombination is up to 10 
times as high as the rate in which alleles are altered by point mutation [209]. As a 
comparison, in the same strains the rate in which individual nucleotides are altered 
by recombination is up to 80 times as high as the rate in which individual nucleotides 
are altered by point mutation [209]. 
The above factors suggest recombination could play an evolutionary role in ad-
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clition to the mechanistic role of giving rise to mutations in stressed bacteria [194). 
Strong selection on the enzyme for changes in activity leads to evolutionary charac-
teristics that mimic recombination and makes it hard to distinguish the evolutionary 
paths taken. This strong selection poses the biggest challenge to establish an evolu-
tionary role for recombination distinct from that of mutation in the development of 
extended-spectrum antibiotic resistance. Nevertheless, there are genetic signatures 
that can determine whether multiple mutations have come together via recombina-
tion or gradual accumulation. In this study we try to shed light on this issue in order 
to establish the evolutionary contributions of mutation and recombination. 
In our previous publications, we have elaborated on the power of recombination to 
speed up evolution in biology [86, 85, 204, 205). This characteristic of recombination 
is of immense importance because assuming infinite time, many different mechanisms 
can produce the desired characteristics in the population. However, since being able 
to evolve at a faster pace than the competition is of essence to the survival of a 
population, the ability to increase the pace of evolution through recombination is 
vitally important. Nevertheless, establishing presence of recombination in clinical 
isolates that have evolved in the wild without any of the controls that are available in 
a lab setting, using only sequence data, is a challenging task. In addition to recurrent 
mutation mimicking recombination signatures and creating false positive detections, 
lack of definitive ancestral trees for the ,8-lactamase genes families, and the length of 
the gene being only 861 nucleotides long in bacterial genes significantly confound the 
detection problem. 
In the Results section we use different recombination detection algorithms to ob-
tain the recombination parameter estimations, p-values, and graphical representations 
for the clinical data sets. In the Materials and Methods section we describe the char-
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acterization of each algorithm. 
8.2 Results 
For this study we employed a suite of best available programs to detect recombination 
in the evolution of antibiotic resistance in clinical bacteria carrying the TEM and SHV 
extended spectrum ,8-lactamase genes. The TEM and SHV genes used in this study 
are listed in Table S1 in the supporting information. The following seven programs 
were employed: DNASP, LDhat, Reticulate, the Max Chi Squared algorithm, the 
Sawyer's Runs test, Phylpro, and the PHI test, in which the Max Chi squared algo-
rithm and the Sawyer's Runs test are implemented in the software START; the PHI 
test is implemented in the software Splits'free. Later we will describe the methodol-
ogy, assumptions, and claims of the tests performed by these programs. Since certain 
strong selection pressures can mimic the effects of recombination [193], we made sure 
to include detection methods that relied upon silent polymorphic sites that are devoid 
of such selection pressures. We also used linear and logistic regression in addition to 
other methods in order to further test the reliability of our results, particularly for 
programs that had great sensitivity along with a higher number of false positives .. 
The results are summarized in Table 8.1 and 8.2. We find significant recombination 
in both the TEM and SHV gene sets. Below we provide more details of each of the 
recombination detection algorithms. 
For better understanding of the results, the software programs used to detect re-
combination were calibrated against data from statistical mechanics simulations of 
evolution able to generate genetic sequences with known characteristics. The algo-
rithms were characterized using a statistical mechanics based simulation [85, 210] 
capable of evolving populations under various parameter values for mutation and re-
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Table 8.1 : Detection of recombination in TEM and HV 
Software DnaSP LDhat Max Chi Squared Sawyer's PHI Test Filter 
Runs Test 
TEM R = 44.4 R= 22 124 recombined p = 0.04 p = 0.15 p = 0.02 
pairs 
SHV R = 10000 R= 100 121 recombined p = 0.03 p = 0.07 N/A 
pairs 
The Sawyer's Runs Test is thought to be the gold standard. The table below shows 
either values for the recombination parameter R, the number of detected 
recombined pairs, or the p-value for the null hypothesis of no recombination. 
Summary of simulation characterization results showing the sensitivity Table 8.2 
d th 'fi 't f 1 'th b d 1 t' 1 t d d t t an e spec1 Cl y 0 an a gon m ase on our eva ua 10n usmg s1mu a e a ase s 
START SplitsTree: 
Software DnaSP LDhat Reticulate Max Chi Sawyer's Phy!Pro The PHI Filter 
Squared Runs Test Test 
Sensitivity Sensitive Sensitive Sensitive Sensitive Insensitive Insensitive Insensitive Insensitive 
Specificity Nonspecific Nonspecific Nonspecific Nonspecific Specific Specific Nonspecific Specific 
TEM 
Recombination Positive Positive Positive Positive Positive Positive Negative Positive 
SHY 
Recombination Positive Positive Positive Positive Positive Positive Negative N/A 
Also shown is whether the algorithm detected recombination in the clinical data. 
The characterization gave the sensitivity, quantified by true positives detected as a 
fraction of all positives in the dataset, and the specificity, quantified by true 
negatives detected as a fraction of all negatives in the dataset, of each algorithm. 
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combination (see Materials and Methods). The characterization gave the sensitivity, 
quantified by true positives detected as a fraction of all positives in the dataset, and 
the specificity, quantified by true negatives detected as a fraction of all negatives in 
the dataset, of each algorithm. 
8.2.1 DnaSP 
Introduction DnaSP, DNA sequence polymorphisms, is a population genetics based 
program that has algorithms allowing for several measurements within and between 
- populations [211, 212]. The recombination test for the program is based on an al-
gorithm that generates the rate of recombination (R), as well as the lower bound 
estimate for the recombination rate (Rm) [213, 214]. The program provides two re-
combination parameters R and Rm with values ranging between 0 and 10,000, with 
one being an estimated recombination rate and the other being the minimum rate of 
recombination that would be required to generate the population characteristics. In 
addition, the program provides the mutation rates (e)' and this allows us to obtain 
a recombination to mutation ratio. Furthermore, the D, D', two other estimates 
for recombination rate (R and R2) are calculated under the linkage disequilibrium 
algorithm of the software [212]. The algorithm assumes an infinite site model, con-
stant population size, random mating, and no population structure. The algorithm 
disregards sites with recurrent mutations and has no selection component. 
Clinical data sets DnaSP provides estimates of various population parameters 
based on the sequence data. If recombination is present one should expect to obtain 
a non-zero rate for recombination with this algorithm and the higher the estimated 
recombination rate the more certain the presence of recombination. For TEM we 
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obtained R = 44.4, Rm = 14, and 8 = 8, and for SHV we obtained R = 10, 000 
(maximum rate available by the program), Rm = 11, and 8 = 7. 
Algorithm characterization DnaSP is sensitive but nonspecific. DnaSP showed 
100% sensitivity with 75 simulated data sets where recombination was present. We 
expected that the false positive detection for this program may be high since our 
simulation and clinical data did not meet the main underlying assumptions of the 
program, which are infinite site approximation, neutral evolution, and constant pop-
ulation size. To our surprise, DnaSP avoided false positive detections except when 
faced with high selection on specific active sites. This result would make DnaSP an 
excellent program for detection of recombination if one is studying datasets that have 
not undergone strong active site fitness selection. One can likely exclude recombina-
tion if the results from this test are not positive, although recombination can never 
be ruled out even if it is not detected. Unfortunately, the clinical data have been 
under strong active site fitness selection, hence we needed to rule out false positive 
detection using our regression methods and did so as explained in subsection Linear 
and Logistic Regression Filters. 
8.2.2 LDhat 
Introduction The LDhat program is based on population genetics methods [215]. 
It implements the approximate likelihood algorithm with some modifications [215]. 
It is adapted to a finite-site model, can use both haplotype as well as genotype data, 
estimates variable recombination rates [216], gives the option of including triftetra-
plasmic sites, and tolerates an arbitrary amount of missing data. This software also 
produces measurements of linkage disequilibrium. 
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Clinical data sets LDhat has three recombination rate estimates, the first two esti-
mating R and Rm as described in subsection DnaSP and the third being the moments 
method calculation of recombination rate, as well as the Watterson's definition of mu-
tation rate. For TEM we obtained R = 22, Rm = 16, R(moments method) = 36, 
and 9(Watterson) = 22. For SHV R = 100, Rm = 10, R(moments method) = 1738, 
and 8(Watterson) = 16. Once again, if recombination is present one should expect 
to obtain a non-zero rate for recombination with this algorithm, and the higher the 
estimated recombination rate the more certain the presence of recombination. 
The program itself also does a randomization test of data by shuffling segments of 
the sequences as an additional measure of reliability by comparing various parameter 
values before and after randomization to examine the likelihood of the data set char-
acteristics happening by coincidence. The randomization results showed that first, a 
reduction in LKmax from 178590 to 0.411; second, a reduction of G4 from 38855 to 
0.3720; third, an increase in corr (r2, d) from 0.01381 to 0.767; and fourth, ali increase 
in corr (D', d) from 0.00563 to 0.4050. As it can be seen, there are very significant 
changes to the estimates of every parameter once the sequences are randomized, in-
dicating that the sequence characteristics of the clinical data sets are not random. 
Furthermore linkage equilibrium ( corr ""' 0) has been indicative of free recombination 
in the literature [217]. 
Algorithm characterization The LDhat is sensitive but nonspecific. Character-
ization of LDhat showed that the algorithm has good sensitivity, and has multiple 
outputs, including LKmax, G4, corr (r2, d), and corr (D', d), which if all confirm each 
other give a more robust conclusion. Unfortunately LDhat also had a false positive 
detection weakness under strong active site fitness selection. Here again the program 
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indicated the presence of recombination. The false positive needs to be detected with 
our regression methods. 
8.2.3 Reticulate 
Introduction Reticulate uses a sites patterns analysis approach [218]. Reticulate 
evolution refers to inter-dependent evolution among different lineages, which can come 
from recombination or inter-speciation, which is not relevant to the populations of 
our study. The program generates a matrix of pairwise compatibilities and provides 
a statistical analysis of the clustering obtained from compatible sites. The algorithm 
computes a Neighbor Similarity Score, does not have any underlying assumptions, 
and can do a sliding window analysis to locate recombination hot spots. 
Clinical data sets For both TEM and SHV, the Reticulate algorithm displays a 
graphical matrix output as shown in Figure 8.1, with the black cells indicating that 
there are polymorphic sites that cannot be explained by maximal parsimony trees in-
corporating mutation without recombination. The higher the portion of incompatible 
cells, the more significant presence of recombination is within the population, and the 
higher the recombination rate. A number of incompatible cells were observed in the 
matrices generated by the Reticulate algorithm for both TEM and SHV, as shown in 
Figure 8.1. Black cells account for 35.1% and 33.6% of the non-diagonal cells in the 
Reticulate output in Figure 8.1 for TEM and SHV, respectively. 
Algorithm characterization Characterization of the Reticulate algorithm found 
it to be sensitive but nonspecific. Again, we needed to rule out false positive using 
our regression methods and did so as explained in subsection Linear and Logistic 
Regression Filters. 
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Figure 8.1 : Reticulate output for TEM (a) and SHV (b) respectively. The locations 
of the polymorphic sites in the genes are labeled on the axes of the squares. The 
black cells indicate genetic patterns that cannot be explained by point mutation as 
the sole mechanism of evolution. 
202 
8.2.4 The Max Chi Squared Algorithm and the Sawyer's Runs Test 
Introduction Pairwise sequence comparisons are the bases of both the Max Chi 
Squared test and the Sawyer's Runs test [219, 220, 221]. The Max Chi Squared 
test is statistical analysis of clustering of polymorphic sites for a pair of sequences. 
The Sawyer's Runs Test is based on gene conversion analysis in a set of sequences 
explained in [221]. This test relies on silent mutation sites for its analysis. It looks to 
determine if there are more consecutive identical silent polymorphic sites in different 
regions than that predicted by general probabilities. Both of these programs do not 
have any underlying assumptions; furthermore, the Sawyer's Runs Test is based on 
silent mutation sites that are entirely unaffected by selection pressures. 
Clinical data sets for the Max Chi Squared algorithm The Max Chi Squared 
algorithm produces p-values for recombination between a pair of sequences by shuffling 
different segments of the sequences many times and examining how many of the 
random shuffles show equal or greater recombination signatures than the original 
pair. For TEM we observed that 124 pairs of sequences had recombination present 
with p-values below 0.05, and we observed 121 pair with p-values below 0.05 for SHV. 
Algorithm characterization for the Max Chi Squared algorithm The char-
acterization of the Max Chi Squared algorithm found it to be sensitive but nonspecific. 
The Max Chi Squared algorithm detected recombination with p-values less than 0.05 
for all the 75 simulated data sets with recombination. Nevertheless, it allowed for 
false positive detection both under strong active site fitness selection as well as general 
selection. Again the program indicates presence of recombination. The false positive 
with strong active site fitness selection needed addressing using the filter (general 
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selection was ruled out by previous software programs). 
Clinical data sets for the Sawyer's Runs test With the Sawyer's Runs test 
we obtained p-values of 0.04 and 0.03 for recombination presence in TEM and SHV 
respectively. The detection of recombination with statistically significant p-values by 
this method is important for three reasons: First the recombination signal was strong 
enough to overcome the insensitivity of the program (see simulation characteriza-
tion below). Second the method utilizes silent mutations largely devoid of selection 
pressure. Third if the domain of allowable mutations is extended beyond the silent 
polymorphic sites to all polymorphic sites (including non-silent ones) the p-values 
go above 0.88 for TEM and 0.60 for SHV. The last factor shows that if one looks 
for recombination based on all polymorphic sites, one could miss the recombination 
signature in the evolution of antibiotic resistance, due to heavy selection pressures 
destroying the recombination signatures. 
Algorithm characterization for the Sawyer's Runs test The characterization 
of the Sawyer's Runs test showed it to be very insensitive but specific. The charac-
terization gave p-values around 0.5 for simulation generated datasets that employed 
recombination. Consequently, we did not obtain any false positive detection using 
this algorithm. The Sawyer's Runs test has 100% specificity with 25 simulated data 
sets where recombination was absent. 
8.2.5 PhylPro 
Introduction PhylPro, Phylogenie Profile Algorithm, is a graphical pairwise se-
quence comparison program [5]. It uses a sliding window algorithm to analyze the 
agreement of patterns of distances in particular regions. Even though graphical rep-
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resentations are able to give cues for patterns that are hard to quantify, this lack of 
quantification can lead to difficulty of interpretation of the results. Nevertheless, the 
graph is based on pairwise correlations and recomb~nation destroys the correlation 
signal. Hence the evidence for recombination becomes more definitive as the square 
or absolute value of results nears zero. The documentation does not mention any 
underlying assumptions for its algorithm. 
Clinical data sets PhylPro produces a graphical pairwise sequence comparison 
that displays the agreement (correlation) of patterns of distances using a sliding 
window analysis. It was the analysis [217] that guided us to use near zero correlation 
of pairwise comparisons, which happened to be the case for TEM and SHV (shown 
in Figure 8.2), as indicating free (or very high) recombination in the TEM and SHV 
genes [217]. 
Algorithm characterization The PhylPro program was insensitive and specific. 
The pattern generated by PhylPro indicated existence of recombination in all the 50 
simulated data sets with recombination present. As for the PhylPro algorithm, char-
acterization showed some distinguishing characteristics between the false positives 
and the true positives, but due to the non-quantitative nature of the program it was 
hard to identify a cut off value for distinguishing between true and false positives. 
The PhylPro program does not provide a quantitative measure of the recombination, 
such as the p-value in the Max Chi Squared algorithm and in the Sawyer's Runs Test. 
We therefore had to identify recombination by inspecting the figure generated by the 
PhylPro. 
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Figure 8.2 : PhylPro results for TEM (a) and SHV (b) respectively. Each black 
curve represents a phylogenetic profile generated by PhylPro [5]. The red curve is 
the mean of all the phylogenetic profiles. In independent evolutionary trajectories 
that would come about in a mutation-only evolution process, the mutations in each 
particular trajectory are strongly correlated to each other. Hence the graph for the 
correlation measure for a gene pool that has evolved under a mutation-only scenario 
would be away from the Correlation = 0 line. Recombination destroys this correla-
tion between different polymorphic sites, causing the graph to significantly deviate 
from the Correlation = 1 line. The higher the recombination rate, the further the 
plot deviates from the Correlation = 1 line and moves towards the Correlation = 0 
line. (a) PhylPro results for TEM are close to the Correlation = 0 line at many 
positions. These low correlations can come from high recombination rates or low 
selection pressure [6]. The selection of TEM is usually intensive in the presence of 
antibiotics. Therefore, these low correlations suggests high recombination rates of 
TEM. (b) Similarly, PhylPro results for SHV are close to the Correlation = 0 line at 
all the positions, suggesting even higher recombination rates of SHV. 
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8.2.6 The PHI Test 
Introduction The PHI test, which is the acronym of the Pairwise Homoplasy Index 
test [222], is performed by the software Splits Tree [223], a phylogenie network analysis 
software [224, 225]. The algorithm is a site pattern analysis using incompatibility 
scoring that provides p-values for recombination presence. This is a general test with 
no underlying assumptions, which claims to discern between recurrent mutation and 
recombination. 
Clinical data sets With the PHI test algorithm we obtained p-values of 0.15 and 
0.07 for recombination presence in TEM and SHV respectively. The p-values being 
above 0.05 was attributed to the insensitivity of the program, as discussed below. 
We regarded the p-values obtained as positive indications of recombination since they 
were two of the lowest p-values that we observed with the PHI test, indicating that the 
recombination in the clinical datasets were far stronger than those generated through 
our simulations. 
Algorithm characterization The PHI test algorithm was characterized to be in-
sensitive and nonspecific. The PHI test yielded p-values generally around 0.50 even 
with recombination present. It was considered as very positive indication that some 
of the lowest p-values obtained by us using the Sawyer's Runs test and PHI test 
were those of the TEM and SHV. However, 3 out of 25 simulated data sets where 
recombination was absent showed p-values less than 0.05. The PHI test is hence 
nonspecific. 
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8.2.7 Linear and Logistic Regression Filters 
Linear and logistic regression filters were employed, using the R software package 
for statistical analysis, in an attempt to classify the false positives and true pos-
itives in different categories and use these findings for the clinical data sets. In 
doing so we tried using the values of the following factors as our input of parameters: 
tetraplasmy (existence of four different/ degenerate alleles at the same nucleotide site), 
triplasmy (existence of three different/denerate alleles at the same nucleotide site), 
polymorphic sites, non-informative polymorphic sites, informative polymorphic sites, 
mutations, tetraplasmy divided by triplasmy, tetraplasmy divided by polymorphic 
sites, tetraplasmy divided by non-informative sites, tetraplasmy divided by informa-
tive sites. The reason behind our original selection of factors related to tetraplasmy 
was that under high selection the mutant enzymes get selected and fixed within the 
population almost immediately. After mutations get fixed, the population goes under 
quasi-neutral evolution. Since recombination increases diversity in neutral evolution 
[226, 227] we suspected that tetraplasmy should be higher in populations where recom-
bination plays a role. The regression resulted in mean values for simulation sequence 
sets with recombination (true positives) and simulation sequence sets without recom-
bination (false positives) that were statistically different (p-value of 1.17 x 10-27). 
The classification rejects 98% of false positives while keeping 20% of true positives 
or alternatively rejects 80% of false positives while keeping 40% of true positives. 
TEM was classified as true positive under both versions of the test (SHV only carried 
triplasmic variants; hence this test was not applicable). The logistic and weighted 
logistic regressions p:roduced similar results without significant differences. 
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8.3 Discussion 
The theoretical importance of recombination and horizontal gene transfer to the emer-
gence of modularity under changing environments and to increased adaptation rate 
in biology has been emphasized [86, 85, 204, 205]. The emergence of modularity is 
reflected by the increased proportion of intramodule connections in the three dimen-
sional protein structure [86]. Evidence for the contribution of recombination to mosaic 
gene structures has been presented [228]. Our findings in this chapter address the sit-
uation where the divergent genes cannot be attributed to any one family of bacteria, 
and a chronological family tree cannot be established among ESBL mutants. 
All but one software program detected recombination (Table 8.2). Only the ex-
tremely insensitive PHI test did not detect recombination in TEM and SHV. The 
results were further reinforced with linear and .logistic regression to make sure the 
results are not due to false positive detection. Considering that these sequences are 
picked by evolutionary selection and obtained from clinical settings, any signature 
from recombination detected in these datasets shows that recombination has already 
played a direct role in the evolution of antibiotic resistance development. Since we 
started this study, the p-values of the Max Chi Squared Test, of the Sawyer's Runs 
Test, and of the PHI Test have gone down steadily with the addition of new sequences 
in GenBank. This gives us extra confidence that with additional data those p-values 
that are higher than the 0.05 threshold may fall below this threshold in time as more 
data points are added. Another measure that we took to reinforce our findings was to 
remove a progressively larger region of the genes that included the active sites, and 
observed the effect on the recombination signature. Under these conditions, we still 
detected recombination for both the TEM and SHV families, though the magnitudes 
of the recombination coefficients were smaller to varying degrees in the TEM, SHV, 
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and simulation datasets. 
Evolution by point mutation alone leaves some results unexplained. First, recom-
bination is known to take place in plasmids on which the resistance genes are located. 
Second, in one case there were three strains with a single point mutation difference 
from the original TEM-1 strain each [193, 229], and there also existed all the eight 
possible combinations of these three mutations in the population in an exhaustive 
manner. The evidence for recombination was so strong that the authors of [229] pro-
posed combination, without using the term recombination, as a strong possibility for 
obtaining the combinatorial variants. We examined the population in order to see 
how many strains could be obtained by simply combining other strains with single 
mutations together. Combining five strains with a single mutation difference from 
TEM-1 each (TEM-2, TEM-12, TEM-17, TEM-19, and TEM-29) gives rise to 11 
new strains that are already in the population (TEM-3, TEM-6, TEM7, TEM-11, 
TEM-15, TEM-16, TEM-18, TEM-26, TEM-44, TEM-129, and TEM-134) providing 
us with a diversity of 17 from the exhaustive 32 possible variants of these 5 muta-
tions in clinical isolates. This high combinatorial diversity suggests the existence of 
recombination in the evolution from the original TEM-1. 
One of the major implications of our results is the potential for increase in di-
versity of .8-lactamase resistance in short timeframes, already observed in clinical 
settings. Though this complements our prior publications [86, 85, 204, 205], as well 
as those from other groups [226], it is not agreed upon by all [230]. An increase in the 
population diversity leads to a higher propensity for evolution of resistance in bacte-
ria carrying these genes. This implies that despite different mutation combinations 
having varying resistance levels, the overall population can contain most, if not all, 
of them to acquire future adaptability. This is of particular importance because it 
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allows the bacteria to.adapt to local fitness loci without being trapped there and still 
be adaptable to future environmental/antibiotic changes. Recombination can explain 
results that otherwise seem unlikely [231]. A calculation of the 99% probability den-
sity of evolutionary pathways for TEM-1 to become resistant to cefota.xime predicted 
10 pathways (231], yet some of the clinically observed data were not present in those 
pathways. This result suggests the presence of recombination. Recombination can 
explain these inconsistencies by allowing for diversity beyond the fittest strains and 
allowing for combining of the mutations in many different ways. With recombination, 
it is important to notice that the bacteria seem to increase their resistance to certain 
antibiotics to moderate levels without being trapped in local minima that can reduce 
their adaptability in the future. 
Since we used ,8-lactamase sequences from clinically resistant bacteria that have 
been evolutionarily selected in real life settings, our findings complement the results 
from [226], as well as those from [197]. Their previous studies had shown for the 
,8-lactamase genes in particular that with random mutation the functionality of the 
new strains declines exponentially with accumulation of mutations due to lack of con-
servation of the protein fold. Recombination in ,8-lactamase genes, however, not only 
avoids an exponential decline, but also has a symmetrical and log-parabolic curve, 
giving rise to "broad sequence diversity with relatively low cost in loss of function" 
[226]. In the present work, we showed that organisms take advantage of such benefits 
by using recombination for their evolution even over short mutational distances in 
the fitness landscape. In our previous publications [86, 85, 204, 205] we had shown 
that the greatest contribution from recombination is increasing the evolution rate of a 
population. Our previous findings along with the new observations in clinical datasets 
and the present results lead us to conclude that recombination, due to its acceleration 
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of evolution in populations, conservative nature in preserving function under the right 
conditions, creation of broad diversity, and exchange of genetic information among 
different organisms, is a significant contributor to evolution. Recombination brings 
mutations together, contributes mechanistically to generate mutations, and creates 
gene rearrangements and amplification. 
8.4 Materials and Methods 
The statistical mechanics based simulation software was developed by our group 
[85, 210]. The program was modified to correspond to our simulation needs in this 
project. We set the sequence length to 900 nucleotides. Mutations were performed at 
the nucleotide level, with fitness a function only of amino acid sequence. Therefore, 
the protein structure contains 300 amino acid residues. We set the ratio of recombi-
nation to mutation to range from 0 to 10, with a quarter the results at a ratio of 0 
and half performed at 1, and the last quarter at 10. We defined the active site, the 
part recognizing the substrate for ESBL, by randomly choosing P amino acids with 
P the size of the active site. We set the strength of selection based on active site, 
which measures the degree of selection on the active site residues, to have a weight of 
1 to 50, with a ratio of 5 chosen for final simulations. Population sizes of 1000 were 
used. These parameters mimic the strong selection pressure observed with the clini-
cally observed TEM and SHV enzyme variants [210]. The simulations went through 
30,000 rounds of replication and selection to generate the data sets. The simulations 
were used to characterize the recombination detection software programs. We used a 
generalized N K model to simulate the fitness of the protein enzyme. The active site 
fitness constant of enzyme and target is of the following form: exp (a- b (U) ), where 
a and b are constants, and we define U, a measure of fitness of interaction where the 
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lower the value of U is the fitter the enzyme has become, for the enzyme by: 
M M P 
u ='"' usd + '"' w?--sd + '"' ur: ~ ~ ~ ~ ~ t (8.1) 
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' y'M (N- K + 1) j=l (8.2) 
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(8.4) 
Here the number of enzyme secondary structures is M = 30 (For our case to be 
comparable to the clinical sequence length we chose M = 30, making the length M x 
N = 300.) The number of enzyme amino acids in the active site is P = 5. The number 
of amino acids in a single secondary structure sub-domain is N = 10, and range of 
local interactions is K = 4 amino acids. There are L = 5 different sub-domains 
in a secondary structure (helices, strands, loops, turns and others) represented by 
the subscript ai. The number of interactions between secondary structures is D = 
6. The first summation is over all the interactions within a secondary structure. 
The second term represents the inter-secondary structure interactions. The total 
number of interaction that a typical amino acid can have is roughly 12, and [2 (k- 1)] 
of them are within secondary structure sub-domain and [D (M- 1) /N] are in the 
inter-secondary structure sub-domain interactions. For sequence length of M x N = 
300, the simulation is a semi-quantitative model of a protein domain. The third 
summation represents the active site measure of fitness and its fitness is represented 
by a reduction in this parameter. The sites considered for the active site fitness 
parameter represented the active site residues in the TEM and SHV structures. This 
allows for simulation study of the evolution of active site residues under different 
conditions. Also there is a strong correlation between the active site fitness and 
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enzyme activity in clinical data [232]. 
Initially we generated 5 optimized high fitness sub-domain pools, each made of 300 
variants corresponding to L = 5 types to have biologically relevant fitness levels for the 
structures to choose from. Out of each set of 300 we pick 3, then going on to generate 
1000 random sequences by different combinations of these segments for 100 different 
secondary structure positions in each sequence. From this initial population, the top 
50% is selected based on our fitness formulation. The next step is to repopulate back 
to the original count, and allow for mutation and recombination, with parameters set 
for any specific scenario, among the new generation. The selection and repopulation 
representing one generation cycle is repeated for 30,000 generations. Further details 
are in [210]. These sequences are used to characterize the software programs that 
were chosen to analyze our clinical sequences. 
The simulations are appropriate for such characterizations due to following rea-
sons: the statistical mechanics GNK model used in the simulation is uncorrelated to 
the detection algorithms that are used in the software programs, the semi-quantitative 
nature of the simulations makes the sequences mimic protein structures closely, and 
the mutation and recombination parameters are adjustable for verification of the re-
combination detection ability of the software programs under different conditions. 
We used the simulation algorithm described above to generate sequences by point 
mutation, recombination, and selection to characterize the recombination detection 
algorithms, and better understand and interpret the results obtained from them. We 
generated 25 sequences with the ratio of recombination to mutation set to 0, 50 
sequences with the ratio of recombination to mutation set to 1, and 25 sequences 
with the ratio of recombination to mutation set to 10. To detect recombination, we 
used the following seven programs: DNASP, LDhat, Reticulate, the Max Chi Squared 
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algorithm, the Sawyer's Runs test, Phylpro, and the PHI test. Note that the Max 
Chi Squared test and the Sawyer's Runs test are performed by the software START 
(Sequence Type Analysis and Recombination Tests) [219]. Additionally, the PHI test 
is performed by the software SplitsTree [223]. 
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Chapter 9 
A Two-Scale Model for Correlation in B Cell VDJ 
Usage of Zebrafish 
The zebrafi.sh ( Danio rerio) is one of the model animals for study of immunology 
because the dynamiCs of the adaptive immune system in zebrafish are similar to 
that in higher animals. In this work, we built a two-scale model to simulate the 
dynamics of B cells in primary and secondary immune reactions in zebrafish and to 
explain the reported correlation between VDJ usage of B cell repertoires in individual 
zebrafish. We use a delay ordinary differential equation (ODE) system to model the 
immune responses in the 6-month lifespan of zebrafish. We use the generalized NK 
model to simulate the B cell maturation process in the primary or the secondary 
immune response to a single type of antigen within 10 days. The generalized N K 
model shows that mature B cells specific to one antigen largely possess a single VDJ 
recombination. In addition, the probability that mature B cells in two zebrafish have 
the same VDJ recombination increases with the B cell population size or the B cell 
selection intensity and decreases with the B cell hypermutation rate. The two-scale 
model shows a distribution of correlation in the VDJ usage of the B cell repertoires 
in two six-month-old zebrafish that is highly similar to that from experiment. This 
work shows that the spin glass theory of the immune response, in combination with a 
long-time ODE model, accurately describes aspects of the immune system dynamics 
in zebrafish. 
216 
9.1 Introduction 
B cell-mediated adaptive immunity exists in jawed animals [76]. B cells protect hosts 
by secreting antibodies that recognize and neutralize pathogens and foreign sub-
stances. Immunity generated by B cells is hence indispensable to the hosts' survival. 
The primary immune response occurs when a novel type of antigen is detected by 
the immune system. The antigen is processed and presented to nai:ve B cells, which 
mature in the germinal center. In the maturation process, the B cells acquire the ca-
pability to recognize and neutralize a specific antigen. First, a nai:ve B cell recombines 
one V gene segment, one D gene segment, and one J gene segment in the genome 
to create the nucleotide sequence encoding the antibody. Second, this nucleotide se-
quence undergoes multiple rounds of somatic hypermutation, and B cells with high 
affinity to the antigen are selected. The selected mature B cells differentiate into the 
antibody-secreting plasma cells or long-lived memory B cells that effectively activate 
the secondary immune response against the same antigen in the future. Janeway 
et al. provide a more detailed review of the B cell-mediated immune reaction [72]. 
Understanding the dynamics of and relationship between VDJ recombination and 
somatic hypermutation informs one about the central mechanism of B cell immunity. 
Recent experimental studies provide information on the B cell maturation process 
in zebrafish. Zebrafish (Dania rerio) have been increasingly used as a model animal 
to study the immune system because experiments on zebrafish are easy to perform, 
zebrafish reproduce quickly, and zebrafish possess one of the most primitive adaptive 
immune systems, which is a model for the adaptive immune. systems in humans and 
mice [77, 78, 79]. The genome of zebrafish contains 39 V gene segments, five D 
gene segments, and five J gene segments, which together encode the V region of 
immunoglobulin IgM heavy chain in zebrafish [80, 81]. High-throughput sequencing 
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of the complete IgM repertoires in 14 six-month-old zebrafish revealed that one fish 
carries up to 500Q-6000 distinct nucleotide sequence of IgM with 39 x 5 x 5 = 975 VDJ 
recombinations [7]. VDJ usage, the probabilities that each of the 975 possible VDJ 
recombinations is used in the IgM repertoire, has a correlation coefficient between 
individual zebrafish up tor= 0.75 [7]. 
In the present study, we developed a two-scale model to illustrate that B cell mat-
uration processes in distinct individuals, even though random, may converge to the 
same VDJ recombination in the same environment of antigens. We use delay ordinary 
differential equations (ODEs) to simulate the immune response against multiple anti-
gens circulating in the environment. We use the generalized N K model to describe B 
cell maturation processes against one antigen. The original N K model builds a ran-
dom rugged energy landscape on which peptides evolve [82, 83]. The parameters of 
the N K model for short peptides have been fit to the observed data. Mora et al. fit a 
random energy model, similar to the N K model, with a large number, approximately 
103 , of parameters to experimentally measured probabilities of D gene segment usage 
in zebrafish [84]. As an extension of the original N K model, the generalized N K 
model takes into account the interaction between distinct subdomains of a protein 
and protein-protein interaction [85]. The generalized N K model can describe mat-
uration of the whole V region of antibodies [34] and evolution of proteins in general 
[86]. In this study, we use the generalized N K model to analyze the convergence in 
the VDJ usage of immune response of two fish exposed to the same set of antigens. 
We extracted results of the generalized N K model to assign VDJ recombination to 
each type of mature B cells, the dynamics of which are solved by the ODE model. 
Correlation coefficients between the VDJ usage calculated from the<:?ry agree with 
experiment, in which most pairs of zebrafish had a weak correlation with r :::; 0.2 and 
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a small fraction of pairs had r > 0.5 [7]. 
The two-scale model is motivated by the nature of immune response. The adap-
tive immune system receives different antigens at various time points. An antigen 
can initiate a primary or secondary immune response, depending on whether the in-
fected individual has seen the antigen before. During the immune response B cells 
undergo rounds of somatic hypermutation and selection. The ODE system models at 
a mean field level the dynamics of B cell repertoires [87, 88]. The generalized NK 
model computes the repertoire of B cells that respond and evolve in response to the 
antigen. The generalized N K model explicitly simulates the somatic hypermutation 
and selection of the B cell repertoire reacting to a specific type of antigen in one 
individual [85, 34]. We combined the ODE model and the generalized N K model to 
build the present two-scale model, a model that can zoom out to yield a global view 
of the dynamics of B cell repertoires and zoom in to focus on the somatic evolution 
of the B cells reacting to one type of antigen. 
The purpose of this study is to model the B cell-mediated immune response and 
to explain the correlation in the VDJ usage in distinct individuals. This model is able 
to describe the mechanism of B cell-mediated immunity and to depict a snapshot of B 
cell repertoires at any time point in the host's life span. The Materials and Methods 
section illustrates the ODE model for multiple types of antigen and the generalized 
N K model for a single type of antigen. The Results and Discussion section shows the 
simulation results at both scales and compares the simulation results to experimental 
data. Finally, we present our conclusions and outlook. 
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9.2 Materials and methods 
The model simulates the B cell-mediated immune response in zebrafish living in an 
environment with multiple types of antigen. This model was built in two scales. At 
the first scale, the model describes the B cells involved in immune response against 
multiple types of antigen. A delay ODE model simulates the maturation process of 
multiple clones of B cells against distinct antigens. At the second scale, the model 
describes B cells reacting to a single type of antigen. A generalized N K model de-
scribes the rugged energy landscape of the antibody V region in the maturation pro-
cess against one antigen, the process of VDJ recombination and subsequent somatic 
hypermutation. Figure 9.1 illustrates the model at both scales. 
The two scales of the model are connected by assigning VDJ recombinations to the 
mature B cells generated by two zebrafish exposed to one type of antigen, according 
to the probability computed by the generalized N K model. The delay ODE system 
computes the dynamics of the number of mature B cells in each immune reaction. 
The generalized N K model computes the immune responses in two zebrafish against 
an antigen, denoted antigen i. Due to selection, the VDJ usage in a single fish 
after the primary response is almost always localized to a single VDJ recombination. 
The generalized N K model computes the probability that this VDJ recombination 
is the same in both fish, p = 0.327, and distinct with probability 1 - p. For each 
primary or secondary immune reaction induced by antigen i modeled by the ODE 
system, we assign the antigen i specific mature B cells one VDJ recombination for two 
zebrafish with probability p, and two distinct VDJ recombinations for two zebrafish 
with probability 1 - p. In this way, the VDJ repertoire for two fish are constructed 
as a function of the antigenic environment. 
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9.2.1 ODE model 
The delay ordinary differential equation (ODE) system computes the dynamics of 
the immune response triggered by antigens. The ODE system is a mean field model 
of the number of B cells responding to antigen over time. The number of mature B 
cells in a zebrafish can reach the order of magnitude of 103 [7]. Zebrafish lived in an 
environment with Nag types of antigens. For one zebrafish, inoculation of antigen i 
triggers the immune response that boosts the number of relatively short-lived B cells 
and long-lived memory B cells in a zebrafish. The immune response of each zebrafish 
against antigen i is modeled by two delay ODEs: 
dxi (t) 
dt 
dyi (t) 
dt 
= CtVi (t- Tt) + CaVi (t) Yi (t)- bxi (t) i=1,2, ... ,Nag (9.1) 
i = 1, 2, ... 1 Nag• (9.2) 
in which state variables Xi and Yi are the numbers of antigen i specific plasma cells, 
which secret antibodies, and memory B cells, respectively. The initial conditions at 
the time of hatching are Xi (0) = 0, Yi (0) = 0 because of lack of antigenic experience. 
The level of antigen i received by the zebrafish, vi, is subject to a random process. 
Antigen inoculation is random, but the same for both zebrafish, since the environment 
is common for both zebrafish. We assume that Nag = 10 distinct types of antigen 
exist in the environment. The zebrafish are in one of two states, the normal state in 
which the antigen is absent, and the infected state in which the. antigen is present 
in the zebrafish. A newborn zebrafish is not inoculated by antigens and so it is in 
the normal state, Vi (0) = 0. In an antigen inoculation, both zebrafish receive one 
randomly selected type of antigen, denoted antigen i. The average time span between 
two events of infection is >. = 30 days. The value of vi (t) jumps from 0 to 100 at 
antigen inoculation, and the zebrafish transit from the normal state to the infected 
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state. The antigen presentation lasts for approximate one week [233]. Therefore, the 
zebrafish transit from the infected state to the normal state and Vi falls back to zero 
after seven days if the host was not inoculated by antigen i in the past seven days. 
The zebrafish stay in the infected state if they were inoculated by antigen i or another 
type of antigen, antigen j, in the past seven days. The ODE system described above 
contains 2Nag equations for both zebrafish. 
When the host received antigen i at time t, a primary immune response is triggered 
if the host is na.lve to this antigen (Yi ( t) = 0). Otherwise a secondary immune 
response is triggered. Antigen i stimulates production of antigen i specific plasma 
cells with rate c1vi (t- Tt) and memory B cells with rate C2Vi (t- r2). In the primary 
immune response, B cells appear around r 1 = 5 days after the initial contact of 
antigen, and memory B cells appear around r 2 = 30 days after the contact [72]. 
In the secondary immune response, existing memory B cells mount an immediate 
reaction to the corresponding antigen with a rate c3vi (t) Yi (t), which is higher than 
the rate CtVi (t- r 1) in the primary immune response because Yi (t) » 1 . The first 
order term bxi in equation 9.1 quantifies the decay of antigen i specific plasma cells 
with rate b = 5 day-1, because most B cells in germinal centers live a short time 
before apoptosis [72]. 
This ODE system was solved by numerical integration. The solution gives the 
composition of mature B cells in a zebrafish challenged by multiple types of antigen 
during its life history. The mature B cells at t = 180 days plus the na.lve repertoire 
represents the B cell repertoire of a 6-month-old zebrafish. 
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9.2.2 Generalized N K model 
The generalized N K model defines the rugged random potential energy landscape, 
in which the antibody V regions of B cells mutate randomly and are under selection 
[85, 34, 204, 234, 86, 235]. The generalized NK model assigns an energy value to 
each antibody V region with a specific amino acid sequence and a tertiary structure. 
The energy negatively correlates to the fitness of the corresponding B cell in the 
maturation process. The energy of an antibody V region is expressed by 
M M P 
u = "" usd + "" wd-sd + "" u~ . L..t a; L..t ~J L..t ~ (9.3) 
i=l i>j=l i=l 
in which M is the number of secondary structural subdomains, P is the number 
of amino acids contributing to the antibody-antigen binding process. The energy 
U is the sum of three components: secondary structural subdomain energies (U~~), 
subdomain-subdomain interaction energies (L:;:;j=l u;f-sd), and chemical binding en-
ergies (L:;::1 un. The parameters of the generalized N K model are fixed in our 
previous papers [85, 34]. 
The secondary structural subdomain energy is expressed by 
(9.4) 
in which N is the number of amino acids in a subdomain and each amino acid in 
the subdomain interact with K - 1 other amino acids in the same subdomain. Here 
N = 10 and K = 4. An antibody V region contains approximately 120 amino acids 
[72] or equivalently M = 12 secondary structures. The identity of the subdomain is 
denoted by ai. There are L = 5 types of subdomains, which are helices, strands, loops, 
turns, and others, Therefore ai = 1, ... , 5. The identity of amino acid in position j 
is represented by aj. The 20 amino acids are categorized into Q = 5 classes, which 
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are negative, positive, polar, hydrophobic, and other. So a3 = 1, ... , 5. For each of 
L types of subdomains, ao:; is a K-dimensional Gaussian array with zero mean and 
unit standard deviation. 
The subdomain-subdomain interaction energy is expressed by 
sd-sd 2 k i i . j j v D uij = DM (M- 1) £; aij ( ah' ... 'ajK/2' ajK/2+1' ... 'ajK) (9.5) 
Between subdomains i and subdomain j (i < j), D = 6 interactions occurs. Each 
interaction involves K /2 interacting amino acids in sub domain i and K /2 interacting 
amino acids in subdomain j. For each pair of subdomains ( i, j), af3 is a K -dimensional 
Gaussian array with zero mean and unit standard deviation. 
The chemical binding energy is expressed by 
(9.6) 
in which ai is the identity of one of the P = 5 amino acids in the antibody V region 
contributing to the binding to the antigen. The quantity ai (ai) is a Gaussian with 
zero mean and unit standard deviation. 
Two generalized N K models with identical parameters were implemented to calcu-
late the immune response against the same antigen in two zebrafish. In each zebrafish, 
the number of B cells was set to Nsize = 2000 because the number of B cells in a ger-
minal center is in the order of magnitude of 103 [236, 237]. The V region contains 
approximately 120 amino acids in which 100, 10, and 10 amino acids are encoded by 
the V, D, and J gene segment, respectively. Thus the generalized N K model fixes the 
length of V region to 120 amino acids and defines amino acid 1-100, 101-110, and 
111-120 as encoded by the V, D, and J gene segment, respectively. There exist five 
types of secondary structures, which are helices, strands, loops, turns, and others, 
and each secondary structure contains around 10 amino acids [85]. For each type of 
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the secondary structure, we built a pool of 300 amino acid sequences with length 10 
and minimized the energy of each of these sequences using Metropolis Monte Carlo 
method [85]. By randomly selecting and recombining 10-residue sequences from the 
five pools, we created 39 V segments consisting of 10 secondary structures, five D 
segments consisting of one secondary structure, and five J segments consisting of one 
secondary structure. These V, D, and J segments were randomly recombined to cre-
ate the initial Nsize = 2000 structures. In each round of simulation, the structures 
underwent somatic hypermutation and selection. The rate of somatic hypermutation 
is about nmut = 0.5 amino acid/structure/generation [72]; thus we set the number 
of mutated amino acid in each generation in each structure to follow a Poisson dis-
tribution with mean >. = 0.5. In each generation, Pcut = 20% of the structures with 
the lowest energy were propagated to the next generation [34]. The duration of pri-
mary immune response is around 10 days, or equivalently 30 generations of B cells 
[233, 72]; thus we set the simulation to comprise 30 rounds of somatic hypermutation 
and selection. The secondary immune response comprises another 30 rounds of so-
matic hypermutation. We recorded the VDJ usage in each zebrafish in each round of 
simulation. 
9.2.3 Model characterization and verification 
The ODE system models the number of antigen i specific B cells in each zebrafish in a 
mean-field approach. The duration of primary and secondary immune response, which 
are explicitly modeled by the number of iterations in the generalized N K model, are 
respectively treated with the duration 71 and 72 in the ODE system. The generalized 
N K model calculates the rapid increase of antibody affinity of mature B cells in the 
primary immune response [34]. The generalized N K model also calculates the further 
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increase of antibody affinity in the secondary immune response [34]. Note that in the 
generalized N K model, the secondary immune response does not necessarily occur 
immediately after the primary immune response. 
The results from this model of the immune system were compared to experiment 
[7]. In particular, the correlation of VDJ usage from the simulation was compared 
with that from the experiment. The high-throughput sequencing experiment by We-
instein et al. presented the IgM heavy chain frequencies of 975 VDJ recombination 
in each zebrafish, and obtained 91 correlation coefficients between the VDJ usage 
in 14 zebrafish [7]. Both the simulated and the experimentally observed correlation 
coefficients fall into four bins: independence (correlation coefficient r :S 0.1), low cor-
relation (0.1 < r :S 0.2), moderate correlation (0.2 < r :S 0.5), and high correlation 
(r > 0.5), following the categorization scheme of Weinstein et al. [7]. The histogram 
of the correlation coefficients generated by our model was compared with that from 
the experiment using Pearson's x2 test. 
9.3 Results and discussion 
9.3.1 Overview of the results 
As described in the Materials and Methods section, the model in this study considers 
both the time course of the number of B cells as well as the sequence identity of 
those B cells, modeled respectively by the ODE and generalized N K models. The 
following text describes the results at both scales of the model, illustrated in figure 
9 .1. The generalized N K model focuses on the B cell maturation process in response 
to challenge by a specific type of antigen. Subsection 9.3.2 presents the results of 
the generalized N K model simulating the maturation process of naive B cells against 
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the one type of antigen. The trajectories of the simulation give the VDJ usage as a 
function of time in the antibody repertoire of each zebrafish and the correlation of the 
VDJ usage between two zebrafish. Note that the immune system may produce mature 
B cells with a distinct VDJ usage against an identical antigen, because the immune 
maturation process is random. Subsection 9.3.3 presents the results of the sensitivity 
analysis of three parameters, which are the number of naive B cells reacting to the 
antigen, the somatic hypermutation rate, and the selection intensity. In subsection 
9.3.4, the distribution of energy changes !::J.U of single mutations in the generalized 
N K model is presented. 
The ODE model defined in equations 9.1 and 9.2 uses the antigens recognized at 
distinct times of the lifespan of zebrafish as the input and obtains the number of each 
type of B cells at one given time. The ODE model does not take into account the 
maturation process of somatic hypermutation. The ODE model takes into account 
selection in a mean field way. In subsection 9.3.5, the algorithm is used to model 
the challenge of antigen Vi as a Poisson process. Equations 9.1 and 9.2 are then 
numerically solved to acquire the dynamics of the number of each type of plasma cell 
and memory B cell. Finally, by combining the correlation data of each type of B 
cell in two zebrafish obtained by the generalized N K model and the number of each 
type of B cells generated by the ODE model, we present the correlation coefficient 
between the VDJ usage of the whole B cell repertoire in two zebrafish. Pearson's 
x2 test shows that the distribution of correlation coefficients between VDJ usage 
in the B cell repertoires in two zebrafish in the model agrees with those measured 
experimentally [7] (p-value = 0.62). 
227 
9.3.2 Primary and secondary immune response against one antigen 
The generalized N K model simulated the dynamics of the sequence diversity of the 
B cells in the primary and secondary immune responses. Mutation and selection 
causes the B cells to be localized in both the amino acid sequence space and the 
VDJ usage. With the same parameters, 1000 independent runs of the generalized 
N K model yielded 1000 individual trajectories, which were also processed to give one 
average trajectory. The number of distinct sequences and the number of VDJ usage 
decreased as the simulation proceeded, as shown in figure 9.2(a). In Nsize = 2000 
na'ive B cells, the average number of genotypes and VDJ recombinations were 1997.9 
and 849.6, respectively. In the primary immune response, the average number of 
genotypes rapidly decreased from the initial value of 1997.9 to 58.8 in the first six 
generations and then slowly decreased to 30.2 at generation 30 in an exponential way. 
In the secondary immune response, the average number of genotypes decreased from 
the value of 30.2 to 11.4 at generation 60 following the same exponential function 
of time. As shown in figure 9.2(a), dynamics of the numbers of genotypes and VDJ 
recombinations show that localization in the VDJ recombinatio:q. space occurred prior 
to that in the sequence space. The number of VDJ recombinations decreased at 
a higher speed than did the number of genotypes. The average number of VDJ 
recombinations reduced from the initial value of 849.6 to 1.94 in 15 generations, 
then decreased to 1.13 at generation 30 at the end of the primary immune response, 
and further to 1.003 at generation 60 at the end of the secondary immune response. 
Thus, the B cells converged to one dominant VDJ recombination in nearly all immune 
responses. A dominant VDJ recombination exists in the 2000 B cells at the end of 
both the primary and the secondary immune response. We calculated the fraction 
of B cells with the dominant VDJ recombination in each of the 1000 runs. Out of 
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the 1000 runs, 950 runs have the fraction greater than 0.85 at the end of the primary 
immune response, and over 950 runs have the fraction equal to 1 at the end of the 
secondary immune response. The dominant VDJ recombinations in two different 
zebrafish is identical at the end of the primary and the secondary immune responses 
with probability p1 = 0.326 and p2 = 0.327, respectively. Because P1 and P2 are 
similar, we defined p = 0.327 as the probability that two different zebrafish have 
the same dominant VDJ recombination at the end of an antigen-specific immune 
response, whether primary or secondary. 
The energy of a VDJ recombination in the initial Nsize = 2000 naive B cells has a 
relationship to the probability that mature B cells converge to this VDJ recombina-
tion. For each of the 1000 runs, we obtained the identity of the VDJ recombination 
in mature B cells at the end of the secondary immune response and calculated its 
rank in the initial energy in the probability distribution of 975 VDJ recombinations in 
naive B cells. The 1000 values of ranks fall into 10 bins that are 1-100, 101-200, ... , 
900-975, as presented in figure 9.2(b). Figure 9.2(b) shows that VDJ recombinations 
with higher ranks in the initial energy have larger probability to be the only VDJ 
recombination in the mature B cells. Comparison between the observed ranks and 
those in a null model shows the significance of this tendency for the VDJ recombina-
tions with higher ranks to be eventually fixed, with the p-value shown below. For each 
run, the null model randomly chose the VDJ recombination in one naive B cell and 
calculated its rank. The 1000 randomly chosen VDJ recombinations in the null model 
had significantly lower ranks than those in the mature B cells (p-value < 6 x 10-24 , 
Wilcoxon signed rank test). The relationship also indicates that the initial energy 
of VDJ recombination is correlated with the identity of the VDJ recombination that 
was eventually fixed in the mature B cells. As a result, the mechanism of VDJ re-
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combination in two zebrafish leads to the correlation of VDJ usage in their B cell 
repertoires, as suggested in the previous work on zebrafish B cell repertoires [7]. 
The generalized N K model allows us to calculate the correlation coefficients be-
tween VDJ usage in two zebrafish of B cells against the same antigen. In each of the 
1000 runs in the simulation, the correlation coefficient values in naive B cells and B 
cells in each generation in the primary and the secondary immune responses show a 
unique dynamics. As described in figure 9.3, naive B cells at generation 0 in two in-
dividuals show uncorrelated VDJ usage. The correlation coefficient increases rapidly 
to around 0.5 in the first three generations and after that showed large variation. At 
the end of the primary immune reaction with 30 generations, most mature B cells are 
evolved from the same VDJ recombination. The generalized N K model presents the 
correlation coefficient r between the VDJ recombinations of the two zebrafish. The 
probability for r > 0.995 at the end of the primary and secondary immune responses 
is 0.301 and 0.327, respectively. The probability for r < 0.1 at the end of the primary 
and secondary immune responses is 0.641 and 0.672, respectively. 
The dynamics of correlation coefficients shown in figure 9.3 reflect the mechanism 
of B cell maturation. Limited by the local point mutation moves of somatic hyper-
mutation, B cells only explore a small neighborhood of the VDJ recombination in 
the sequence space in the first three generations. Therefore the energy of B cells in 
the first three generations largely depends on the energy of the VDJ recombination. 
Selection pressure removes VDJ recombinations with high energy in the zebrafish 
and increases the correlation coefficient between two zebrafish. After the third gen-
eration, B cells explore broader areas in the energy landscape, and the energies of 
B cells depend less on the initial VDJ recombination. Thus the B cell maturation 
process becomes more random after the third generation. The trajectories of corre-
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lation coefficients in figure 9.3 converge to -1/975 or 1 because the mature B cells 
against one antigen in most individuals show only one VDJ recombination, see figure 
9.2(a). The correlation coefficient between VDJ usage in two zebrafish is -1/975 
if the mature B cells have distinct VDJ recombinations in the two zebrafish. The 
correlation coefficient is 1 if the VDJ recombination is identical in the two zebrafish. 
Correlations -1/975 and 1 are, therefore, two absorbing states in the random process 
of correlation coefficients. Figure 9.3 then shows that the VDJ usage in B cells is 
localized in the primary immune response; the secondary immune responses do not 
change the VDJ usage in most cases. 
9.3.3 Parameter sensitivity in the generalized N K model 
The dynamics of B cell maturation processes simulated in the generalized N K model 
depend on several factors, including Nsize as the number of B cells reacting to the 
antigen, nmut as the average number of point mutations in each generation, and Pcut 
as the proportion of B cells propagated to the next generation. With the correlation 
coefficients r between VDJ usage calculated in the generalized N K model, the relative 
frequency that r > 0.995 after the secondary immune response defines the probability, 
p, that mature B cells in two individuals converge to the same VDJ recombination. 
Note that r > 0.995 implies almost always the same VDJ recombination in two fish. 
Similarly, the probability, q, that mature B cells converge to two distinct VDJ recom-
binations is defined as the relative frequency with r < 0.1 after the secondary immune 
response. The result of the generalized N K model shows that the first probability 
p = 0.327 and the second is q = 0.672. Note that the sum of the probabilities could 
be less than one if greater than one VDJ recombination exists in either fish. 
As shown in section 9.3.2, B cells in two zebrafish from the primary immune 
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response against the same antigen converged to one identical VDJ recombination with 
probability p and converged to two distinct VDJ recombinations with probability q. 
There existed a small probability 1-p-q that VDJ recombination was not converged 
in either zebrafish. Figure 9.4(a) plots p, q, and 1-p- q as the function of Nsize· The 
value of p increased rapidly from 0.207 when Nsize = 1000 to 0.475 when Nsize = 10000 
and were insensitive to Nsize with Nsize > 10000. The probability 1 - p - q for non-
converged VDJ recombinations increased with Nsize· 
The increasing trends of p and 1 - p - q come from the delayed localization of 
the VDJ recombination with larger Nsize· As illustrated by figures 9.4(b) and 9.4(c), 
primary immune responses with greater Nsize localize B cells in the sequence space 
and in the VDJ recombination space more slowly than do those with lower Nsize· The 
B cells thus explore the energy landscape associated with the sequence space, along 
with the different VDJ recombinations, for a longer period of time. A larger value 
of Nsize also enables the B cells to generate more mutants and to explore a broader 
subregion of the energy landscape. The B cells in two zebrafish, both of which explore 
the energy landscape more intensively, have a higher chance to evolve to the same 
local minimum in the energy landscape. 
When the value of Nsize is fixed, the values of nmut and Pcut affect the B cell 
maturation process. The effect of varying nmut and Pcut is reflected in two indices of 
the process, which are p defined above and Nmax defined as the maximum number of 
B cells with identical sequence at the end of the primary immune response. If Nmax 
is close to Nsize, most of the mature B cells from the primary immune response share 
the same genotype. The values used in the generalized N K model are nmut = 0.5 and 
Pcut = 0.2. Here Nsize possesses a fixed value and both nmut and Pcut independently 
vary from 0.1 to 1.0, as shown in figures 9.5 and 9.6. The values of both p and Nmax 
232 
decrease quickly with Pcut· The values of p and Nrnax fall to near zero with Pcut > 0.9. 
Both p and N max are less sensitive to nrnut. 
The two parameters nrnut and Pcut govern the process of B cell somatic hyper-
mutation. The values of mutation rate nrnut and selection pressure Pcut observed in 
experiment have evolved during the evolutionary history of the immune systems [238]. 
The low sensitivity to nrnut in figures 9.5 and 9.6 indicates that with a hypermutation 
rate nrnut on the order of magnitude 10-1 /sequence/generation, the immune system 
maintains the capability to explore the sequence space and locate the local minima in 
the energy landscape. On the other hand, the selection pressure Pcut controls the B 
cell exploration in the rugged energy landscape. A small value of Pcut confines the B 
cells in compact regions in the sequence space by only allowing B cell genotypes with 
lowest energy to propagate to the next generation. Smaller values of Pcut cause both 
zebrafish to have a higher chance to reach the same local energy minima, as described 
in figure 9.6, and result in increased correlation in the VDJ usage, as illustrated in 
figure 9.5. 
9.3.4 Distribution of the energy change b..U of a point mutation 
The generalized N K model used in this work was used to compute the statistics of 
potential energy U and b..U, which is the energy difference caused by a point mutation, 
with experimental data on the point mutation of proteins. The generalized N K model 
for the primary and secondary immune responses simulated the maturation of 1000 
antigen-specific B cells with a 50-generation timespan. In each generation from 0 to 
60, b..U was calculated by temporarily introducing a random mutation in each B cell. 
The simulation was repeated 20 times. Thus, a total of 61 x 1000 x 20 = 1.22 x 106 
values of b..U and the corresponding energy U before the mutation were calculated. 
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Figure 9.7(a) describes the distribution of !:l.U. The point mutations with !:l.U < 0 
comprise 3.8% of the 1.22 x 106 mutations simulated in the generalized N K model. 
This fraction is 4.9% in the experimental data of point mutations affecting protein 
affinity [238]. Figure 9. 7(b) plots the data points (U, !:l.U) generated in the simulation 
in a two-dimensional space. The linear regression between U and !:l.U produces a trend 
line: 
!:l.U = -0.027U + 0.109. (9.7) 
The slope of this trend line is significantly different from zero (p-value < 2.2 x 10-16). 
The negative slope is expected because !:l.U is expected to have a symmetric distri-
bution with center zero when U equals to zero in the generalized N K model [85, 34]. 
Equation 9.7 is consistent with this expectation within error bars. However, figure 
9.7(b) also illustrates that the correlation between U and !:l.U is weak (R2 = 0.018). 
This weakly correlated U and !:l.U were also observed in the experimental data of 
affinity-related amino acid mutations in the PINT database [238]. 
9.3.5 Co-effect. of multiple types of antigens 
The generalized N K model analyzes the immune response against a single type of 
antigen. In reality, the zebrafish are challenged by various types of antigens in their 
lifespan. Each type of antigen induces a distinct immune response producing specific 
mature B cells. First, the numerical solution of the delay ODE system defined by 
equations 9.1 and 9.2 gives the dynamics, which derive the B cell repertoire at time 
t, of each type of mature B cells. Second, the results from the generalized N K model 
assign the identity of VDJ recombinations to each type of antigen-specific mature 
B cells in each zebrafish. The correlation coefficients of VDJ usage in the B cell 
repertoires in two zebrafish agree with those observed in experiment [7]. 
234 
The solution of the ODE model defined by the equations 9.1 and 9.2 is determined 
by the presence of each antigen i denoted by vi (t), t = 0-180 days. In the simulation, 
we first randomly selected antigens to which the zebrafish are exposed at several time 
points. The dynamic system defined by equations 9.1 and 9.2 was numerically solved 
using the parameters c1 = 1, C:! = 0.1, and c3 = 0.03. The physical meanings of these 
parameters are given in section 9.2.1. Figure 9.8 shows the dynamics of the total 
plasma cells and the total memory B cells, respectively, determined by one run of 
the simulation. Each peak of plasma B cells corresponds· to an antigen inoculation. 
For each instance of the simulation there are distinct dynamics of plasma cells and 
memory B cells due to the different antigenic environments. The simulation was 
repeated 6000 times. Each run gave the dynamics of the ODE model. The results for 
the 6000 runs are used to analyze the correlation of the VDJ recombinations in both 
zebrafish. 
The correlation between the two zebrafish is illustrated by the snapshot of the 
composition of plasma cells and memory B cells at one time point. A previous exper-
iment measured the VDJ usage in 6-month-old zebrafish [7] and so the snapshot time 
was day 180. Corresponding to the 10 types of antigen, each of the 6000 runs of the 
simulation generated the numbers of the 10 kinds of antigen-specific mature B cells, 
each of which consisted of plasma cells and memory B cells. As calculated by the gen-
eralized N K model, each type of mature B cells shares the same VDJ recombination 
in two zebrafish with probability p = 0.327. Using this result, we assigned each type 
of mature B cells in the two zebrafish identical VDJ recombination with probability 
p = 0.327 and distinct VDJ recombination otherwise. Besides the mature B cells, a 
substantial number of naive B cells circulate in zebrafish. The number of naive B cells 
in one zebrafish was fixed to 105 , following the literature [7]. In the model, each naive 
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B cell possesses a random VDJ recombination and there is no correlation between 
VDJ usage in the nai:ve B cells of two zebrafish. For each zebrafish, the model yielded 
the VDJ usage in each zebrafish by counting the frequency of each VDJ recombina-
tion in nai:ve and mature B cells. The model also calculated the correlation coefficient 
between the VDJ usage in two zebrafish for each run of the simulation. In total, the 
model presented 6000 model-calculated correlation coefficients. 
The distribution of the 91 correlation coefficients between the VDJ usage in B 
cell repertoires in distinct zebrafish in experiment [7] and that of the 6000 correla-
tion coefficients generated in the model are similar. We adopted the experimental 
categorization scheme for the correlation coefficient [7], which classifies the correla-
tion coefficients r in four bins: no correlation with r < 0.1, low correlation with 
0.1 ~ r < 0.2, moderate correlation with 0.2 ~ r < 0.5, and high correlation with 
r ~ 0.5. Figure 9.9(a) shows the relative frequency of correlation coefficients in ex-
periment in each of the four bins. Figure 9.9(b) shows the distribution of correlation 
coefficients from the simulation. A high level of similarity exists between these two 
frequency distributions (p-value = 0.62, Pearson x2 test). 
9.4 Conclusion and outlook 
In this work, a two-scale model illustrates the zebrafish immune response in the 
presence of multiple types of antigens. Establishing the model in two scales allows 
incorporation of different mathematical tools with specific focuses into the system. 
The first scale of the model is the set of delay ODEs, which is a mean-field ap-
proximation on the genotype of B cells specific to one type of antigen. The dynamical 
system defined by the ODEs receives the challenge of distinct types of antigen as the 
input signal. The solution of the ODE system gives the composition of the mature 
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B cell repertoire at any time point between 0 and 180 days. The correlation between 
VDJ usage in the B cell repertoires in two zebrafish is determined by the dynamics of 
B cell compositions and the probability p, calculated by the generalized N K model, 
that the same antigen induces B cells with identical VDJ usage. The correlation data 
of VDJ usage calculated in the two-scale model agree with those from the experiments 
[7]. 
The second scale of the model is the generalized N K model focusing on the somatic 
evolution of B cells specific to a single type of antigen. Each type of antigen in the 
environment leads to distinct memory B cell evolution. We here use the generalized 
N K model for each type of antigen to build the energy landscape. This generalized 
N K model accurately describes the somatic evolution of B cells against each antigen. 
The generalized N K model describes the affinity maturation process. The random 
walk B cells with lower energy in the rugged energy landscape have higher probability 
to survive and produce progeny. Selection over B cells removes genotypes and VDJ 
usages with high energy and hence substantially localizes the B cells in the rugged 
energy landscape and in the 39 x 5 x 5 VDJ recombination space. VDJ usage is 
localized and fixed in the primary immune response. The localization, however, is 
not a deterministic process. Primary immune response has the probability p to yield 
mature B cells with an identical VDJ usage in two zebrafish, as calculated by the 
generalized N K model. The probability p increases with Nsize, the number of B cells 
reacting to a specific type of antigen, while decreasing with nmut and Pcut, which are 
the somatic hypermutation rate and the survival rate in the selection, respectively. 
With a large number of B cells reacting to a specific type of antigen, Nsize B cells 
explore a broader region of the energy landscape and have a higher chance to find 
the same local minimum in the primary immune reaction in two zebrafish. A high 
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level of nmut increases the uncertainty in the B cell maturation process. A high level 
of Pcut increases the tendency to fix the B cell in the current location in the energy 
landscape. Therefore the probability p decreases with both nmut and Pcut· 
The correlation between. VDJ usage in two zebrafish indicates that evolution is 
not a completely random process. In the generalized N K model, the VDJ usage 
in naive B cells is independently initialized in different zebrafish. The probability 
p that two zebrafish possess mature B cells with identical VDJ usage is calculated 
by the generalized N K model. The generalized N K model asserts that the somatic 
evolution is not an unbiased random walk; the selection pressure and the energy 
landscape affected by the specific antigen strongly drive the somatic evolution of B 
cells in distinct zebrafish in one identical direction. In the ODE model, correlation 
of the VDJ usage in the B cell repertoire on day 180 also shows that the B cell 
somatic evolution in two zebrafish may be correlated if they are challenged by the 
same antigen at the same time. Consequently, closely related antigen challenges could 
induce immune responses with similar characters in distinct individuals. 
This two-scale model is flexible and extensible to analyze the immune system 
dynamics in zebrafish and higher species. The study on the zebrafish B cell repertoire 
can be extended by analyzing the immune system inzebrafish at different ages. The B 
cell repertoire in these individuals may reveal the dynamics of development of immune 
systems challenged by various types of antigen, and further calibrate the ODE model. 
Like the environments with identical challenging antigens discussed above, closely 
related genomes may also cause correlated VDJ usage. We propose sequencing of 
the B cell repertoire of zebrafish in different families living in different controllable 
environments to test the contribution to VDJ usage of two factors: zebrafish genome 
and antigens in the environment. If the correlation of VDJ usage in distinct zebrafish 
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strongly depends on their genetic similarity, their genomes are a determinant of VDJ 
usage. If not, VDJ usage is independent of the genome of each individual. The two-
scale model analyzing the adaptive immune system in zebrafish, a model animal in 
immunity, could also be extended to study the adaptive immune response in higher 
species. 
This model describes the mechanism of B cell maturation and humoral immunity 
in a quantitative way. In the maturation process, the B cells are first localized to 
one VDJ recombination and then further increase the binding affinity to the antigen 
by hypermutation and selection. VDJ recombinations with high initial affinity to 
the antigen prior to the somatic hypermutation have large chances to be selected in 
the maturation process and to be present in the mature B cells. The hypermutation 
and selection of the B cells are not deterministic, and so two zebrafish inoculated 
by the same type of antigen generate mature B cells with identical VDJ usages with 
probability p. The probability p increases with Nsize, the number of B cells in the 
germinal center, decreases with nmut, the hypermutation rate, and decreases with Pcut, 
the fraction of B cells surviving each round of selection. As the B cell maturation 
proceeds, available sequences with higher affi:nity to the antigen become rarer. This 
trend explains the rapid increase of affinity in the primary immune response and the 
relatively slower increase of affinity in the secondary immune response. The experi-
mental data show that the theoretical description presented here matches aspects of 
the zebrafish immune system evolutionary dynamics. 
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Figure 9.1 : Illustration of the two-scale model of zebrafish immune response. The 
timeline arrow represents the zebrafish life history from 0 (hatch) to 180 days. To 
the right of the timeline is the first scale. Antigen challenged the zebrafish at 'several 
random timepoints. Each challenge led to a primary or secondary immune response. 
To the left of the timeline arrow is the second scale of the model. The flow chart 
describes the generalized N K model. Distinct secondary structures represented by 
squares with different colors were first built by minimizing the energy using Metropolis 
Monte Carlo method. These secondary structures randomly recombined to form 
V, D, and J segments, which randomly recombined to form the V region of the 
IgM heavy chain. The V region underwent 30 rounds of mutation and selection 
in the primary immune response and another 30 rounds in the secondary immune 
response. In this figure , as an example, the generalized N K model describes the 
primary immune response against the second antigen this zebrafish met in its lifetime, 
which is represented by the blue star. 
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Figure 9.2: (a) The numbers of distinct genotypes and VDJ recombination in the pri-
mary (generation 1-30) and secondary (generation 31-60) immune responses against 
one antigen involving Nsize = 2000 naive B cells. The number of VDJ recombination 
decreased ·much faster than that of B cell genotypes. In most cases all the B cells 
showed 1-2 VDJ recombinations at the end of the primary immune response and one 
VDJ recombination at the end of the secondary immune response. (b) Probability 
distribution at generation 60 of the rank of probabilities of 39 x 5 x 5 = 975 VDJ 
recombination in Nsize = 2000 na'ive B cells reacting to one type of antigen. This 
probability distribution used 1000 rank data generated by running the generalized 
model1000 times. The na'ive VDJ ranks fell into 10 bins with rank 1-100, 101-200, 
... , 901-975. Bin 10 with rank 901-975 was empty. 
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Figure 9.3 : Trajectories of correlation coefficients r between VDJ usage of B cells 
in two zebrafish reacting to one certain antigen. The simulation consisted of 1000 
runs, each of which generated the correlation coefficient r between naive B cells in 
generation 0 and their progenies in generation 1-30 in the primary immune response 
and in generation 31-60 in the secondary immune response. The first 100 out of 1000 
trajectories are here plotted for clarity. 
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Figure 9.4 : (a) Relationship between the number of B cells reacting to one antigen, 
defined as Nsize, and the correlation data between two zebrafish. Measured by the 
generalized N K model, the correlation coefficient r between the VDJ usage in the 
mature B cells from the secondary immune response fell into three categories: identical 
(r > 0.995), distinct (r < 0.1), and unfixed VDJ usage, with probabilities p, q, and 
1-p- q, respectively. The values of p, q, and 1- p- q were plotted respectively as 
the functions of Nsize ranging from 103 to 105. (b) The number of distinct genotypes 
in each generation of the B cells in primary immune response. The x- and y- axes are 
the same as those in figure 9.2(a). This diagram presents the dynamics of genotype 
numbers in three cases, Nsize = 1000, Nsize = 2000, and Nsize = 10000, respectively. 
(c) Same as (b), except for the number of different VDJ recombinations. 
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Figure 9.5 : The effect of the average number of point mutations in each generation, 
nmut, and the proportion of B cells propagated to the next generation, Pcut, on the 
probability p that two zebrafish developed mature B cells with correlated VDJ recom-
bination against the antigen recognized by both zebrafish at the end of the secondary 
immune response. Each point on the surfaces shows the value of p calculated from 
the generalized N K model as a function of nmut and Pcut· Each of the four subfigures 
is shown for distinct numbers of antigen-specific B cells Nsize: (a) Nsize = 1000, (b) 
Nsize = 2000, (c) Nsize = 5000, and (d) Nsize = 10000. 
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Figure 9.6 : The maximum number of B cells with identical sequence at the end of 
the secondary immune response, Nmax, as a function of nmut and Pcut· As in figure 9.5, 
Nsize as the number of antigen-specific B cells has a constant value in each subfigure: 
(a) Nsize = 1000, (b) Nsize = 2000, (c) Nsize = 5000, and (d) Nsize = 10000. 
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Figure 9. 7 : (a) The histogram of the energy difference !:::..U = (J- U associated with a 
point mutation in the generalized N K model, in which U and (J are the energy values 
before and after the point mutation. We calcqlate U and (J for 1000 B cells at 61 
generations. The values of t:::..U ranged from -1.78 to 3.69. The histogram was equally 
divided in the interval ( -2, 4) by 12 bins. The relative frequency of the mutations 
with !:::..U < 0 is 0.038. (b) The original energy, U, versus the energy difference, !:::..U, 
during 20 runs of the generalized N K model. The horizontal dashed line is !:::..U = 0. 
The solid line is the trend line between U and !:::..U fit through the data. On average 
U decreases with the generation. At generation 0, U is typically close to -10, and at 
generation 60, U is typically close to -25. 
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Figure 9.8 : Dynamics of mature B cells on day Q-180 in one zebrafish reacting to all 
types of the antigen in the environment. The numbers of plasma cells and memory 
B cells are the ·sums of all types of plasma cells and memory B cells, respectively. 
Each zebrafish was challenged by 10 types of antigen, the inoculation time of which 
followed a Poisson process as described in the main text. The dynamics shown in this 
figure are from one trajectory of the Poisson challenge process. 
247 
0.7.------.----~-----.---....------, 
0.6 
0.5 
0.2 
0.1 
no correlation low moderate high 
Correlation between two zebrafish 
(a) 
0.7.------.----~-----.---....------, 
0.6 
0.5 
0.2 
0.1 
no correlation low moderate high 
Correlation between two zebrafish 
(b) 
Figure 9.9 : Distribution of correlation coefficients between the VDJ usage in B cell 
repertoires in distinct zebrafish on day 180. Using the categorization scheme in [7], 
the correlation coefficients r fall into four bins: no correlation with r < 0.1, low 
correlation with 0.1 :::;; r < 0.2, moderate correlation with 0.2 :::;; r < 0.5, and high 
correlation with r :::;; 0.5. The height of each bar quantifies the relative frequencies 
of the correlation coefficient data in each bin. (a) Correlation coefficient data in the 
experiment [7]. (b) A total of 6000 correlation coefficients were generated by the 
model. 
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Chapter 10 
Understanding Original Antigenic Sin in Influenza 
with a Dynamical System 
Original antigenic sin is the phenomenon in which prior exposure t.o an antigen leads 
to a subsequent suboptimal immune response to a related antigen. Immune memory 
normally allows for an improved and rapid response to antigens previously seen and 
is the mechanism by which vaccination works. We here develop a dynamical system 
model of the mechanism of original antigenic sin in influenza, clarifying and explaining 
the detailed spin-glass treatment of original antigenic sin [34]. The dynamical system 
describes the virus load as it propagates through healthy and infected cells, the naive 
and memory B cell concentrations, and the affinity of the immune response. Explicit 
correspondences between the microscopic variables of the spin-glass model and the 
dynamical system model will be given. The dynamical system model reproduces 
the phenomenon of original antigenic sin, and describes how competition between 
different B-cells compromises the overall effect of the immune system. The trade off 
between the naive and memory immune responses as a function of antigenic distance 
between the initial and subsequent antigens is displayed. The suboptimal immune 
response of the original antigenic sin is observed for intermediate antigenic distances. 
10.1 Introduction 
Immune memory is mounted from previous infection or vaccination, stores the infor-
mation for recognizing the corresponding antigen, and is activated during the future 
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infection of the same type of pathogen. Long-term immune memory has been ob-
served for various pathogens including smallpox [89], malaria [90], hepatitis B [91], 
dengue [92], and Influenza A [93]. This long-lasting effect prevents the reinfection 
by pathogens such as smallpox via recognizing and rapidly eliminating those rein-
fected pathogen particles. Smallpox virus, also called variola virus, propagates only 
in humans and has a relatively low mutation rate [35]. In contrast, Influenza A virus 
propagates in human, pigs, and aquatic birds, with a higher mutation rate that is ap-
proximately 2.0 X 10-6 /nucleotide/infectious cycle [37], or 1.6 X 10-5 /amino acid/day. 
Calculation of the binding free energy between human antibodies and circulating In-
fluenza A strains shows that the virus mutates away from the genotypes that code for 
hemagglutinin proteins that are well recognized by the human immune system [94]. 
Thus for Influenza A, there is a significant antigenic distance between the circulating 
strain in a given year and the immune memory from previous years. 
Original antigenic sin is the phenomenon in which prior exposure to an antigen 
leads to a subsequent suboptimal immune response to a related antigen. In some 
years, when the antigenic distance between the vaccine strain and the circulating 
strains fell into a certain range, the existence of original antigenic sin frustrated the 
effort to decrease Influenza A infection rate by vaccination. Historical data of the In-
fluenza A vaccine indicates that vaccine efficacy does not monotonically decrease with 
the distance between the vaccine strains and the circulating strains,_ but rather has 
a minimum at an intermediate level of antigenic distance [2]. Interestingly, since the 
efficacy of the vaccine with this intermediate antigenic distance from the circulating 
strains is lower than the case with larger distance, which is equivalent to unvaccinated 
people, original antigenic sin could make vaccinated people more susceptible to the 
virus than those who are unvaccinated. 
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One of the earliest works discussing the mechanism of original antigenic sin at the 
antibody level includes [34], which attributed original antigenic sin to the localization 
of subsequent immune response in the amino acid sequence space around the primary 
one. The affinity between an antibody and an antigen is given by the generalized 
NK model (GNK model) derived from the NK model originally introduced to model 
a rugged fitness landscape [82, 95] and evolution processes [96, 97, 98], to model the 
three-dimensional structure of protein molecules rather than peptides. The sequences 
of a group of antibodies for Influenza A are allowed to mutate freely and independently 
in the affinity landscape to maximize the individual affinities to the virus. B cells 
that make antibodies with highest affinities are expanded and propagated to the next 
round of the simulation. The mutation of the virus is captured by changing the fitness 
landscape. The final average affinity correlates well with the observed data in history 
[2]. 
In this chapter, a set of ordinary differential equations (ODE) is employed to 
present a deterministic explanation of original antigenic sin equivalent to both the 
observed data [2] and the GNK model [34]. Previously, various ODE models were 
established to describe and simulate the process of virus infection and the reaction of 
the host immune system [239, 240, 241, 242, 243, 244], the basic elements of which 
are described in [245]. Automatons have been used to model the spatial distribution 
varying with time of the tissue cells and the virus [246, 247]. 
The main purpose of this chapter is to build a deterministic model equivalent 
to the GNK model [34], and to reproduce the observed original antigenic sin phe-
nomenon using an ODE-based deterministic approach. Most of the parameters come 
from experimental data, leaving a minimal number of parameters to be estimated. 
The terms in the ODE system have clear physical meanings, so our model explicitly 
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illustrates the details of the infection process. 
10.2 Materials and Methods 
10.2.1 Characters of Influenza A Virus and Infection 
In the following sections of this chapter, we select Influenza A as the model to dis-
cuss the mechanism of original antigenic sin. Influenza A is a type of RNA virus, 
belonging to the family Orthomyxoviridae. A functional Influenza A particle consists 
of a spherical lipid bilayer shell, with 8 distinct RNA strains that encode 11 kinds of 
proteins. Two kinds of glycoproteins, hemagglutinin (HA) and neuraminidase (NA), 
adhere to the surface of the virus particle. HA contributes to the binding of the 
virus particle to the sialic acid on the surface of the target upper respiratory tract 
epithelial cells and facilitates subsequent fusion and entry [18, 19, 20]. NA is the key 
component that facilitates virus release from surface membrane of infected cells [21]. 
Nucleocapsid protein (NP), a nucleoprotein, encapsulates and transports viral RNA 
inside the host cell [22]. The matrix protein, Ml, binds to the inner side of the viral 
lipid bilayer membrane and helps assemble virus particles inside host cells, and is the 
central component in budding of virus particles [21]. M2, a glycoprotein inside the 
lipid bilayer, serves as the ion channel adjusting the pH value inside the virus par-
ticle, uncoating the virus particle, and contributes to efficient virion replication [23]. 
Additionally, there are two non-structural proteins, namely NS1 and nuclear export 
protein (NEP, formerly named NS2), as well as four RNA polymerases replicating the 
virus RNA in the nucleus of the infected cell, namely PA, PB1, recently discovered 
PB1-F2 [24], and PB2. NS1 interferes with the cellular antivirus system [25], and 
NEP exports newly synthesized viral ribonucleoprotein (RNP) complexes comprising 
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viral RNA, NP, and PB1 from the nucleus [26]. 
Influenza A infection follows a common dynamical process. The infection occurs 
in the epithelial cells on the surface of upper respiratory tract in those bronchi that 
are larger than 3.3 mm [240]. The incubation period between the infection and 
the emergence of symptoms ranges from one day to five days, but is typically two 
days. The host starts to shed infectious virus particle approximately 24 hours prior 
to formation of symptoms. Initially, the typical concentration of Influenza A virus 
particles is 10-13 M. The virus load usually reaches a maximum 3 x 10-9 Min two 
days after infection, and falls back to the initial level six days after infection [240]. 
Influenza A virus is cytopathic and destroys the infected cell, causing the dead cells 
to accumulate in situ until they are cleaned. The percentage of dead epithelial cells 
reaches the maximum percentage of 3Q-50% on Day 2, and decreases to 10% on 
Day 5. If the maximum percentage is lower than 10% during the whole process, 
no symptom will occur [240]. The immune system is activated by the existence 
of the virus particles. Antibodies lgG and lgA are the most important immune 
components controlling the disease, followed by the CDS cytotoxic T-cells [72]. The 
level of B cells and plasma cells increase by 102 times and 2 x 104 times in 7 days, 
respectively [240]. Primary infection without previous immune memory generates 
memory antibodies making up 0.1%- 1% of the total antibodies, with the affinity 
106 M-1 , concentration 10-13 M [72, 244]. Among the naive antibodies, those capable 
to recognize the antigen occupy 0.001% - 0.01% of the total antibodies, with the 
affinity 104 M-1, concentration 10-15 M [72, 244]. 
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10.2.2 Model Development and Description 
We use a simplified model consisting of the major factors in the tissue and immune 
system to describe the dynamics of Influenza A infection and recovery, with all the 
state variables listed in Table 10.1. The concentration of epithelial cells on the upper 
respiratory tract is kept around a certain homeostatic level H0 , which is also the sum 
of concentrations of healthy cells (H), infected cells (I), and dead cells killed by the 
Influenza A virus (D), respectively. Free Influenza A virus particles (V) are released 
from infected. cell, and eliminated by the host immune system. We only consider the 
effects of antibodies since antibodies are the dominant factor in neutralizing Influenza 
A virus. Two types of antibodies exist in the model: the na'ive antibodies without 
previous maturation, and the memory antibodies generated and reserved from the 
last infection of Influenza A. The concentrations of them are defined as X1 and X2, 
respectively. The humoral immune system recognizes and removes antigens bound by 
antibodies. With the definition of antibody affinity 
[Ag:Ab] 
Ka = [Ag] [Ab] (10.1) 
the concentration of Influenza A virus particles bound to antibodies is proportional 
to the concentration of free Influenza A virus particles and antibodies, along with 
the affinity U1 and U2 between the antigens and the nai've and memory antibodies, 
respectively. The maximal affinity is Umax· 
From the above information, a set of ODEs is built to describe the scenario that 
there exist in host immune system na'ive antibodies with low initial affinity and mem-
ory antibodies with higher initial affinity having persisted since the last infection. A 
minimal state variable set Z = (H, I, V,X11 X 2 , U1) is selected comprising the healthy 
and infected cells H and I, virus load V, concentrations of nai've antibodies and 
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memory antibodies xl and x2, as well as the affinity of na'ive antibodies ul. 
dH 
>.D- [3VH (10.2) = dt 
d/ {3VH- a! (10.3) = dt 
dV ki- J.£V- P U1X1 v- P u2x2v (10.4) dt -
dX1 
c(Z, t) U1X1 _ bX1 (10.5) = dt U1X1 + U2X2 
dX2 
c (Z, t) U2X2 -bx2 (10.6) dt - U1X1 + U2X2 
dU1 
s U1X1 V (Umax- U1). (10;7) = dt 
The homeostasis of epithelial cells gives an additional algebraic function for the con-
centration of dead cell D 
D=H0 -H-I. (10.8) 
Equation 10.2 describes the dynamics of the concentration of healthy epithelial 
cells. The repair mechanism is activated only if any damage in epithelial cells is 
detected (D =I 0), and new healthy cells are regenerated with the rate >.D due to this 
loss [240]. Alternative expressions include regeneration rate=>. [243] or >.DH [244]. 
In the stochastic model in [247], the regeneration rate is 0 when D = 0, and has a 
mathematical expectancy of >.H when D =I 0. The average life span of trachea cells 
is 47.5 days in human [248], while the time for epithelial cell regeneration is 0.3- 1 
day [249, 240], showing that the cell division is not the major driving force for cell 
regeneration. With this consideration in mind, we select the format in [240]. The 
infection rate {3 represents affinity between virus and sialic acid, as well as the number 
of sialic acid molecules on the surface of the cell. The protective effect of interferon 
is neglected for this simplified model. 
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Equation 10.3 characterizes the concentration of infected cells. All the infected 
cells are originally healthy cell, and are killed by the virus by the rate a. 
Equation 10.4 depicts the generation and elimination of the free virus particles. 
Free virus particles are released from the infected cells by the rate k. The half-life of 
free virus particles is 1/ J.L. Virus bound by antibodies is neutralized, and is the target 
for the immune system that clears the virus. Thus the clearing rate is proportional 
to the concentration of antigens bound by antibodies, [Ag:Ab]. From equation 10.1, 
the clean rate is proportional to the affinity of the antibody Ui, the concentration of 
corresponding antibodies Xi and free virus particles V, respectively. 
Equation 10.5 and 10.6 show the secretion and decay of naive antibodies and mem-
ory antibodies. Antigen presenting cells (APC) process the material from pathogen 
and present the antigen on their surface, activating na!ve T cells. Parts of those 
activated T cells proliferate and differentiate into Th2 helper T cells. Th2 cells and 
free virions activate B cells together [72]. The intensity of activating signal for anti-
bodies, c (Z, t), is a function of time to be determined later, depending on the virus 
load, APC, and na!ve T cells. Naive B cells mature in germinal centers, undergoing 
proliferation and somatic hypermutation. Mutated B cells are selected by competing 
for binding antigen and activation signal from Th2 cells surrounding the germinal 
center. The morphology of germinal centers determines that the interface between 
the B cell region and Th2 cell region is approximately constant, and so is the amount 
of antigens inside the germinal center. Therefore B cells inside the germinal center 
compete with each other for limited activating signal. The ratio of the intensity of 
activating signal for na!ve and memory B cells is U1XI/U2X2 • The decay rate of both 
naive and memory antibodies is b. 
Since the hypermutated B cells are selected by the affinity to the antigen, increase 
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Table 10.1 : Descriptions and units of the variables in the model. 
Variable Description • Unit 
H Concentration of healthy cells 1.7 x 10-11 M 
I Concentration of infected cells 1.7 x 10-11 M 
V Concentration of virus particles 1.7 x 10-11 M 
X1 Concentration of nai:ve antibodies recognizing the virus 1.7 x 10-11 M 
X2 Concentration of memory antibodies reserved from the last infection 1.7 x 10-11 M 
U1 Affinity of nai:ve antibodies recognizing the virus 1.0 x 107 M-1 
U2 Affinity of memory antibodies recognizing the virus 1.0 x 107 M- 1 
D Concentration of dead cells 1.7 x 10-11 M 
of the affinity of na!ve antibody U1 is driven by the successful binding between the 
naive antibody and the antigen. Equation 10.7 indicates that the increase rate of the 
affinity is proportional to the concentration of Ag:Ab complex. The logistic factor 
(Umax- Ul) ensures that the probability forB cells to mutate to a state with higher 
affinity decreases with the process of maturation. 
10.2.3 Reduced Units and Parameter Estimation 
To facilitate the numerical calculation, reduced units are used for all the state vari-
ables. For the state variables H, I, V, X1, and X2 , the unit is defined as the 
homeostatic concentration of epithelial cells in the upper respiratory tract, which 
is 1. 7 X 10-11 M [240, 244]. The unit of u1 and u2 is defined as the maximum affinity 
between memory antibody and antigen, which is 1.0 x 107 M-1 [72]. The reduced 
units for all the variables in equation 10.2- 10.7 are listed in Table 10.1. 
The majority of parameters in this model are acquired from previous experiments. 
Those data fall into two groups of numbers that are compatible. A detailed picture 
of influenza disease in the cellular level was depicted by [240, 239, 244, 249], taking 
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Table 10.2 : Parameters extracted from experimental data. 
Physical meaning Parameter Parameter Initial 
set 1 set 2 estimation 
~ Regeneration rate of healthy epithelial cells 2 
(3 Infection rate 0.34 0.27 
a Death rate of infected epithelial cells 1.5 4.0 
k Number of virus released by each infected epithelial cell 510 480 
JL Nonspecific virus removal rate 1.7 3.0 
p Virus removal rate by antibodies 619.2 
b Decay rate of antibodies 0.043 
co Production rate of antibodies 1.0 
8 Antibody maturation rate 100 
into account the concentrations of cells and virions, as well as the APC, interferon, 
Th1 and Th2 helper cells, CTL, interferon, B cells, plasma cells, and antibodies. This 
picture gives the first set of parameters. The second set of parameters is extracted 
from an independent Influenza A infection experiment in 6 human volunteers [242], 
where a simpler ODE model with a fixed parametric form is built to fit the measured 
daily virus load from nasal wash. The two sets of parameter presented in the reduced 
units are listed in Table 10.2. Despite the different approaches, the variables (3, a, k, 
and f.L from [240, 239, 244, 249] and [242] are similar. 
Compared to some previous models [240, 244], a major simplification in this chap-
ter is neglecting the propagation of the activation signal originated by the detection 
of virus, through a chain consisting of APC, Th2 cells, and B cells. Instead, we in-
troduce a time-dependent parameter c (Z, t) as the activation signal for antibodies. 
In a typical infection process, the level of APC reaches the peak simultaneously with 
the virus load on Day 2 [240]. Virus load falls back to the initial level on Day 6 [240], 
while the half lives of APC, helper T cells, B cells, and plasma cells (Table 10.3) 
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Table 10.3 : Decay rates of different immune cells. 
Immune cell Decay rate/day-1 Reference 
APC (in stimulated state) 1 (244] 
Macrophage 1 [240] 
Th1 helper cell 1 [240] 
Th2 helper cell 1 (240] 
B cell 0.1 [240] 
Plasma cell 0.4 [240] 
are comparable to the duration of the whole infection process. Thus the duration of 
maturation of B cells and the generation of antibodies is estimated to be 14 days, 
continuing after most Influenza A virus particles are removed. Accordingly, the func-
tion c (Z, t) has the initial value of zero, is assigned the value of Co when V reaches 
0.1, and remains Co for 14 days, before going back to 0 again. From the output of 
the models in (240, 244], the initial estimation for Co is fixed as 1.0, and s is initially 
estimated as 100. 
10.3 Results 
10.3.1 Time Courses of Infection and Recovery 
With all parameters including Co and s defined and fixed, we use the stiff differen-
tial equation solver ode23s in MATLAB to numerically solve equations 10.2- 10.7. 
The first set of parameters listed in the left column of Table 10.2 is adopted. As 
described in the Materials and Methods section, at the moment of infection, all the 
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epithelial cells are healthy cells, the initial virus load is variable, typically 1% of 
the concentration of epithelial cells. The concentration of naive antibody capable to 
recognize the antigen is approximately 10-4 of the concentration of epithelial cells, 
while that of memory antibody is 10-2 of the concentration of epithelial cells. Ini-
tial affinity of naive antibodies to the antigen is 104 M-1 , 10-3 of the maximum 
affinity. Using the previously introduced reduced units, the initial values Z (0) = 
(H (o), I (o), v (o), X1 (o), X2 (O), S1 (O)) = (1, o, 0.01, 10-4 , 10-2,10-4 , 10-3). The 
time span for the simulation is 0 - 20 days. The solved trajectories of state variables 
Z are compared to the kinetics observed in reality to verify the values of parameters. 
Two cases are simulated to describe the dynamics of all state variables. The 
first one has a weak cross immunity between memory antibodies generated in the 
previous infection and the current virus, corresponding to the scenario that the virus 
mutates substantially from the previous strains. The second one has a strong cross 
immunity, which is used to simulate the infection caused by Influenza A without 
intensive escape mutation. The affinity of memory antibodies is U2 = 10-3 for the 
first case, and U2 = 0.5 for the second case. The details of the dynamics are shown 
in Figure 10.1 and 10.2. 
Figure 10.1 describes the whole process of infection and recovery with a weak 
immune memory U2 = 10-3 . Symptoms with approximately 30% of the epithelial 
cells killed is observed at the beginning of the infection. The peak of the proportion 
of dead cell D occurs on Day 1 - Day 2, agreeing with the experimental data. On Day 
5, the percentage of dead cell falls under 10%. At the same time of the increase of 
the percentage of dead cells, the virus load V increases by 103 - 104 fold, reaching the 
climax on Day 1, similar to the experimental results of 104 - 105 fold increase on Day 
2. The virus load V decreases to the initial level on Day 3- Day 4. A 105 fold increase 
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Figure 10.1 : Time courses of proportions of healthy cell (H), infected cell (I), 
and dead cell (D), virus load (V), concentration of na'ive and memory antibodies 
(X1 and X2), and the affinity of naive antibody (U1). with the condition U2 = w-3 . 
Initially, H (o) = 1, I (o) = D (O) = o, v (O) = 0.01, X1 (O) = w-4 , X 2 (o) = w-2 , 
and ul (0) = w-3 . 
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Figure 10.2 : Time courses of proportions of healthy cell (H), infected cell (I), 
and dead cell (D), virus load (V), concentration of naive and memory antibodies 
(Xt and X2), and the affinity of naive antibody (U1). We set the condition U2 = 0.5. 
The initial values of all the state variables equal those in Figure 10.1. 
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of the concentration of na!ve antibody occurs during the infection and recovery, and 
the affinity of nai:ve antibody approaches to the maximum level Umax = 1. The 
concentration of memory antibodies X2 has an initial102 fold increase, and decreases 
approximately exponentially after Day 1 with the rate 0.0427, similar to the decay 
rate of antibodies b = 0.043. Thus almost no memory antibody is produced after Day 
1. 
Figure 10.2 shows the dynamics with a strong immune memory U2 = 0.5. No 
obvious proportion of dead cells is accumulated and thus no symptoms are observable 
in the infected person. The virus load is suppressed remarkably compared to Figure 
10.1. This scenario depicts the effect of a successful vaccination. Compared to Figure 
10.1, the increase of the concentration of nai:ve antibodies disappears, the value of 
X 1 decreases approximately exponentially with the rate 0.0423, close to the decay 
rate of antibodies b = 0.043, indicating that nai:ve antibodies are barely produced 
during the whole process. No significant somatic hypermutation is observed in those 
corresponding B cells, hence the nai:ve antibody affinity almost keeps constant, which 
is confirmed in the plot of U1. There is a larger expansion of the memory antibodies: 
the value of X 2 on Day 7 is approximately 10 fold higher than the corresponding 
value in Figure 10.1. 
Nai:ve antibodies dominate the memory antibodies with lower affinity, and memory 
antibodies with high affinity dominate nai:ve antibody. The transition of these two 
types of antibodies corresponds to a critical region of the memory antibody affinity 
U2 • In the following discussion, values of U2 in the whole range 10-3 ~ U2 ~ 1 are 
examined in the model, rendering a picture of the changing character of the dynamics, 
such as the peak of virus load and dead cell percentage, as well as the cumulative effect 
and the average affinity of antibodies. The model will reproduce original antigenic 
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sin shown in the experimental data in the intermediate level of u2. 
10.3.2 A General Picture of Original Antigenic Sin 
To illustrate the phenomenon of original antigenic sin, values of U2 in the range 10-3 to 
1.0 are chosen. The minimum value, Ufin = 10-3 , reflects the case that the previously 
generated memory antibodies barely recognize the antigen, and the maximum value, 
Ufin = 1.0, demonstrates the strongest memory immunity with largest affinity of the 
antibodies. The intermediate level of U2 simulates the scenario in which previously 
generated antibodies have the decreased capability to recognize the antigen due to 
the escape mutation of the Influenza A virus or imperfect vaccine selection. 100 
independent simulations were run for all these cases. The maximum virus load and the 
maximum percentage of dead cells were recorded for each simulation. The integrated 
effects of naive antibodies and memory antibodies are calculated with 
x~nt = J xl (t) ul (t) dt 
x~nt j X2 (t) U2 (t) dt. 
Similarly, the final average affinity of the antibodies for each simulation is 
uavg = { xl (t) ul (t) + x2 (t) u2 (t)} . 
x1 (t) + x2 (t) 
t=20 
(10.9) 
(10.10) 
(10.11) 
By equation 10.7, the affinity of naive antibodies (Ul) is monotonically increasing 
while the affinity of memory antibodies (U2) is kept constant, so equation 10.11 shows 
the average antibody affinity after the 20-day maturation of naive antibodies, when 
the patient has recovered from the disease. Figure 10.3 depicts the maximum virus 
load, percentage of dead cells, integrated effects of naive and memory antibodies, and 
final average affinity of the antibodies as the function of the affinity of the memory 
antibodies generated in the previous Influenza A infection. 
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b 
c 
Figure 10.3 : Trajectories of maximum virus loads, maximum percentages of dead 
cell, maximum immune effects of na'ive and memory antibodies by equation 10.9 
and 10.10, respectively, and trajectory of final avarage affinities of the antibodies by 
equation 10.11 in a series of independent simulations, as the function of the affinity of 
the memory antibodies (U2). The dashed lines in a and bare the level of maximum 
virus loads and maximum percentages of dead cells with the lowest memory antibody 
affinity u2 = 10-3 ' respectively. 
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Figure 10.3a presents a picture of original antigenic sin in the viewpoint of max-
imum percentage of dead cells. With U2 = U2in = 10-3 , the maximum percent-
age of dead cell DQ'ax is 30.6%. Original antigenic sin is observed in the inter-
val w-3 < u2 < 5.0 X w-2. The peak of this curve, 40.8%, is obtained with 
U2 = 3.8 X 10-3 , and is 33.3% higher than the maximum percentage with lowest 
U2 . This 33.3% increase is significant for the percentage of dead epithelial cells. 
When U2 > 0.1, the maximum percentage of dead cells falls below 10% indicating 
no obvious symptom is observed in the infected person. When the antigenic distance 
from the immune system to the Influenza A virus is small, the immune system can 
control the virus effectively. 
Like Figure 10.3a, Figure 10.3b shows the nonmonotonicity of maximum virus load 
V during the infection and recovery process as a function of the affinity of memory 
antibodies. The maximum virus load Vomax with lowest memory antibody affinity 
U2in = w-3 is Vomax = 45.0. The maximum virus load with w-3 < u2 < 1.2 X w-2 
is higher than Vomax = 45.0, where original antigenic sin occurs. The maximum virus 
load in the intervall.6 X w-3 < u2 < 2.8 X w-3 doubles Vomax. With u2 > 0.11, the 
maximum virus load is effectively suppressed to be less than unity, agreeing with the 
fact that memory antibodies effectively recognize and eliminate pathogens with weak 
escape mutation [2]. 
Figure 10.3c describes the cumulative effect Xfnt and XJnt .of both naive and 
memory antibodies calculatedwith equation 10.9 and 10.10 during the whole process 
of infection. There is a threshold u2 = 5.0 X w-3 below which the effect of naive 
antibodies is in a plateau with xfnt > 100. xfnt decreases sharply from 100 to 
9.0 X 10-5 in a narrow region 5.0 X 10-3 < U2 < 9.3 X 10-3 . XJnt increases almost 
linearly with u2 from 7.7 X w-3 (U2 = w-3) to 133.8 (U2 = 1.0). Between the 
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cumulative effect of na.lve and memory antibodies Xfnt and x~nt, Xfnt is larger than 
x~nt when u2 < 8.1 X 10-3' and smaller otherwise. Since xfnt decreases quickly with 
U2 near U2 = 8.1 X 10-3, there is a large difference between Xfnt and X~nt for most 
values of U2 , indicating that there is generally one dominant type of antibody, na.lve 
or memory, which makes the major contribution to the control of Influenza A. 
Figure 10.3d plots the final average affinity uavg of all the antibodies after recovery. 
The form of equation 10.7 ensures the monotonic increase of U1, whereas the trend of 
increase is highly changeable depending on U2 • Similar with Figure 10.3{c), a plateau 
with uavg > 0.9 exists with U2 < 4.0 X 10-a, and uavg decreases substantially from 
0.82 to 8.8 X 10-3 when U2 increases from 5.3 X 10-3 to 8.7 X 10-3. Note that the 
sudden decrease in the overall effect of na.lve antibodies in Figure 10.3 also occurs in 
the same region of U2. When U2 > 8.7 X 10-3, uavg increases approximately linearly 
with U2 , which is mainly the contribution of the affinity of memory antibodies. 
10.3.3 Mechanism of Original Antigenic Sin 
The dynamics system defined by equation 10.2 - 10.7 is split into two subsystems, 
i.e. an actuator and a controller, with weak coupling between them. Equation 10.2 
- 10.4 is the actuator with H, I, V as the state variables, while equation 10.5- 10.7 
is the controller with X1, X2, U1 as the state variables. The control of the actuator 
is implemented by the expression E = U1X 1 + U2X 2 > 0. That is, equation 10.4 is 
equivalent to 
dV 
- = kl - p.V - pEV dt . (10.12) 
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The actuator consisting of equation 10:2, 10.3, and 10.12 has two steady states: 
(H(oo),J(oo),V(oo))1 = (1,0,0) 
(H (oo), I (oo), V (oo))2 = (a (J.L + pE) A [k,B- a (J.L + pE)] A [k,B- a (J.L + pE)]) k,B ' k,B(a+A) ',B(a+A)(J.L+pE) · 
By calculating the eigenvalues of the Jacobian of the actuator, we see the first steady 
state is stable for any E > 0, the second one is stable only if 0 < E < 0.18. With 
strong immune response, E is large and the only steady state reflects the complete 
recovery from the disease. During the process, large E also ameliorates the infection of 
healthy cells by directly suppressing the proliferation of virus. Numerical simulation 
for the actuator illustrates the dependence on E of the dynamics of Influenza A 
infection. Figure 10.4 displays the effect of E: E larger than 0.18 removes all the 
virus and dead cells, and larger values of E result in higher decay rate of both D and 
V. Therefore, E is the single factor in this model controlling dead cell proportion 
and virus load. 
The other subsystem is the controller comprising the state variables X 11 X 2, and 
V. The controller observes the state variables in the actuator in the form of the 
time-variant factor c (Z, t), which jumps from 0 to eo when the virus load V reaches 
0.1, and remains Co for 14 days. Due to the quick proliferation of virus in the initial 
stage of infection, c (Z, t) approximates the constant Co· The dynamics of factor E is 
expressed as 
dE 
dt 
(10.13) 
The first term in the right hand side of equation 10.13, U2d (X1 + X2 ) /dt, is the 
product of U2 and the derivative of a first order process X1 +X2 , the latter of which is 
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Figure 10.4: 'Irajectories of dead cell proportion (D) and virus load (V) with different 
(E). In each trajectory, H (0) = 1, I (0) = 0, V (0) = 100, and E is constant. Small 
E such as 0.1 is not able to remove all the virus when t---+ oo. Larger decay rates of 
both D and V are observed for larger E. 
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Figure 10.5 : Trajectories of the controlling effect E = U1X1 + U2X 2 • In each trajec-
tory, H (O) = 1, I (O) == o, v (O) = 0.01, Xt(O) = 10-4 , X2 (O) = 10-2 , and Ut(O) = 
10-3 . Each trajectory corresponds to one value of U2 • Small E such as 0.1 is not 
able to remove all the virus when t ----t oo. Larger decay rates of both D and V are 
observed for larger E. 
independent of U2 by adding equation 10.5 to equation 10.6. The form of equation 10.5 
and 10.7 determines the suppression on X 1 (t) and U1 (t) by U2 , hence the monotonic 
decrease of the term X 1 dU1 / dt with the increase of .U2 . In the case with small U2 , the 
factor (U1 - U2 ) > 0 during almost the whole the process (see Figure 10.1), thus the 
third term (U1 - U2 ) dXtfdt decreases with U2• If U2 is large, X1 is approximately 
constant, and the change of this term is negligible. Consequently, the first term in 
equation 10.13 goes up with U2 and the other terms goes down with U2 • Figure 10.5 
shows the quantitative property of E as a functional of U2 : when U2 increases from 
10-3 to 1, increase of the second and the third terms of E do not compensate the 
decrease of the first term, yielding a suppression of E in the intermediate level of U2. 
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The source of original antigenic sin is the interaction among the state variables 
in the controller, or the immune system. When U2 is small or large, one type of 
antibody is dominant so that the immune system responds with having only one type 
of antibody. For intermediate U2 , the interaction and competition of two types of 
antibodies lead to a decreased immune effect E, which yields less regulation of the 
tissue. This is original antigenic sin. We observe increased influenza illness rate [2] 
related to the increase of D and V during the process, as well as decreased final average 
affinity of antibodies [34] related to the decrease of E. Not.e that the average affinity 
is defined as uavg = Ej (X1 + X2 ) where (X1 + X 2) are approximately independent 
of u2 as discussed above. 
10.3.4 Sensitivity Analysis 
Sensitivity analysis for most of the parameters in this model has been performed 
in [244]. So we focus on two remaining parameters - Co and s. The parameter c0 
characterizes stimulation of the immune system when the virus load increases beyond 
the threshold 0.1. Since a simplified model comprising the most important factors 
of both tissue and immune system is given in this chapter, the effects of APC and 
Th2 cells are combined into the parameter Co· The parameter s reflects the somatic 
hypermutation process of the B cell to produce antibodies with high affinity to the 
antigens. Here we give a sensitivity analysis to each parameter. 
Figure 10.6 describes the behavior of the dynamical system with different param-
eters co and s. The patterns of maximum percentage of dead cells with large U2 are 
insensitive to s, and the patterns of average antibody affinity with small and large 
U2 are also insensitive to both Co and s, but sensitive with intermediate U2 • The 
threshold where the memory antibodies replace the naive antibodies as dominant de-
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Figure 10.6 : Sensitivity analysis of parameters Co and s. (a) and (b) Maximum 
percentage of dead cells and average antibody affinity for different Co· (c) and (d) 
Maximum percentage of dead cells and average antibody affinity for different s. Initial 
conditions and parameters other than eo and s are the same as those in Figure 10.3. 
creases with increasing co and increases with increasing s. However, the dynamics for 
all these values of Co and s reproduce the general trend for the common dynamical 
process of Influenza A infection discussed in Section 10.2.1. Thus the existence of 
original antigenic sin is also guaranteed for all these parameters sets. 
10.4 Discussion 
The ODE model expressed in terms of equation 10.2 to 10.7 represents a significant 
simplification to the previous models describing Influenza A kinetics [240, 244], while 
introducing a second type of antibodies to capture the competition and cooperation 
272 
between antibodies of different genotypes. The effects of Thl cells, CTL, interferon, 
and cells protected by interferon are in aggregate by the parameter values of the 
model. The antibody activation chain consisting of APC, Th2 cells, and B cells is 
captured by the factor c (Z, t) rather than explicitly modeled with differential equa-
tions. 
The concentration of CTL increases by 100 times in the first 7 days after the 
infection [240] to remove infected cells. The cross immunity is usually strong in 
cellular immune system for different Influenza A strains [240], while the effect of 
humoral immune system decreases substantially for a new Influenza A strain with a 
large evolutionary distance from the previous strain infecting the host [2]. Thus the 
effects of CTL against different invading Influenza A strains are more homogeneous 
than those of antibodies. That is, CTL induced by the previous Influenza A infection 
generally retain the cross immunity against the current invading virus despite virus 
evolution [240]. In contrast, reaction of antibodies decreases with increasing antigenic 
distance increases between the current virus strain and the prior exposure strain. Thus 
the effect of CTL is more stable compared to that of antibody, and can be accounted 
for by constant parameter values to describe the pattern of original antigenic sin. 
For the same reason, the protection for healthy cells by interferon secreted by 
infected epithelial cells is not explicitly considered either. Additionally, interferon and 
protected cells are not essential to the dynamics of infection and recovery: absence of 
interferon does not affect the final elimination of all virus and dead cells [244]. As the 
elements in the activation chain, APC, Th2 cells, and B cells have little interaction 
with the elements in the model outside the activation chain, instead, their main 
function is to activate the downstream elements. Hence a simple function c (Z, t) is 
introduced to capture activation. 
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Equation 10.2- 10.4 constitute a general form for infection in tissue caused by a 
cytopathic virus that is controlled mainly by antibodies. This model can be extended 
to consider the details of CTL and interferon in the immune system. The model could 
also be extended to consider a family of cytopathic viruses by using equations 10.2-
10.4 with different parameter sets (-X, (3, a, k, J.t) characterizing each virus in pathogen 
space. The cytopathic viruses fall into two categories: those inducing acute disease 
and those inducing chronic disease. Virus in the first category, such as Influenza 
A virus, are cleared in a short period of time, thus relatively few escape mutations 
occur. The immune system therefore mutates itself towards a fixed target. The 
differential equations 10.5 - 10.7 describing the immune system do not require any 
modification for the escape mutation of the virus. On the other hand, virus in the 
second category including HIV, persist for years in the host, and keep mutating away 
from the immune system. A new set of differential equations is needed to model this 
case. First, additional terms are required for equation 10.7 to describe the trend to 
decrease the affinity of memory antibodies. Second, if the immune system is also 
attacked by the virus, equation 10.5 and 10.6 should also contains terms for this 
effect. 
Despite possessing different mathematical forms, there is an implicit parallelism 
between the dynamical model presented in this chapter and the spin glass model [34]. 
Both models consider naive and memory antibodies together, and introduce a com-
petition factor modeling the competition for the survival and opportunity for somatic 
hypermutation between these two types of antibodies. In the dynamical model, the 
maturation of the naive antibody follows a logistic process with a maximum affinity, 
while in the spin glass model, the antibodies have random walks on a rugged and 
random landscape [82] where the density of neighboring states with higher affinity is 
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low for states with high affinity. The dynamical model keeps two antibody strains for 
naive and memory affinity, respectively. The spin glass model, however, tracks 1000 
na'ive antibodies and another 1000 memory antibodies. After a 30-round iteration, 
the number of antibodies with different genotypes generally converges to fewer than 
5, which is close to the dynamical model where both naive and memory antibodies 
are monoclonal. 
The ODE system applied in this model is deterministic while the real process 
of virus infection and recovery is a stochastic process. Stochastic factors have been 
established for a stochastic dynamic system that obtained equivalent results to this 
model [34]. The dynamical model assumes both na'ive and memory antibodies to 
be monoclonal, which could be changed in the ODE by introducing more model 
genotypes for both kinds of antibodies. Hence the competition factors U1XI/(U1X1 + 
U2X2) and U2X2/(U1X1 + U2X2) could be replaced by a tournament-like algorithm 
involving all the surviving antibodies. With the method of splitting the system into 
an actuator and a controller, this model also provides a starting point for analysis by 
nonlinear control theory to explain suboptimality in the immune system. The present 
simple form, however, provides valuable input to the vaccine development process. 
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Chapter 11 
Conclusion 
For both HlNl (Chapter 2) and H3N2 [2], the HI assay correlates less well with vac-
cine effectiveness than does Pepitope· Collection of HI assay data measuring antigenic 
distance is also more time-consuming and more expensive compared to the Pepitope 
model. Many hundreds of strains are circulating and collected in an average flu sea-
son, thus an HI table with tens of thousands of entries needs to be built to assess the 
antigenic distance between each pair of strains. With the high-throughput sequenc-
ing technology generating hemagglutinin sequence data, such antigenic distances are 
easily measured with the sequence-based antigenic distance measure Pepitope, which 
correlates to a greater degree with vaccine effectiveness than do the HI data. 
The Pepitope model is developed to provide researcher and health authorities with 
a new tool to quantify antigenic distance and design the vaccine. We do not suggest 
that Pepitope should substitute for the current HI assay, but rather suggest that Pepitope 
serves as an additional assessment when selecting vaccine strains. Using Pepitope to 
supplement to HI assay data may allow researchers and health authorities to more 
precisely quantify the antigenic distance between dominant circulating strains and 
candidate vaccine strains. The adoption of the Pepitope theory may also allow re-
searchers to minimize the cost and the number of ferret experiments and to correct 
HI assay data in some situations. 
The Pepitope model is applied to predict vaccine effectiveness and to select vaccine 
strains. Interestingly, the expected vaccine effectiveness is greater against HlNl than 
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H3N2, suggesting a stronger immune response against HlNl than H3N2. The evolu-
tion rate of hemagglutinin in HlNl is also shown to be greater than that in H3N2, 
presumably due to greater immune selection pressure. 
Shannon entropy is a powerful tool to determine the epitope regions in Hl hemag-
glutinin. We use Shannon entropy and relative entropy as two state variables of H3N2 
evolution. The entropy method is able to predict H3N2 evolution and migration in 
the next season. First, the Shannon entropy data in one season strongly correlate 
with the relative entropy data from that season to the next season. If higher Shan-
non entropy of the virus is observed in one season, higher virus evolutionary rate is 
expected from this season to the next season. Second, the relative entropy values 
between virus sequences from China, Japan, the USA, and Europe indicate that the 
H3N2 virus migration from China to Japan and the USA, and identify a novel migra-
tion path from the USA and Europe. The relative entropy values in and out of China, 
the epicenter, show that evolutionary rate is higher in China than in the migration 
paths. Moreover, the entropy method was demonstrated on two applications. First, 
selection pressure of the H3 hemagglutinin is mainly in 54 amino acid positions. Sec-
ond, the top exposed part in the three-dimensional structure of HA trimer covered by 
epitopes A and B is under the highest level of selection. These results substantiate 
current thinking on H3N2 evolution, and show that the selection pressure is focused 
in a subset of amino acid positions in the epitopes, with epitopes A and B on the 
top of hemagglutinin dominant making the largest contribution to the H3N2 evolu-
tion. These predictions and applications show that the entropy method is not only 
predictive but also descriptive. 
Mutation of the H3 hemagglutinin on the surface of the the influenza virus de-
creases the ability of the immune system to recognize the flu and decreases the efficacy 
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of the annual vaccine. We show that influenza tends to increase the number of charged 
amino acids in the regions of hemagglutinin that the immune system recognizes, prob-
ably because this reduces ability of antibodies to bind hemagglutinin. An interesting 
corollary of this selection is that the number of charges in the dominant epitope of 
the dominant circulating virus strain is never fewer than that in the vaccine strain, 
chosen early in the season. We developed a model of the evolution of charge in hemag-
glutinin by partitioning 20 amino acids into two categories: charged and uncharged, 
calibrated this model on virus evolution data in humans, and demonstrated the model 
on Guinea pig animal model studies. 
Protein evolution models such as PAM model and BLOSUM model typically apply 
to the evolution of bacteria, archaea, and eukaryota. For influenza virus, the harsh 
and changing environment due to immune pressure on the virus, makes its evolution a 
non-equilibrium dynamics, especially in the time period after its initial emergence in 
humans. The RAMM model supports the hypothesis that the rate of charge evolution 
is greater in regions of hemagglutinin recognized by the immune system than in 
proteins in general. Such temporal and spatial heterogeneity requires a method such 
as we have presented here for modeling the virus evolution. 
We introduced the Einstein crystal as a technology to improve the results of free 
energy calculation. By calculating the free energy difference of each amino acid sub-
stitution, we obtained the free energy landscape for substitutions in epitope B of 
hemagglutinin. There is notable variation between the values of free energy differ-
ences of different substitutions at different sites, because the identities of original and 
substituting amino acids, as well as the locations of amino acid substitutions, affect to 
differing degrees the antibody binding process. In this free energy landscape, we sug-
gest that virus tends to evolve to higher !::l.!::l.G values to escape binding of antibody. 
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Counterbalancing this selection is random drift. Historical amino acid substitutions 
in epitope B and Monte Carlo simulations of the virus evolution using the free energy 
based virus fitness, in which random genetic drift of the virus adds statistical noise 
into the virus evolution process, showed that selected substitutions are biased to those 
with positive D.D.G values. 
Due to the genetic proximity of the TEM and SHV ,8-lactamase genes in bacte-
ria with different resistance phenotypes, with typically 1-5 amino acid substitutions 
conferring resistance to antibiotics, it has been long suspected that transitions of re-
sistance between different antibiotics comes about by accumulation of single DNA 
point mutations at specific locations. It has been well established that recombina-
tion plays a role in the mechanisms that bring about the higher rates of mutation 
in stressed bacteria. To our knowledge, at the onset of this research there had been 
none and currently there is one characterization of recombination among naturally 
evolved ,8-lactamase resistance variants from clinical strains [197]. We analyzed DNA 
sequences of the genes for naturally evolved variants of TEM and SHV ,8-lactamases 
to establish if recombination plays an evolutionary role in resistance development 
by combining mutations originating in different genes. All but one of our detection 
methods indicated the presence of recombination signatures in the gene sequences 
from clinical isolates. Our findings support a role of recombination in the evolution 
of extended spectrum antibiotic resistance, suggesting that recombination directly 
acts on resistance genes to recombine selected mutations. 
HA specific immunity plays a key role in H3N2 virus evolution. The fixation 
of mutations of H3N2 virus in both nai:ve and immune animal appeared to be non-
random events as immune pressure can lead to mutations accumulating in dominant 
epitopes. We found that the mutations driven by immunity are frequently associated 
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with charge, hydrophobicity, and lost glycosylations. The results of the present study 
increase our understanding of the direction of evolution in influenza and may provide 
useful insights for the selection of strains to be included in the seasonal vaccine. 
Our two-scale model describes the mechanism of B cell maturation and humoral 
immunity in a quantitative way. In the maturation process, the B cells are first lo-
calized to one VDJ recombination and then further increase the binding affinity to 
the antigen by hypermutation and selection. VDJ recombinations with high initial 
affinity to the antigen prior to the somatic hypermutation have large chances to be 
selected in the maturation process and to be present in the mature B cells. The 
hypermutation and selection of the B cells are not deterministic, and so two zebrafish 
inoculated by the same type of antigen generate mature B cells with identical VDJ 
usages with probability p. The probability p increases with Nsize, the number of B 
cells in the germinal center, decreases with nmut, the hypermutation rate, and de-
creases with Pcut, the fraction of B cells surviving each round of selection. As the 
B cell maturation proceeds, available sequences with higher affinity to the antigen 
become rarer. This trend explains the rapid increase of affinity in the primary im-
mune response and the relatively slower increase of affinity in the secondary immune 
response. The experimental data show that the theoretical description presented here 
matches aspects of the zebrafish immune system evolutionary dynamics. 
We build a deterministic model equivalent to the GNK model [34], and to re-
produce the observed original antigenic sin phenomenon using an ODE-based deter-
ministic approach. Most of the parameters come from experimental data, leaving a 
minimal number of parameters to be estimated. The terms in the ODE system have 
clear physical meanings, so our model explicitly illustrates the details of the infection 
process. 
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